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Introduction 
Transplantation has significantly reduced mortality and morbidity in patients 
with end stage renal disease. One of the most important developments in renal 
transplantation is the introduction of new immunosuppressive agents for the 
prevention of acute rejection. Until the 1980s, the conventional immuno-
suppressive therapy consisted of a purine synthesis inhibitor azathioprine and 
corticosteroids. They were the only immunosuppressive agents for 
maintenance therapy. Sometimes an induction course of anti-lymphocyte 
globulin (ALG) was also administered together in order to reduce the risk of 
acute rejection1. Cyclosporine A, a calcineurin inhibitor (CNI), was introduced in 
renal transplantation in early 1980s2. The major advantage was a reduction in 
the incidence of acute rejection and improvement in 1-year graft survival3-5. 
Several randomized studies also demonstrated that cyclosporine-based 
immunosuppression had advantages over conventional immunosuppression as 
it resulted in a reduced need to use corticosteroids6-8. Consequently, in 
combination with corticosteroids and azathioprine, cyclosporine became the 
standard immunosuppressive agent and it remained so through the mid 1990s. 
Cyclosporine/Sandimmun (Sandoz, Switzerland) was later replaced by 
cyclosporine/Neoral (Novartis, Switzerland), a microemulsion formula with a 
bile-independent and consistent absorption profile, which led to lower inter-
patient and intra-patient variability than Sandimmun9. In the 1990s, a number of 
new immunosuppressive agents were introduced in clinical transplantation.  
• In the group of CNI: tacrolimus (FK 506, Prograf; Fujisawa/Astellas, Japan). 
• In the group of lymphocyte-selective purine synthesis inhibitors: 
mycophenolate mofetil (Cellcept; Roche, Switzerland) and mycophenolic 
acid (Myfortic; Novartis, Switzerland).  
• In the group of mammalian target of rapamycin (mTOR, inhibitors of 
cytokine signal transduction): the macrolides sirolimus (Rapamune; Wyeth, 
USA) and everolimus (Certican; Novartis, Switzerland).  
• In the group of interleukin-2 (IL-2) receptor antagonist: basiliximab 
(Simulect, Novartis, Switzerland) and daclizumab (Zenapax, Roche, 
Switzerland).  
The sites of action of different immunosuppressive agents are shown in Figure 
1.1. Most patients currently undergoing solid organ transplantation are started 
on either cyclosporine or tacrolimus. There has been a shift towards a more 
frequent use of tacrolimus after kidney transplantation in worldwide, especially 
in the United States10. Optimization of both efficacy and safety of the 
immunosuppressive regimen is key to improving long-term transplant outcome. 
This thesis will focus on different aspects of optimizing tacrolimus therapy, 
especially in Chinese renal transplant recipients. 
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Figure 1.1 Sites of intervention for immunosuppressive drugs. The calcineurin inhibitors 
cyclosporine and/or tacrolimus inhibit the phosphatase calcineurin. CD25-specific 
monoclonal antibodies disrupt the binding interleukin-2 (IL-2) to its receptor; sirolimus 
acts on cytokine-signal transduction (signal 3); and mycophenolic acid (MPA) on 
guanosine-base synthesis (S phase). The monoclonal antibody OKT3 binds the T-cell 
receptor, resulting in T-cell depletion. APC, antigen-presenting cell; CTLA4, cytotoxic 
T lymphocyte antigen 4; GMP, guanosine monophosphate; I B, inhibitory B; IMP, 
inosine monophosphate; JAK3, Janus kinase 3; L, ligand; MTOR, mammalian target of 
rapamycin; NFAT, nuclear factor of activated T-cells; NF- B, nuclear factor- B; PKB, 
protein kinase B; R, receptor; STAT5, signal transducer and activator of transcription 
5; TCR, T-cell receptor; TLR4, Toll-like receptor 4; ZAP70, zeta-chain-associated 
protein 70. Adapted by permission from Macmillan Publishers Ltd: Nature Immunology 
Reviews (Kahan BD. Nat Rev. Imm 3, 831-838), copyright (2003). 
. 
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Tacrolimus and cyclosporine 
Despite structural differences, tacrolimus and cyclosporine share a similar 
cellular mechanism of action, though tacrolimus is 100 times more potent than 
cyclosporine in vitro in inhibiting T-cell proliferative responses, including mixed 
lymphocyte reactivity and cytotoxic T-cell generation11. After entry into the cell, 
both agents bind to their respective cytosolic immunophilins: cyclosporine to 
cyclophilin and tacrolimus to the FK506-binding protein (FKBP-12 and 
FKBP-52). The drug-immunophilin complex binds to and inhibits the activity of 
the calcineurin, a calcium/calmodulin-dependent protein phosphatase that is 
expressed in all mammalian tissues12,13. As a result, the complex interrupts the 
calcium-dependent signal transduction pathway in T-cells14,15. Inhibition of 
calcineurin by cyclosporine or tacrolimus leads to interference with the nuclear 
translocation of various nuclear factors such as the cytosolic subunit of the 
nuclear factor of activated T-cells (NF-AT) which are involved in the 
transcription of cytokine genes. Moreover, inhibition of calcineurin also 
antagonizes the interaction of another transcription factor, cyclic adenosine-
monophosphate (c-AMP) response element-binding protein (CREB), with its 
DNA-binding site CRE, inhibiting c-AMP-directed transcriptional events16,17. As 
a result, the transcription of early T-cell activation genes is suppressed, 
affecting the production of many cytokines, namely IL-2, IL-3, IL-4, TNF-α, 
interferon-γ, GM-CSF, and the ligand of CD4018,19. In addition, the drug-
immunophilin complex has recently been recognized as blocking the 
calcineurin-independent jun N-terminal kinase (JNK) and p38 signalling 
pathways in the activation of T-cells20,21. JNK and p38 are subgroups of protein 
kinases belonging to a super-family of mitogen-activated protein kinases 
(MAPK). A cascade of MAPK is activated after activation of T-cell receptor in 
the presence of the CD28 co-stimulatory receptor. Cooperative activation of 
JNK and p38 in conjunction with ERK (another subgroup of MAPK) leads to 
activation of transcription factors like activator-protein-1 (AP-1)18. 
Differences between tacrolimus and cyclosporine in 
mode of action and side effects 
Although both tacrolimus and cyclosporine inhibit the enzyme calcineurin and, 
subsequently, IL-2 transcription, the greater immunosuppressive efficacy of 
tacrolimus on molar base, as discussed in this introduction, suggests that it has 
additional immunomodulating properties over cyclosporine that favor graft 
acceptance. Moreover, several molecular differences have been documented 
in experimental studies, animal studies and studies in various organ 
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transplantations that may provide additional explanation for the differences in 
efficacy as well as in safety that have been observed in clinical practice (Table 
1.1). The major side effects of tacrolimus and cyclosporine are shown in Table 
1.2. 
 
Table 1.1 Mechanistic differences between tacrolimus and cyclosporine. 
Tacrolimus (vs cyclosporine) 
Greater immunosuppressive effects 
   Association with the glucocorticoid receptor 
   Lower levels of antibodies production 
   Inhibition of IL-2, IL-5 and IL-7 
   Inhibition of primed T-cells 
   Potentiation of apoptosis 
   Suppression of IL-10 and IL-10-mediated cytotoxic cell infiltration 
Less nephrotoxicity 
   Not associated with increased TGF-ß production 
Decreased TGF-ß type 1 receptor expression 
 
 
Table 1.2 Major side effects of the calcineurin inhibitors cyclosporine and tacrolimus. 
Side effects Tacrolimus Cyclosporine 
Nephrotoxicity 
Hypertension 
Post-transplant diabetes mellitus 
Hyperlipidemia   
Neurotoxicity 
Hirsutism 
Gingival hyperplasia 
↑ 
↑ 
↑↑ 
- 
↑↑ 
- 
- 
↑↑ 
↑↑ 
↑ 
↑↑ 
↑ 
↑↑ 
↑↑ 
↑↑ large increase, ↑ small increase, - no increase 
 
 
In contrast to cyclosporine-binding protein, FKBP-52 is associated with the 
glucocorticoid receptor complex. Usually the glucocorticoid receptor is released 
from this complex by the binding of steroids. The released receptor then 
migrates to the nucleus, where it binds to the glucocorticoid response elements 
(GRE) in the regulatory regions of genes or modulates the binding of other 
transcription factors, such as AP-1, and the signal transducers and activators of 
transcription (STAT) factors. Moreover, the released glucocorticoid receptor 
inhibits other transcription factors, like nuclear factor kappa-B (NF-kB). AP-1, 
STAT, and NF-kB all play a role in the regulation of genes involved in the 
immune response. Binding of tacrolimus to FKBP-52 may alter the affinity of 
the glucocorticoid receptor for steroids. This may release the receptor from the 
complex and create a steroid mimetic effect which may explain the steroid 
sparing effect of tacrolimus compared to cyclosporine22. 
Thesis_Cheung_v2.pdf
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Due to the blockade of cytokine production by T-cells, proliferation of B-cells 
and production of antibodies are also inhibited23. There is more inhibition of 
antibody production by tacrolimus than by cyclosporine24. Tacrolimus also has 
an effect on cytokine formation induced by IL-2. It suppresses the production of 
IL-5 induced by IL-2 stimulation of the IL-2 receptor25. In contrast to 
cyclosporine which only inhibits naïve T-cells, tacrolimus was found to inhibit 
both native T-cells and primed T-cells in clinically relevant concentrations26. 
Tacrolimus was able to enhance apoptosis in antigen-stimulated T-cells while 
cyclosporine had no effect27. Tacrolimus potentiates T-cell apoptosis induced 
by steroids28. It also inhibits the migration of activated lymphocytes and the 
production of chemotactic factors by these cells29. In contrast to cyclosporine, 
tacrolimus appears to suppress intragraft IL-10 production and subsequent 
local infiltration of cytotoxic T-cells and natural killer cells by decreasing the 
release of such cytotoxic factors as granzyme B and perforin-130. All these 
findings may explain the observation that tacrolimus can reverse steroid-
resistant rejections in patients receiving cyclosporine31,32. 
Another mechanism among the immunosuppressive properties of cyclosporine, 
but not tacrolimus, is mediated by its augmentation of the production of 
TGF-ß33-35. In addition to its immunosuppressive properties, TGF-ß can induce 
fibrosis formation, leading to chronic allograft dysfunction. FKBP-12 binds to 
the TGF-ß type 1 receptor36,37. It acts as an anchor of calcineurin to the 
receptor. The complex of FKBP-12 and calcineurin prevents the receptor from 
being activated. Tacrolimus, which binds to FKBP-12 and inactivates 
calcineurin, has appeared to exhibit growth inhibition mediated by TGF-ß37. 
The downstream blockade of calcineurin and subsequent gene transcription is 
important for interruption of the TGF-ß effects. This may be essential in the 
aspect of development of renal fibrosis. On the other hand, cyclosporine 
induces the expression of type 1 TGF-ß receptors38. In fact, tacrolimus has 
been shown to have less fibrogenic potential than cyclosporine39. 
Interleukin-2 receptor antagonist 
The IL-2 receptor antagonists basiliximab and daclizumab have become widely 
adopted since their introduction in the mid-90s. Initially, IL-2 receptor 
antagonists were administered only as adjunctive immunosuppression within 
full-exposure CNI-based regimens. Nowadays, clinicians have increasingly 
investigated the use of IL-2 receptor antagonists in other protocols including 
steroid-sparing and CNI-sparing regimens. IL-2 is the messenger for many 
parts of the acute rejection process. For messages to be transmitted from cell 
to cell, IL-2 must bind to the IL-2 receptor on the receiving cell. The receptor is 
expressed only on activated T-cells and consists of three transmembrane 
Thesis_Cheung_v2.pdf
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protein chains: α(CD25), β(CD122), and γ(CD132). Also known as the CD25 
antigen, IL-2 receptor α must associate with the ß-subunit to form the IL-2 
binding site. Binding of IL-2 with the receptor transduces a signal across the 
cell membrane and triggers T lymphocytes to undergo clonal expansion. 
Engineered antibody products directed at this receptor are designed to block 
the activation of antigen-specific T lymphocytes selectively by binding the 
α-subunit and inhibiting formation of the complete binding site, therefore 
inhibiting binding of IL-2 and transduction of the signal40. 
Daclizumab was the first IL-2 receptor antagonist approved by the Food and 
Drug Administration (FDA) in December 1997. It is a modified human IgG1 
monoclonal antibody consisting of 90% human and 10% murine amino acid 
sequences. The murine sequences are the complementarity-determining 
regions to CD25 and are fused with human constant and variable regions of the 
IgG molecule. Basiliximab was approved by the FDA in May 1998 for the 
prevention of kidney allograft rejection in patients receiving concomitant 
cyclosporine and steroids. Basiliximab is a monoclonal antibody produced by 
chimerization of a CD25-specific murine antibody with the constant regions of 
human IgG1 heavy chain and kappa light chain. This chimerized monoclonal 
antibody is obtained from a mouse myeloma cell line that has been engineered 
to express plasmids that contain the human heavy chain- and light chain-
constant regions and mouse heavy chain- and light chain-variable regions.  
Pharmacokinetics of tacrolimus 
Oral tacrolimus, in a solid dispersible formulation developed for clinical use, is 
rapidly absorbed throughout the whole gut. However, the absorption shows a 
large inter- and intra-individual variability. The oral bioavailability is roughly 25 
percent mainly as a result of extensive metabolism by enzymes in the bowel 
mucosa (Figure 1.2). The mean tacrolimus exposure after a single 5 mg oral 
dose in healthy Latin American and African American subjects was 18 and 39 
percent less, respectively, than in Caucasians41, suggesting a racial difference 
in pharmacokinetics of tacrolimus. The total drug exposure throughout the 
period from one dose until the next is the area under the concentration-time 
curve (AUC). Time to reach plasma peak concentrations (Cmax) usually occur 
within two hours. However, tacrolimus absorption is decreased if administered 
immediately after a standard American breakfast rich in fat content42 . After 
ingestion of tacrolimus 0.25 to 1.5 hours after such meal, Cmax decreased by 
50-75% and the AUC decreased by 25-40% relative to fasting condition. 
Therefore, in order to maximize absorption, all patients were advised not to eat 
or drink anything from two hours before until one hour after ingestion of 
tacrolimus. However, in another study by Christiaans et al., there was only 
Thesis_Cheung_v2.pdf
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minor difference in tacrolimus AUC, no matter whether the drug is taken fasting 
or together with a standardized continental breakfast43. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Pharmacokinetics of tacrolimus after absorption. 
 
 
Tacrolimus is lipophilic and can undergo extensive body distribution. In the 
blood, most of the absorbed drug is taken up by erythrocytes. In the plasma, it 
binds to proteins. Tacrolimus accumulates mainly in lung, spleen, heart, kidney, 
and pancreas. 
Tacrolimus is extensively metabolized by the cytochrome P450 3A in the liver 
(>99%). There is also some metabolism in the gut mucosa via intestinal 
cytochrome P450. Tacrolimus is metabolized to at least 15 metabolites, the 
predominant being 13-O-demethyl-tacrolimus. 13-O-demethyl-tacrolimus has 
an immunosuppressive activity which is one-tenth of that of the parent 
compound. The minor metabolite 31-O-demethyl-tacrolimus may possess 
equal immunosuppressive potency to the parent drug44-46. 
Tacrolimus metabolites are mainly (>90%) biliary eliminated with around 5% 
being excreted in the urine. The elimination half-life is nine hours but liver 
dysfunction can prolong its half-life47-50. Drug levels then fall until they are at the 
lowest, or trough, level (C0) immediately before the next dose.  
Drug interactions  
Since tacrolimus is metabolized by hepatic cytochrome P450 3A isoenzymes, a 
variety of important drug interactions with drugs that either affect or are 
metabolized by these enzymes can occur.46 Table 1.3 shows inhibitors and 
Absorption process
To faeces 15%
CYP3A4
Metabolism 50%
CYP3A4
First pass metabolism 10%
25% to blood
Gut lumen
Gut wall
Portal vein
Liver
Available dose
Eliminated dose
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inducers of cytochrome P450 3A that have been reported to interact with 
tacrolimus metabolism. 
 
Table 1.3 Potential inhibitors and inducers of cytochrome P450 3A isoenzymes which can 
interfere tacrolimus metabolism. 
CYP3A inhibitors Increase tacrolimus levels 
     Bromocriptine 
     Cimetidine 
     Ciprofloxacin 
     Cisapride 
     Clarithromycin 
     Clotrimazole 
     Danazol 
     Diltiazem 
     Erythromycin 
     Fluconazole 
     Gestodene 
     Itraconazole 
     Ketoconazole 
     Metoclopramide 
     Grapefruit juice 
     Nicardipine 
     Nifedipine 
     Protease inhibitors 
     Troleandromycin 
     Verapamil 
CYP3A inducers Decrease tacrolimus level   
     Barbiturates 
     Carbamazepine 
     Phenobarbital 
     Phenytoin 
     Rifabutin 
     Rifampicin 
     St John’s wort 
 
Therapeutic drug monitoring  
The main concern regarding the immunosuppressive drugs is their narrow 
therapeutic indices. Subtherapeutic blood concentrations are associated with 
an increased risk of acute rejection while overdosing may increase the risk of 
over-immunosuppression, with subsequent increased risk of infection and 
malignancies. Additionally there are also numerous drug-specific adverse 
effects. The large inter-patient variability in oral bioavailability of tacrolimus and 
cyclosporine, the narrow therapeutic window, and drug interaction mean that 
the dosage needs to be individualized. As a result, therapeutic drug monitoring 
(TDM) is essential for dosage guiding. The most exact way to monitor drug 
exposure is by making pharmacokinetic profiles: from immediately before one 
drug dose is ingested until immediately before the next drug dose is ingested, 
drug levels are measured at several time points (e.g. 10-12 times). From the 
curve thus obtained, the total drug exposure (AUC0-12), C0, Cmax, the time when 
the maximum concentration is reached (tmax), and the half life (t1/2) can be 
calculated (Figure 1.3). Because obtaining complete pharmacokinetic profiles 
for every patient is not feasible in clinical practice, a parameter strongly 
correlating with AUC0-12 was sought.  
Many centres rely on measurements of tacrolimus C0 because it is generally 
thought that they can reflect AUC0-12 51. Indeed there are different 
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pharmacokinetics studies showing good correlation between C0 and 
AUC0-12 52-55. In the US and European trials, whole blood tacrolimus and 
cyclosporine trough levels were used for drug monitoring and dosage 
adjustment56-59. However, there have been different studies yielding different 
results. In a pharmacokinetic study reported by our group60, it was found that 
C0 did not have a significant correlation with AUC0-12  in Chinese renal 
transplant recipients (R2=0.12; P=0.17). On the other hand, abbreviated AUC 
obtained by two-time point regression equation using 2-hour (C2) and 4-hour 
(C4) tacrolimus concentrations obtained an R2 of 0.93. In a study of 40 liver 
transplant patients, Macchi-Andanson et al.61 investigated the ability of 
Bayesian fitting procedures to predict C0 concentrations. They found that C0 
provided the least information about the dynamic behaviour of the drug in the 
patient and they suggested two samples a day could provide increased 
information about drug absorption, distribution and elimination. It was agreed 
by Stolk et al.62 who studied eight stable renal transplant patients for the 
prediction of AUC0-12. By using multiple stepwise regression analysis, they 
found that the predictive power of C5 and C2 (R2=0.983) were much higher than 
C0 (R2=0.642). Recently, Scholten et al. reported that the 95% prediction 
interval was reduced by 50%, when a two-point sampling strategy was used 
consisting of a C0 level and a second sample obtained between 2-4 hours post 
dose63. As a result, limited sampling strategy and abbreviated AUC method 
was used for dose optimization in our centre.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Pharmacokinetic profile of tacrolimus: AUC as parameter for total drug exposure, and 
the main pharmacokinetic description parameters. 
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Cyclosporine C0 is also not a sensitive indicator of total drug exposure and 
subsequent clinical events64. As a result, the optimal way for cyclosporine 
monitoring has been reviewed in recent years. Investigators have advocated 
using time point sampling to estimate AUC0-12 65. Each clinician has a choice of 
several equations, involving the use of two or three time-points, which produce 
results with similar accuracy and precision66,67. Meier-Kriesche et al. found that 
limited sampling strategies using a 1.5-hour sample may predict AUC0-12 more 
accurately than those using a 2-hour sample67. In Hong Kong, we used the 
two-time point regression equation obtained from the Chinese population to 
estimate the AUC0-12 68. 
Pharmacogenetics and renal transplantation  
At present, TDM is used to address the issue of inter-individual variation in 
pharmacokinetics of CNIs. However, many patients experience a significant 
delay in achieving target blood concentrations, significantly increasing the risk 
of acute graft rejection69. The narrow therapeutic index of these agents 
prevents use of a strategy based on a higher initial dose for all patients. There 
is a clear unmet need for a strategy to allow individualized immunosuppressive 
drug dosing in the period immediately following transplantation.  
Prior knowledge of genetic polymorphisms, combined with critical patient data 
and concomitant medications may aid initial dosing, allowing early attainment 
of therapeutic blood concentrations, potentially reducing adverse events related 
to over- or underdosing. In the general population, it is estimated that genetics 
accounts for 20% to 95% of the variability in drug disposition and effects70. 
Other non-genetic factors, such as organ function, drug interactions, and the 
nature of the disease will also influence the effects of medication. The recent 
identification of genetic polymorphisms in drug-metabolizing enzymes and drug 
transporters led to the hypothesis that genetic factors may be implicated in the 
inter-individual variability of the pharmacokinetic or pharmacodynamic 
characteristics of immunosuppressive drugs, major side effects, and 
immunologic risks. The promising role of pharmacogenetics and pharma-
cogenomics in the effort to elucidate the inherited basis of differences between 
individual responses to drugs lies in the potential ability to identify the right drug 
and dose for each patient. By definition, pharmacogenetics deals with the role 
of few candidate genes, whereas pharmacogenomics uses a genome-wide 
approach for polymorphisms determination. After administration, the drug is 
absorbed and distributed to its site of action, where it interacts with targets 
such as receptors and enzymes, undergoes metabolism, and is then excreted. 
Each of these processes might involve clinically significant genetic variations.  
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Most of the pharmacogenetic traits first identified were discovered by 
phenotypic analysis detecting a bi- or trimodality of an enzymatic activity71. 
Azathioprine, metabolized in part by S-methylation catalyzed by the enzyme 
thiopurine methyltransferase (TPMT), is an example. Large inter-individual 
differences were reported in TPMT activity, which was found to be inherited in 
an autosomal codominant fashion72. When individuals with low or undetectable 
TPMT activity received standard doses of azathioprine, they had elevated 
concentrations of the active metabolites 6-thioguanine nucleotides and drug-
induced myelosuppression. On the other hand, azathioprine efficacy will be 
reduced in patients with very high levels of TPMT activity which can be 
attributed to its rapid metabolization73,74. TPMT activity correlates with both 
short- and long-term results after renal transplantation75. Subsequently, these 
variations in TPMT activity were attributed to genetic polymorphisms within the 
TPMT gene. TPMT*3A, the most common variant allele responsible for low 
TPMT activity in whites, encodes a protein with two single nucleotide 
polymorphisms (SNP), G460A in exon 7 and A719G in exon 10, leading to 
modifications in the amino acid sequence. The phenotypic test for TPMT 
activity determination in red blood cells and, subsequently, DNA-based tests, 
were among the first pharmacogenetic tests to be used in clinical practice. 
Cytochrome P450 (CYP) proteins can be classified into families and 
subfamilies on the basis of amino acid sequence similarities. Members of the 
CYP3A subfamily are implicated in the metabolism of structurally diverse 
endobiotics, drugs, and protoxic or procarcinogenic molecules. Substantial 
inter-individual differences in CYP3A expression contribute greatly to variations 
in the oral bioavailability and systemic clearance of CYP3A substrates76. 
Human CYP3A activities reflect the heterogeneous expression of at least three 
CYP3A members, CYP3A4, CYP3A5, and CYP3A7, which are adjacent to 
each other on chromosome band 7q21. CYP3A7 is normally only expressed in 
fetal liver. CYP3A4 and CYP3A5 have been identified as the major enzymes 
responsible for the disposition of tacrolimus77. Although a number of CYP3A4 
polymorphisms have been identified, they are rare and do not contribute 
significantly to CYP3A4 expression variability. On the other hand, analysis 
revealed that only individuals with at least one CYP3A5*1 allele (A at position 
6986) produce high levels of full-length CYP3A5 mRNA and express CYP3A5, 
which then accounts for at least 50% of the total CYP3A content78. Those with 
the CYP3A5*3 allele (G at position 6986) display sequence variability in 
intron 3 that creates a cryptic splice site and encodes an aberrantly spliced 
mRNA with a premature stop codon, leading to the absence of protein 
expression.  
Tacrolimus is also a substrate of P-gp which is encoded by the human ABCB1 
gene (also called multidrug resistance-1 [MDR1]). One of the main functions of 
P-gp is to ensure the energy-dependent cellular efflux of substrates. The P-gp 
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expression in the intestinal wall and in the proximal tubular cells of the kidneys 
suggests that it may have a role in the absorption and excretion of xenobiotics. 
In the gut, alteration in its expression, function, or both raises the absorption of 
its substrates79. Various SNP have been identified within the ABCB1 gene over 
the recent few years80. An SNP, located in exon 26 (exon 26 3435C>T), was 
associated with variations in the intestinal expression and function of P-gp. 
However, this SNP is a silent polymorphism that does not result in any amino 
acid changes. It was suggested that it may be in linkage disequilibrium with 
other functional polymorphisms within the ABCB1 gene. A co-segregation of 
exon 26 3435T with the T allele of the non-synonymous exon 21 SNP (exon 21 
2677G>T), resulting in an A893S amino acid change, and also with the T allele 
of the synonymous exon 12 SNP (exon 12 1236C>T) was reported. This 
disequilibrium led to haplotype analysis of the ABCB1 gene, to identify the links 
between the genomic variations represented by each haplotype on ABCB1 
function, because this approach takes into account the combination of SNP 
present in an allele80 and might be more predictive of changes in response to 
drugs than SNP-based approaches.  
Application of dried blood spot in renal transplantation 
Dried blood spot (DBS) is very common for screening metabolic disorders in 
newborns81. Moreover, its use in TDM has been reported for several drugs 
such as antimalarials and antiretrovirals82,83. There are several possible 
advantages of DBS over venous sampling. First of all, blood sampling in 
centers may involve a long journey and absence from work duty. DBS can be 
performed easily at home by patients and the sampling papers containing the 
DBS can be mailed back to centers using envelopes. Moreover, use of DBS 
can relieve the burden of blood sampling of clinical staff. Use of DBS in 
cyclosporine monitoring in solid organ transplantation has been explored84-87. 
Recently, a method for measurement of tacrolimus level, based on DBS and 
high-performance liquid chromatography tandem-mass spectrometry 
(HPLC-MS), has been developed88,89. 
Most of the published studies correlate the clinical outcomes with tacrolimus 
level using immunoassay-based methods. It should be realized that these 
methods measure both the parent drug and several of its metabolites. Enzyme-
linked immunosorbent assay (ELISA), though reliable in routine use, is very 
time-consuming, and the results are not available for at least 24 hours. Two 
other methods are more suitable for routine quantification of tacrolimus in 
whole blood. The first is the manual immunoassay Incstar Proc-Trac (Diasorin 
Inc, Italy), modified in 1996 (Incstar Proc-Trac II, Diasorin Inc), with an analyzer 
time of 3-4 hours. The very high sensitivity (0.5 ng/ml) makes it useful in 
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special cases90. The second method is a semiautomatic, microparticulate 
enzyme immunoassay (MEIA, Abbott, USA). The initial version had a detection 
limit of 5 ng/ml, thus lacking the sensitivity required for monitoring patients 
maintained on low levels of tacrolimus. In 1997, the second generation assay 
(TAC II, IMx analyzer, Abbott), with a sensitivity of 1.5 ng/ml, became available. 
With this method, results can be obtained in less than an hour90. This is the 
assay commonly used for testing large patient populations and used in 
hospitals for clinical practice. Nowadays HPLC-MS is the most accurate, 
sensitive and specific assay for TDM of tacrolimus, with a detection limit of 
0.2 ng/ml. It can separately quantify the parent compound and its metabolites90. 
Clinical outcome studies revealed that tacrolimus monitoring with HPLC-MS is 
safe and effective91,92. 
Preservation of renal function 
The most important immunological reason for graft failure in the initial period 
after transplantation is acute rejection. Acute rejections are confirmed by 
performing renal biopsy. In the last decennium, consensus was reached to 
grade the severity of a rejection on histological grounds93. The most important 
risk factors for acute rejections are mismatches in the human leukocyte antigen 
(HLA) system, especially HLA-DR mismatches94-96. Blacks and young age are 
also associated with increased risk of rejection95,97-101. Sensitized patients with 
antibodies to HLA antigens, as reflected in the percentage of panel-reactive 
antibodies (PRA), also have an enhanced risk of rejection95,102-104. Patients may 
become sensitized by previous blood transfusions, pregnancies, or organ 
transplantations. 
After the initial six months, a major cause of graft dysfunction is chronic 
allograft nephropathy (CAN). CAN is characterized by a gradual decrease in 
transplant function and development of hypertension and proteinuria105,106. The 
current criteria for CAN are given by the Banff Working Classification of Renal 
Allograft Pathology, which originated in a meeting held in Banff, Canada in 
1991 107 The Banff 97 working classification of renal allograft pathology is 
followed worldwide93. Histology shows vasculopathy: initimal thickening, 
smooth muscle cell proliferation, and multi-layering of peri-tubular capillary 
basement membranes, glomerulopathy, tubular atrophy (TA), and interstitial 
fibrosis (IF)108. Renal function and proteinuria one year after transplantation are 
important surrogate markers for the development of CAN and graft 
survival109-113. In the last decennium, it became clear that several factors, 
including immunologic and non-immunologic factors are involved in the 
development of CAN (Figure 1.4)114. Acute rejections, especially recurrent 
acute rejections115 and vascular rejections116, are known risk factors for CAN. 
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Moreover, donor and transplant characteristics predispose to CAN. Graft 
survival is related to the number of nephrons transplanted117,118. Thus kidneys 
from marginal donors usually perform less well than kidneys from optimal 
donors.119,120 Ischemia-reperfusion damage is also reflected in graft survival. 
The longer the period of ischemia, the worse the graft survival will be119,121,122. 
Hyperfiltration, relative overflow in remaining nephrons, is an important factor in 
the development of CAN111. Cardiovascular risk factors such as 
hypertension123,124, hyperlipidemia125-127 and diabetes mellitus119,128 all 
contribute to the development of CAN. Finally nephrotoxicity by both CNIs, 
cyclosporine and tacrolimus, contribute to CAN as well.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Risk factors for the development of chronic allograft nephropathy. 
 
 
Both CNIs differ considerably in nephrotoxicity (Table 1.4). In healthy 
volunteers, glomerular filtration rate, renal plasma flow and renal blood flow 
were decreased while renal vascular resistance, blood pressure and serum 
creatinine were increased significantly during Neoral cyclosporine treatment. 
On the other hand, all these parameters remained unchanged while using 
tacrolimus129. In renal transplant recipients, the effects of tacrolimus and Neoral 
cyclosporine on renal hemodynamics were different. After a dose of Neoral 
cyclosporine, but not after tacrolimus, a phasic hypoperfusion of variable 
severity within small-to-medium-sized intrarenal arteries was induced soon 
after dosing130. Therefore renal function is expected to be better with 
Chronic allograft nephropathy
Donor size
Donor gender
Donor age
Marginal donor
Ischemia-reperfusion
Brain death
Preservation
Hyperfiltration
Obesity
Hypertension
Hyperlipidemia
Diabetes/PTDM
CNI-toxicity
Other nehrotoxic drugs
HLA-matching
Sensitization
Race
Gender
Age
Cellular
Humoral
Non-compliance
Suboptimal immunosuppression
Delayed graft
function
CAN
Acute rejection Chronic rejection
Early phase Late phase
Thesis_Cheung_v2.pdf
22⏐Chapter 1 
tacrolimus-based therapy. This difference in functional nephrotoxicity might 
contribute to structural lesions found in chronic CNI nephrotoxicity129. Van 
Duijnhoven et al. analyzed uncomplicated transplantations from living donors 
and showed that the creatinine clearance achieved at one year post-
transplantation in tacrolimus-treated recipients was comparable to the 
remaining creatinine clearance of the donors131. Moreover, in a randomized 
trial comparing tacrolimus and mycophenolate mofetil (MMF) versus rapamycin 
and MMF, there was no difference in GFR between tacrolimus-based and CNI-
free arms up to two years post-transplantation132. 
The difference in nephrotoxic properties of both CNIs was also shown in 
conversion studies. Patients with chronic transplant dysfunction had improved 
creatinine after conversion from Neoral cyclosporine to tacrolimus133-137. 
Moreover, some case reports also showed disappearance of nephrotoxicity in 
histology after conversion138. Jurewicz observed a better GFR from three 
months up to five years post-transplantation in the tacrolimus-treated patients 
compared to the Neoral cyclosporine-treated patients. He also showed that the 
slope of the GFR in Neoral cyclosporine-treated patients significantly declined 
in contrast to the tacrolimus-treated patients139. 
 
Table 1.4 Evidence that tacrolimus has a low nephrotoxic potential. 
Evidence Reference 
No effect on renal hemodynamics in healthy volunteers Klein129 
Hypoperfusion within small to medium-sized intrarenal arteries in renal grafts 
shortly after cyclosporine microemulsion but absent in tacrolimus  
Nankivell130 
Comparable creatinine clearance between recipient and living donor after one 
year 
Duijnhoven131 
Stable creatinine clearance after first year post-transplantation Jurewicz139 
Improvement in renal function by conversion from cyclosporine to tacrolimus Artz133 
Rescue of cyclosporine toxicity or CAN by conversion to tacrolimus Cantarovitch134 
Margreiter135  
Hohage136 Meier137 
Tacrolimus+MMF+prednisolone produces similar GFR compared with CNI-free 
regimen using sirolimus+MMF+prednisolone 
Larson132 
Post-transplant diabetes mellitus 
In the first year after transplantation, abnormal glucose metabolism, especially 
transient hyperglycemia, occur frequently. However, there was a lack of 
uniform definition. Depending on the definition, incidences of post-transplant 
diabetes mellitus (PTDM) of approximately 5-40% have been reported in 
patients after renal transplantation140-142. Some investigators only include those 
patients using insulin treatment for a period of at least 30 days56, while others 
also include patients taking oral glucose-lowering drugs (need for drug 
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treatment). These definitions underreport the actual incidence of PTDM. 
Diagnosis should be made on the World Health Organization (WHO) or the 
American Diabetes Association (ADA) criteria in the maintenance phase 
without infection or rejection, and with stable defined dosages and levels of 
immunosuppressive agents. 
Several risk factors for the occurrence of PTDM have been described. These 
include genetic factors, race, family history of diabetes, older age, high body 
mass index, hepatitis C virus positivity, and the use of CNIs and 
corticosteroids56,57,142-145. In fact, PTDM is not a separate entity but just a sign 
of an underlying abnormal glucose metabolism that is uncovered by 
immunosuppression. Abnormal glucose metabolism is common in pre-
transplant patients. Only by using CNIs in combination with corticosteroids will 
more patients develop PTDM than with other agents in combination with 
steroids146. 
Steroids disturb glucose tolerance by enhancing insulin resistance147. They 
play a significant role in the development of PTDM148,149. Ten milligram of 
prednisolone can result in a 250% increased insulin demand for maintaining 
normoglycemia150. Withdrawal of steroids in cyclosporine-treated patients has 
been shown to reduce the incidence of PTDM and to improve glycemic 
control151. Cyclosporine also has an effect on glucose metabolism. Renal 
transplant patients using cyclosporine and corticosteroids were seen to have a 
higher incidence of PTDM than patients treated with azathioprine and even 
higher dosages of steroids152. Reducing the dose of cyclosporine reversed the 
diabetes in the majority of affected patients152. Glucose tolerance also 
improved after conversion from cyclosporine to azathioprine153. In vitro 
experiments have shown that cyclosporine dose-dependently inhibited insulin 
secretion154,155. High-dose tacrolimus was shown to decrease insulin mRNA 
transcription and reduce insulin production in rats. When tacrolimus was 
stopped after two weeks, insulin production returned to normal. There are high 
levels of FKBP-52 in pancreatic beta-cells, which might account for the peculiar 
sensitivity of these cells to tacrolimus156. A study by van Duijnhoven et al. also 
showed that tacrolimus affects insulin release but does not affect insulin 
resistance157. Cyclosporine and tacrolimus can both induce glucose 
intolerance, although the risk of developing PTDM appears to be higher in 
patients using tacrolimus, especially when combined with corticosteroids158. 
Low incidence of PTDM has been reported in tacrolimus-based regimens 
without corticosteroids137,159. 
PTDM has been associated with a decreased quality of life and substantial 
morbidity resulting from an increased susceptibility to infections and most 
importantly, cardiovascular complications. Development of PTDM or impaired 
fasting glucose (IGF) after renal transplantation increases the risk of cardiac 
events, peripheral vascular disease, graft failure and death128,160,161. PTDM is 
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associated with more than 60% increase in risk of graft failure and an almost a 
90% increase in risk of death160. Less severe hyperglycemic abnormalities are 
also associated with increased cardiovascular risk. In renal transplant 
recipients, Cosio et al. have demonstrated that IFG (5.6-6.9 mmol/l) is 
associated with a significantly higher incidence of cardiac events and 
peripheral vascular disease compared to normoglycemic recipients162. In view 
of the high incidence of cardiovascular mortality and morbidity among renal 
transplant recipients, aggressive management of glucose metabolism 
abnormalities is essential. 
Metabolic syndrome 
Metabolic syndrome (MS) is a topic of considerable interest nowadays. It has 
been argued that the spectacular continuous increase in life expectancy and 
general health during the last decades may come to a halt or even be reversed 
by the ongoing epidemic of obesity163. MS is a cluster of interrelated common 
clinical disorders, including obesity, insulin resistance, glucose intolerance, 
hypertension and dyslipidemia. Obesity is considered the phenotypic hallmark 
of MS that contributes to insulin resistance, hyperinsulinemia, and dyslipidemia. 
Among the numerous definitions of MS (World Health Organization, European 
Group for the Study of Insulin Resistance, American Association of Clinical 
Endocrinologists, and International Diabetes Federation [IDF]), the one 
proposed by the National Cholesterol Education Program (NCEP) Expert Panel 
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III [NCEP-ATPIII])164 is most widely used. In this thesis, 
both NCEP-ATPIII and IDF were used (Table 1.5). The concept of MS was 
originally created to predict cardiovascular risk. It has been well recognized that 
MS is closely associated with atherosclerotic cardiovascular disease in the 
general population165. Given the link between cardiovascular and renal risks, it 
is not surprising that obesity and MS are related to renal malfunction166-169. A 
community-based population study demonstrated that established 
cardiovascular disease risk factors are associated with the development of 
new-onset kidney disease170. The reason why obesity increases the risk for 
end stage renal failure in the general population is the link between obesity and 
diabetes on one hand and with hypertension on the other hand171. Even when 
corrected for these two indirect mechanisms, the relation between obesity and 
chronic kidney disease persists172. The proposed mechanisms include 
increased glomerular filtration rate and renal blood flow, glomerulomegaly, 
podocyte damage, and even focal segmental glomerulosclerosis173-175. The 
increased risk of mortality and morbidity related to MS and its components 
occur not only in Caucasian, but also extend to Chinese population176. 
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Table 1.5 Definition of metabolic syndrome according to NCEP-ATIII and IDF criteria164,185. 
Risk factors 
1. Serum triglyceride level ≥1.69mmol/L (≥150 mg/dl) or specific treatment for this lipid 
abnormality,  
2. Serum high density lipoprotein (HDL)-cholesterol level <1.04 mmol/l (<40 mg/dl) in men or 
<1.29 mmol/l (<50 mg/dl) in women or specific treatment for this lipid abnormality,  
3. Systolic blood pressure (SBP) ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg (high 
blood pressure) or use of antihypertensive medication,  
4. Fasting plasma glucose level ≥100 mg/dl (≥5.6 mmol/l) or use of antidiabetic medication,  
5. Waist girth >102 cm for men or >88 cm for women (original NCEP-ATPIII criteria) and waist 
girth ≥90 cm for men or ≥80 cm for women (modified NCEP-ATPIII criteria for Asians).  
NCEP-ATPIII criteria: three or more of the risk factors  
IDF criteria: Subjects who had central obesity (defined as waist circumference ≥90 cm for men 
or ≥80 cm for women in Chinese) plus two or more risk factors 
 
 
Recently it has been found that MS is also common in renal transplant 
recipients177. As in the general population, MS is associated with an increased 
risk of renal dysfunction and cardiovascular mortality in renal transplant 
recipients177-179. A number of factors, other than obesity, may contribute both to 
insulin resistance and modification of MS parameters in these patients. In early 
post-transplant period, use of high dose corticosteroids, together with CNIs are 
likely to play a major role in the development of MS180. By steroid-free 
transplantation, both the insulin resistance and chance of obesity might 
decrease, thereby reducing the incidence of MS. Previous studies showed that 
HDL cholesterol and diabetes were strong independent risk factors for 
atherosclerotic events after transplantation181,182. Factors contributing to MS are 
closely interconnected and define a very high-risk population for atherosclerotic 
events. MS is also associated with other cardiovascular risk factors such as 
low-grade inflammation, higher urine protein excretion, and progressive loss of 
renal function183,184. All together, clustering of both traditional and non-
traditional risk factors in renal transplant recipients with MS contribute to the 
greater incidence of atherosclerotic events in this population.   
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Aim of the thesis 
The purpose of this thesis is to study the following 
Preservation of long-term renal graft function 
1. Whether there is any difference in maintaining renal graft function between 
tacrolimus- and Neoral cyclosporine-based immunosuppressive therapy in 
renal transplant recipients using paired kidney analysis. (Chapter 2) 
2. Whether addition of IL-2 receptor antagonist can further improve acute 
rejection and renal function in tacrolimus-based primary Chinese renal 
transplant recipients. (Chapter 3) 
3. Use of tacrolimus and other risk factors associated with the development of 
glucose metabolism abnormalities in Chinese renal transplant recipients 
using ADA criteria. (Chapter 4) 
4. Prevalence of metabolic syndrome in Chinese renal transplant recipients 
using NCEP-ATIII and IDF criteria. (Chapter 5) 
Therapeutic drug monitoring and pharmacogenetics in renal 
transplantation 
1. Influence of CYP 3A and ABCB1 gene polymorphisms in tacrolimus 
pharmacokinetics in Chinese renal transplant recipients. (Chapter 6) 
2. Influence of CYP3A and ABCB1 gene polymorphisms in tacrolimus 
pharmacokinetics in early and late post renal transplant Caucasian patients. 
(Chapter 7) 
3. Use of DBS and HPLC-MS in tacrolimus monitoring in renal transplant 
recipients. (Chapter 8) 
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Few studies used paired kidneys for comparison between tacrolimus and cyclosporine 
in renal transplantation. Most of the published data used whole blood trough levels for 
drug monitoring. However, use of limited sampling strategy and abbreviated formula to 
estimate the 12-hour area under concentration-time curve (AUC0-12) allowed better 
prediction of drug exposure. Sixty-six first cadaveric renal transplant recipients receiving 
paired kidneys were randomized to receive either tacrolimus-based (n=33) or 
cyclosporine microemulsion (Neoral)-based therapies (n=33). Abbreviated AUC0-12 was 
used for drug monitoring and dose titration.  Mean  follow-up duration was 2.8 +/- 2 
years. The patient and graft survival were comparable. Fewer incidence of acute 
rejection was observed in tacrolimus group (15% vs. 27.3%) though the difference was 
not significant (P=0.23). The absolute value and the rate of decline of creatinine 
clearance were both significantly better in tacrolimus-treated patients. Prevalence of 
hypertension, post-transplant diabetes mellitus, infection and malignancy were similar in 
both groups. Prevalence of hypercholesterolemia (11/33 vs. 4/33) and gum hypertrophy 
(6/33 vs 1/33) were more common in cyclosporine-treated patients (P=0.04 in both 
parameters). This was the first prospective, randomized study with paired kidney 
analysis showing the renal function was significantly better in tacrolimus-treated patients 
than in cyclosporine-treated patients. 
Abstract 
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Introduction 
One of the most important developments in renal transplantation in recent 
years was the introduction of new immunosuppressive agents for the 
prevention of acute rejection. Until the 1980s, corticosteroids and azathioprine 
were the main immunosuppressive agents. Cyclosporine was introduced in 
renal transplantation in the 1984 1. The major advantages included reduction in 
the incidence of acute rejection and improvement in 1-year graft survival2-4.   
Since 1995, cyclosporine/Sandimmune (Sandoz, Switzerland) was gradually 
replaced by cyclosporine/Neoral (Novartis, Switzerland), a microemulsion 
formula with a bile-independent and consistent absorption profile which led to 
lower intra-patient variability than Sandimmune5. In controlled trials, Neoral had 
proven to be superior to Sandimmune in the prevention of acute rejection6-8. 
After 1995, tacrolimus (FK 506) (Prograf, Fujisawa, Japan), another calcineurin 
inhibitor, was employed by many centers as an alternative therapy to Neoral. 
Acute allograft rejection was significantly reduced with tacrolimus-based 
therapy compared with cyclosporine-based therapy in different large-center 
randomized trials and meta-analysis9-14. It had been argued that this superior 
effect of tacrolimus over cyclosporine might not be observed with the improved 
microemulsion formulation of cyclosporine. In this regard, randomized trials had 
been performed to compare tacrolimus and Neoral cyclosporine15-22. The 
superior results of tacrolimus-based therapy persisted even after changing to 
Neoral cyclosporine which had a more consistent absorption. The better short-
term results had translated into improved long-term outcome. Long-term follow 
up results from the two multicenter trials revealed a more stable renal function 
and longer projected half-life in those patients receiving tacrolimus-based 
therapy compared to cyclosporine-based therapy23,24. Use of tacrolimus 
resulted in advantages in cardiovascular risk profile in terms of reduction in the 
prevalence of hypertension and hyperlipidemia9,11,12,17,18,25. Although 
tacrolimus-therapy was associated with an increased incidence of post-
transplant diabetes mellitus9,10,14, most of them were reversible and dose 
dependent14,23. 
Despite of the available information, there were few published comparative 
data on paired kidney analysis. Moreover, majority of the published data used 
whole blood trough level for dose monitoring and titration of tacrolimus and 
cyclosporine therapies. It had been shown that the trough level had a poor 
correlation with AUC0-12 26-31. Our group favoured the use of limited sampling 
strategy and abbreviated formula to estimate the AUC0-12 which allowed better 
prediction of drug exposure26. 
This was the first open-label controlled randomized trial with paired kidney 
analysis to compare the efficacy and safety of tacrolimus with Neoral 
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cyclosporine-based immunosuppressive therapy in first cadaveric renal 
transplant recipients using estimated AUC0-12 approach for dose titration. 
Materials and methods 
Trial design 
This was a prospective, open-label, randomized, parallel group study. All 
Chinese patients receiving paired kidneys in their first cadaveric renal 
transplants consecutively between 1st June 1998 and 31st December 2004 in 
Queen Elizabeth Hospital, Hong Kong were included in the study. Follow-up 
outcome data were collected until 31st March 2005. 
The study was performed in accordance with Declaration of Helsinki. Informed 
and written consent were obtained and the patients were randomized to 
receive triple immunosuppressive therapy with either tacrolimus or Neoral 
cyclosporine, concomitantly with prednisolone and azathioprine therapy. The 
randomization process occurred pre-operatively and was on 1:1 basis. 
Immunosuppressive regimens 
Neoral cyclosporine was initially administered orally as a loading dose of 
10 mg/kg within 12 hours of surgery and then 5 mg/kg twice daily. Abbreviated 
formula based on limited sampling strategy was used in this study to estimate 
the cyclosporine area under 12-hour concentration- time curve (AUC0-12). 
Calculation of cyclosporine AUC0-12  was based on the formula: 452.4 + C0 * 
17.5 + C1.5 * 1.89 [C0: cyclosporine trough level; C1.5: 1.5-hr post dose 
cyclosporine level]31. The dose of cyclosporine was gradually titrated to 
maintain the abbreviated AUC0-12 at around 6000-8000 ng*hr/ml in the first 3 
months post-transplant and 4000-6000 ng*hr/ml from three months post-
transplant onwards33. Whole blood levels of cyclosporine were monitored by 
Abbott TDX monoclonal specific assay (Abbott Laboratories, Abbott Park, IL, 
USA). 
Tacrolimus was administered orally as capsules with loading dose of 0.3 mg/kg 
within 12 hours of surgery and then 0.15 mg/kg twice daily. Abbreviated 
tacrolimus AUC0-12 monitoring was used. Calculation of tacrolimus AUC0-12 was 
by the formula: 16.2 + C2 * 2.4 + C4 * 5.9 [C2: 2-hr post dose tacrolimus level; 
C4: 4-hr post dose tacrolimus level]. Based on our previous pilot study in stable 
patients on tacrolimus, AUC0-12 value was kept at around 100-150 ng*hr/ml in 
first three months and around 80-100 ng*hr/ml after three months26. Whole 
blood levels of tacrolimus were monitored by means of IMx tacrolimus II assay 
(Abbott Laboratories, Abbott Park, IL, USA). 
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Concomitant immunosuppressive therapy was identical in the two arms of the 
trial. A bolus dose of intravenous methylprednisolone 500 mg was given on 
day 1. This was followed by intravenous hydrocortisone 100 mg every six hours 
for three days and followed by oral prednisolone 30 mg daily. The dose of 
prednisolone was gradually tapered after the first month at a rate of 2.5 mg 
every two weeks and then maintained at 5 mg daily. Azathioprine was given at 
a dose of 1.5 mg /kg daily since day 1. 
Since 1999, some of our patients also received interleukin-2 (IL-2) receptor 
antagonist during induction therapy on a voluntary basis. Patients on Neoral 
cyclosporine was given Basiliximab (Simulect, Novartis, Switzerland) while 
patients on tacrolimus was given Daclizumab (Zenapax, Roche, USA). 
Basiliximab was given at a dose of 20 mg around two hours before 
transplantation and the second dose was given four days after transplantation. 
Daclizumab was given at 1 mg/kg infusion around two hours before 
transplantation and then every 14 days for four more doses.   
If a rejection episode occurred, our protocol prescribed pulse methyl-
prednisolone therapy as first-line treatment with the dosage of 500 mg daily for 
three days. In case of steroid resistant rejection, appropriate antibody therapy 
was started. 
Clinical outcome parameters 
Primary endpoints were patient survival, graft survival and the overall rate of 
acute rejection. Graft loss was defined as the need to resume long term 
dialysis, re-transplantation, transplant nephrectomy or death. Rejection was 
defined as any episode with the relevant clinical and laboratory signs and 
symptoms and all clinically apparent episodes of rejection were confirmed by 
core biopsy. Rejection was classified according to Banff 97 classification34 after 
assessment by local pathologists. 
The secondary endpoints were the course of renal function, the cardiovascular 
risk profile, the incidence of infection and malignancy. Renal function 
parameters were serum creatinine and estimated creatinine clearance (CrCl) 
by means of Cockcroft-Gault formula and expressed in ml/min35. The 
annualized change of CrCl (ml/min per year) was used to monitor the 
progression of renal function decline. Positive value means improvement or 
stabilization of renal function while negative value means decline in CrCl. 
The cardiovascular risk profile was assessed by the incidence of hypertension, 
hypercholesterolemia and diabetes mellitus. Hypercholesterolemia was defined 
as total cholesterol greater than 5.8 mM (224 mg/dl) or requiring lipid-lowering 
agent. The use of drugs for hypertension or hypercholesterolemia was 
established from the medical record. Post-transplant diabetes mellitus was 
defined as fasting blood glucose more than 7 mM (126 mg/dl) on two occasions 
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at any time after transplantation in those patients with no previous history of 
diabetes mellitus. 
Statistical analysis 
The intention-to-treat population was used for analyses of both efficacy and 
safety and included all randomized patients who underwent transplantation and 
received at least one dose of study medication. Values were expressed as 
mean (standard deviation) or median (range). Baseline and demographic data 
were compared by Student’s t test, Pearson’s χ2 test or Fisher’s exact test 
where appropriate. Pearson’s χ2 test or Fisher’s exact test was used to 
compare the rates of adverse events between treatment groups. Kaplan-Meier 
Model and log-rank test were used to compare the patient survival, graft 
survival and rejection-free survival. The annualized change of CrCl for each 
patient was determined using simple linear regression. At least three estimates 
over two consecutive years of follow-up were required to calculate the 
annualized change of CrCl. A P-value of <0.05 was considered to be 
statistically significant. 
Results 
One hundred consecutive Chinese cadaveric renal transplant recipients were 
performed during the study period. Among them, 66 patients received paired 
cadaveric kidneys (for each pair of graft kidneys from the same donor, one was 
transplanted in tacrolimus group and the other transplanted in cyclosporine 
group). The remaining 34 patients received unpaired cadaveric kidneys (when 
only one kidney was available for transplantation because of single kidney 
donation or sharing with other transplant centers). In this study, only those 
paired kidney recipients were analyzed. 
There were 33 patients randomized to each group and the mean follow-up 
duration was 2.8 +/- 2 years. The baseline characteristics were depicted in 
Table 2.1. No statistically significant differences were observed in baseline 
parameters in both groups of patients. There were also no differences between 
those with or without IL-2 receptor antagonists (Table 2.2).  
Patient survival  
Two patients in the tacrolimus group (6.1%) died with a functioning graft during 
the study. One patient died one year after renal transplantation because of 
acute myocardial infarction while the other died of carcinoma of stomach 3.5 
years after kidney transplant. On the other hand, the patient survival in the 
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cyclosporine group was 100% during the study. There was no significant 
difference in patient survival (P=0.16). 
 
Tabel 2.1 Baseline characteristics of the paired kidneys.  
 Tacrolimus 
(n=33) 
Cyclosporine 
(n=33) 
P value 
Age (years) 42.4 +/- 7.5 41.2 +/- 12.6 0.65a 
Male (n (%)) 17 (51.5) 20 (60.6) 0.46b 
HLA-AB (≥2 mismatch)(n(%)) 27 (81.8) 28 (84.8) 0.74b 
HLA-DR (≥1 mismatch)(n(%)) 27 (81.8) 31 (93.9) 0.13b 
    
PRA (%) 22.3 +/- 33.2 19.3 +/- 26.7  0.69a 
    
Donor age (years) 47.4 +/- 13.6 47.4 +/- 13.6 1.00a 
Donor kidney weight (grams) 182.5 +/- 42.7 182.1 +/- 47.6 0.97a 
Cold ischemic time (hours) 10.0 +/- 6.8 7.9 +/- 4.8 0.15a 
Anastomotic time (minutes) 47.2 +/- 9.8 50.9 +/- 16.8 0.28a 
Use of IL-2 receptor antagonist (n (%)) 20 (60.6) 19 (57.6) 0.80b 
Primary cause of renal failure (n (%)) 
   Chronic glomerulonephritis 
   Diabetes mellitus 
   Polycystic kidney disease 
   Others/unknown 
 
20 (60.6) 
3 (9.1) 
2 (6.1) 
 8 (24.2) 
 
20 (60.6) 
2 (6.1) 
0 (0) 
11 (33.3) 
 
1.00b 
1.00b 
0.47b 
0.41b 
Values expressed as mean +/- standard deviation or number (percentage) 
a Student’s t test, b Pearson’s chi squared test 
PRA (panel-reactive antibody) 
 
Tabel 2.2 Baseline characteristics of the patients with or without IL-2 receptor antagonists.  
 Patients with IL-2R 
antagonists (n=39) 
Patients without IL-2R 
antagonists (n=27) 
P value 
Age (years) 40.9 +/- 10.0 43.1 +/- 10.9 0.39a 
HLA-A&-B(≥2 mismatch)(n(%)) 33 (84.6) 22 (81.5) 0.73b 
HLA-DR (≥1 mismatch)(n(%)) 34 (87.1) 24 (88.9) 0.84b 
PRA (%) 17.5 +/- 28.0 25.5 +/- 32.5 0.29a 
Donor age (years) 48.6 +/-18.2 44.6 +/- 10.8 0.39a 
Donor kidney weight (grams) 189.6 +/- 36.1 171.5 +/- 54.2 0.12a 
Cold ischemic time (hours) 9.5 +/- 6.4 8.5 +/- 5.0 0.51a 
Anastomotic time (minutes) 48.2 +/- 8.8 50.0 +/- 18.6 0.62a 
Values expressed as mean +/- standard deviation or number (percentage) 
a Student’s t test, b Pearson’s chi squared test 
PRA (panel-reactive antibody) 
Graft survival 
A total of five patients had graft failure in the first year. Three of them belonged 
to the tacrolimus group while two belonged to cyclosporine group. Early graft 
nephrectomy was done in two patients because of graft vascular thrombosis 
(one in either group), in two patients (one in either group) because of graft 
artery anastomotic leakage and in one patient (tacrolimus group) because of 
Thesis_Cheung_v2.pdf
44⏐Chapter 2 
rupture of graft kidney. The ruptured graft was shown to have Banff type III 
acute rejection on histology. The first-year graft survival rate, not censored for 
death, in the tacrolimus group during the study was 91% while in the 
cyclosporine group, it was 94%. There was also no difference between both 
groups (P=0.25). 
Acute rejection 
A total of 14 patients (five patients in tacrolimus group and nine patients in 
cyclosporine group) were treated for acute rejection. All were confirmed by 
renal biopsy. The histological type of the rejection was depicted in Table 2.3. 
All patients responded to pulse steroid therapy except the patient in the 
tacrolimus group with type III rejection requiring graft nephrectomy for ruptured 
graft kidney while the one in the cyclosporine group with type IIB required 
plasmapheresis. The patient with type III rejection in the cyclosporine group 
responded well with pulse steroid. Fewer acute rejections were observed in the 
tacrolimus group: 15% (5/33) vs. 27.3% (9/33) but the difference was not 
statistically significant (P=0.23). The rejection free survival was similar (P=0.25; 
Figure 2.1). 
 
Tabel 2.3 Types of acute rejection (Banff 97 classification). 
Episodes of acute rejection Tacrolimus (n=5) Cyclosporine (n=9) 
Borderline 0 1 
Type IA 0 3 
Type IB 3 1 
Type II A 1 2 
Type II B 0 1 
Type III 1 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Kaplan-Meier estimates of rejection-free survival. 
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Renal function 
The creatinine clearance (CrCl) was calculated using Cockcroft-Gault formula 
and was shown in Table 2.4 and Figure 2.2. In the first three months, there was 
no significant difference between both groups. However, the creatinine 
clearance was significantly better with tacrolimus therapy than cyclosporine 
therapy from six months onwards. There was no difference in the use of 
angiotensin converting enzyme inhibitors or angiotension II receptor blockers 
between them (2/33 in tacrolimus group vs. 3/33 in cyclosporine group, 
P=0.64). 
 
Table 2.4 Changes of creatinine clearance over time (intention to treat). 
Mean +/- SD CrCl 
(ml/min) 
Tacrolimus 
group 
Number of 
patients 
Cyclosporine 
group 
Number of 
patients 
P value 
  1-month  49 +/- 15 30 42 +/- 18 31 0.143 
  3-month  60 +/- 18 30 51 +/- 18 31 0.072 
  6-month  54 +/- 14 30 46 +/- 16 31 0.043 
12-month  60 +/- 15 30 46 +/- 14 31 0.002 
24-month  61 +/- 16 24 48 +/- 15 26 0.012 
36-month  66 +/- 20 22 50 +/- 14 24 0.033 
48-month  64 +/- 16 15 48 +/- 15 18 0.050 
60-month 79 +/-  7 10 56 +/- 17 13 0.012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Changes of creatinine clearance over time. 
 
 
If we excluded those with acute clinical rejection and compared the paired 
kidneys again, the creatinine clearance was still significantly better with 
tacrolimus therapy than cyclosporine therapy from one year onwards (Table 
2.5). 
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After excluding a pair of primary non functioning kidneys, we compared the 
remaining 32 pairs of kidneys separately. Twenty four patients belonging to 
tacrolimus group had a better creatinine clearance than their counterparts. On 
the other hand, only eight patients belonging to cyclosporine group had a better 
creatinine clearance.   
 
Table 2.5 Changes of creatinine clearance over time after excluding those with acute rejection. 
Mean +/- SD CrCl 
(ml/min) 
Tacrolimus 
group 
Number of 
patients 
Cyclosporine 
group 
Number of 
patients 
P value 
6-month 55 +/- 14 27 45 +/- 18 26 0.176 
12-month 61 +/- 14 26 50 +/- 14 24 0.025 
24-month 61 +/- 16 24 51 +/- 15 24 0.050 
36-month 66 +/- 20 22 50 +/- 14 24 0.033 
48-month 64 +/- 17 15 48 +/- 15 18 0.050 
60-month 79 +/-  7 10 56 +/- 17 13 0.012 
 
Stability of renal function over time 
The annualized change in CrCl in the tacrolimus group was 2.73 +/- 5.14 
ml/min per year while in the cyclosporine group, the annualized change in CrCl 
was -1.13 +/- 4.08 ml/min per year. The difference was statistically significant 
(P<0.01). A total of 80% of tacrolimus-treated patients had improvement in 
CrCl while 20% had a decline. This was significantly better than cyclosporine-
treated patients (42.1% had improvement while 57.9% showed a decline) 
(P=0.02). 
Dose of immunosuppressive agents 
In the tacrolimus group, the starting dose was 0.3 mg/kg/day and gradually 
decreased to 0.07 +/- 0.01 mg/kg/day as the maintenance dose. In the 
cyclosporine group, the starting dose was 10 mg/kg/day and gradually 
decreased to the maintenance dose at 2.86 +/- 0.71 mg/kg/day (Table 2.6).  
 
Table 2.6 Change of dose of immunosuppressive agents over time. 
Mean +/- SD dose of drug Tacrolimus (mg/kg/day) Neoral (mg/kg/day) 
0-day 0.30 10 
2-week 0.21 +/- 0.06 7.20 +/- 1.16 
1-month 0.18 +/- 0.07 5.84 +/- 1.71 
3-month 0.12 +/- 0.06 4.08 +/- 1.20 
6-month 0.09 +/- 0.05 3.61 +/- 0.99 
12-month 0.07 +/- 0.03 3.61 +/- 1.06 
24-month 0.06 +/- 0.02 3.28 +/- 0.78 
36-month 0.06 +/- 0.02 3.18 +/- 0.80 
48-month 0.07 +/- 0.01 3.06 +/- 0.81 
60-month 0.07 +/- 0.01 2.86 +/- 0.71 
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Level of immunosuppressive agents 
For monitoring and dosage adjustment, AUC0-12 levels of tacrolimus and 
cyclosporine were estimated by using abbreviated equations26,32. These were 
shown in Table 2.7. 
 
Table 2.7 Change of AUC of immunosuppressive agents over time. 
Mean +/-SD AUC0-12 (ng*hr/ml ) Tacrolimus Cyclosporine 
2-week 149  +/- 42 9828  +/- 4839 
1-month 143  +/- 53 7573  +/- 1389 
3-month 126  +/- 33 5482  +/- 1661 
6-month 109  +/- 24 4813  +/- 1351 
12-month  98  +/- 25 4007  +/-  948 
24-month  96  +/- 26 3706  +/-  652 
36-month  90  +/- 22  4438  +/- 1028 
48-month  97  +/- 26  4843  +/-  2280 
60-month  98  +/- 10  4951  +/-   308 
Hypercholesterolemia 
Significantly more patients in the cyclosporine group (11/33, 33.3%) suffered 
from hypercholesterolemia when compared with tacrolimus group (4/33, 
12.1%) (P=0.04; Table 2.8). 
 
Table 2.8 Complications in tacrolimus and Neoral cyclosporine group. 
Complications, n (%) Tacrolimus 
(n=33) 
Cyclosporine 
(n=33) 
P value 
Hypertension  27 (81.8%)  25 (75.8%) 0.52 
Hypercholesterolemia  4 (12.1%)  11 (33.3%) 0.04 
Diabetes mellitus  3 (9.1%)  2 (6.1%) 0.64 
Urinary tract infection  10 (30.3%)  8 (24.2%) 0.58 
Opportunistic infection  13 (39.4%)  16 (48.4%) 0.25 
Malignancy  2 (6.1%)  2 (6.1%) 1 
Hypertension 
There was no significant difference between the cyclosporine group (25/33, 
75.8%) and tacrolimus group (27/33, 81.8%) (P=0.52; Table 2.8). Patients in 
the cyclosporine group tended to use more antihypertensive medications 
(2.1 +/- 1.6 in cyclosporine group versus 1.9 +/- 1.3 in tacrolimus group), 
however, it did not reach statistically significant level (P=0.61). 
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Post-transplant diabetes mellitus 
The incidence of post-transplant diabetes mellitus was higher in tacrolimus 
group, but the difference was not statistically significant [9.1% (3/33) in 
tacrolimus group versus 6.1% (2/33) in cyclosporine group, P=0.64; Table 2.8]. 
Of the three patients suffering from post-transplant diabetes mellitus in the 
tacrolimus group, one was able to withdraw all diabetic medications within the 
first year. On the other hand, the two patients in the cyclosporine group 
required diabetic medications during the study period. 
Infection 
The episodes of bacterial urinary tract infection were slightly more common in 
tacrolimus group (10/33 in tacrolimus group versus 8/33 in cyclosporine group). 
However, the difference was not significant (P=0.58; Table 2.8). For 
opportunistic infection, the incidence in both groups was also comparable 
(13/33 in tacrolimus group versus 16/33 in cyclosporine group, P=0.25; Table 
2.8).  
Malignancy 
There were two patients in each group (6.1%) who developed malignancy after 
transplant. In the tacrolimus group, one had carcinoma of stomach while the 
other had carcinoma of thyroid. In the cyclosporine group, one had Kaposi 
sarcoma and the other had hepatocellular carcinoma. No statistical significant 
differences were observed between them (Table 2.8). 
Neurotoxicity 
There were more tremor and numbness in tacrolimus group (21/33 in 
tacrolimus group versus 16/33 in cyclosporine group) but the difference was 
not statistically significant (P=0.21). 
Cosmetic side effects 
Acne and hirsutism were comparable in both groups but the gum hypertrophy 
was more common in cyclosporine group (1/33 in tacrolimus group versus 6/33 
in cyclosporine group, P=0.04). 
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Discussion 
Although there were many studies comparing tacrolimus and cyclosporine 
Sandimmune or Neoral in renal transplant recipients in recent years, most of 
the patients involved were Caucasian. There were very few similar comparative 
studies in Chinese patients. All of the patients in our study were from a 
homogeneous population. They were Chinese patients undergoing first 
cadaveric renal transplantation. To eliminate the confounding factors attributed 
to differences in the donor kidney status, patients recruited in this study 
received paired cadaveric kidneys (one to each group) which allowed better 
comparison between the two groups under similar donor factors. To the best of 
our knowledge, this was the first published single center and randomized trial 
with paired kidney analysis for direct comparison of tacrolimus and 
cyclosporine therapies. Furthermore, all the published data were based on the 
drug trough level for dose titration of both tacrolimus and cyclosporine. To 
improve the accuracy of therapeutic drug monitoring, we employed area under 
the curve (AUC0-12) estimated by limited sampling equations to compare the 
efficacy and safety of tacrolimus and cyclosporine therapies.   
In the U.S. and European trials, whole blood tacrolimus and cyclosporine 
trough levels were used for drug monitoring and dosage adjustment9-12. On the 
other hand, abbreviated AUC method was used for dose optimization in our 
center. Many centers relied on measurements of tacrolimus trough level (C0) 
because it was generally thought that they could reflect AUC0-12 36. However, 
different studies yielded different results recently26,27,37,38. Our group had 
reported a pharmacokinetic study in 18 stable Chinese renal transplant 
recipients26. We found that C0 had a poor correlation with AUC0-12 (R2=0.12). 
On the other hand, abbreviated AUC0-12 obtained by two-time point regression 
equation using 2-hour (C2) and 4-hour (C4) tacrolimus concentrations obtained 
a R2 value of 0.93. In present study, the target abbreviated AUC0-12 for 
tacrolimus was 100 ng*hr/ml after three months. By extrapolation of the 
relationship between C0 and AUC0-12, this corresponded to a C0 of around 
6 ng/ml. This explained the lower tacrolimus dose and lower incidence of post-
transplant diabetes in our center. Moreover, cyclosporine trough level was not 
a reliable indicator of total drug exposure and subsequent clinical events39. As 
a result, investigators had advocated using time point sampling to estimate 
AUC0-12 29-32. In our study, we used the two-time point regression equation 
obtained from the Chinese population to estimate the AUC0-12 32. 
The use of IL-2 receptor antagonists in some of our patients might introduce 
bias to this study. However, we showed that there were no differences in the 
baseline characteristics between those receiving IL-2 receptor antagonists and 
those did not. Moreover, there was also no difference in the percentage of 
patients on IL-2 receptor antagonists in both treatment groups. Although two 
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different preparations of IL-2 receptor antagonists were used, there were no 
controlled studies showing any differences between basiliximab and 
daclizumab in terms of prevention of acute rejection, incidence of infections 
and malignancies40. We could say that use of IL-2 receptor antagonists were 
identical in both arms. 
Both tacrolimus and cyclosporine were nephrotoxic drugs41. Many studies 
showed that the renal function was comparable between tacrolimus and 
cyclosporine after transplantation9-11,15,16,18,21. In a study using paired kidney 
analysis42, serum creatinine was significant lower in tacrolimus group. 
However, the slope of 1/Cr did not appear to be different between the two 
agents. In present study, we calculated the creatinine clearance using 
Cockcroft-Gault formula. Equation derived from the Modification of Diet in 
Renal Disease (MDRD) study was not used in our study because it had not 
been validated in Chinese population43-45. We found that patients treated with 
tacrolimus had a significant better creatinine clearance starting from six months 
after transplantation. The difference sustained throughout the 5-year period. 
The maintenance of renal function in the tacrolimus group was further evident 
by slower decline of creatinine clearance during the follow-up period. We also 
found that more patients in Neoral cyclosporine group suffered from 
deterioration in renal function. Since this was a paired kidney analysis, the 
difference was unlikely due to the differences in any donor variables. One of 
the main reasons for this deterioration could be due to the development of 
chronic allograft nephropathy in the cyclosporine group. In a study of healthy 
volunteers by Klein et al, tacrolimus had no effect on renal hemodynamics and 
systemic blood pressure. In contrast, cyclosporine led to a decrease in GFR 
and renal plasma flow and an increase in blood pressure. This difference in 
functional nephrotoxicity might contribute to structural lesions found in chronic 
calcineurin-inhibitor nephrotoxicity46. This would affect the long term renal graft 
survival. Another possible explanation for the better renal function in 
tacrolimus-based patients might be related to the lower incidence of subclinical 
rejection. Subclinical rejection was shown to correlate closely with subsequent 
allograft dysfunction47,48. However, it could not be shown in this study because 
protocol biopsies were not performed in our center. 
In conclusion, we found that both the absolute value and the rate of decline in 
creatinine clearance over time were significantly better in tacrolimus group 
compared to cyclosporine group in this paired kidney analysis. A lower 
incidence of acute rejection was also observed in our Chinese patients when 
compared with the Caucasian. The use of abbreviated AUC0-12 might provide 
an alternate tool for drug monitoring, especially with the many limitations of 
using trough level as discussed above. Although there was a lower incidence of 
acute rejection in tacrolimus group, the difference was not statistically 
significant. The patient and graft survival were comparable in both groups of 
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patients. No significant differences were noted between tacrolimus and 
cyclosporine-based therapies in terms of prevalence of hypertension, post-
transplant diabetes mellitus, infection, malignancy and neurotoxicity. However, 
hyperlipidemia and gum hypertrophy were more common in cyclosporine 
group. 
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Abstract 
The aim of the study is to evaluate the efficacy and safety of a tacrolimus-based 
immuno-suppressive regimen with and without induction therapy using daclizumab in 
first cadaveric renal transplant recipients. Since January 2001, we studied the effect of 
daclizumab in a nonrandomized and prospective study of 36 sequential first cadaveric 
renal transplant recipients. They were compared with a historical control group of 21 
sequential first cadaveric renal transplant recipients without induction therapy. All 
patients received tacrolimus, azathioprine and corticosteroids as concomitant 
immunosuppressive therapy. Daclizumab was given at 1 mg/kg infusion two hours 
before transplantation and then every 14 days for four more doses. Outcomes 
measured included incidence of acute rejection, patient survival, graft survival, 
annualized change in creatinine clearance (CrCl), cardiovascular risk profile, infection 
and malignancy. Fewer biopsy proven acute rejections were observed in the induction 
treatment group: 11.1% (4/36) versus 19% (4/21) but the rejection free survival was 
similar (P=0.37). The patient survival and graft survival were comparable. The renal 
function was similar in both groups. There were also no significant difference in 
infection, malignancy and cardiovascular risk profile in both groups. Adding daclizumab 
to a tacrolimus-based therapy is safe but cannot further improve clinical efficacy. 
Thesis_Cheung_v2.pdf
 Daclizumab in tacrolimus-based renal tx.⏐57 
Introduction 
Daclizumab, a humanized anti-interleukin-2 (IL-2) receptor monoclonal 
antibody, was first approved for immunosuppressive treatment in renal 
transplantation in 1997. It inhibits IL-2 mediated activation of lymphocytes and 
impairs the immune response. Use of daclizumab could decrease the incidence 
of acute rejection1-3. However, there was no difference in patient and graft 
survival at three years post renal transplantation in patients treated with 
daclizumab when compared with placebo1,2. 
Different studies have demonstrated that tacrolimus was superior than 
cyclosporine in the reduction of acute rejection and improve in long term graft 
survival4-6. Although it has been shown that combining IL-2 receptor antibody 
with cyclosporine can reduce the incidence of acute rejection, the benefits of 
use of IL-2 receptor antibody in tacrolimus-based patients were not well shown. 
In fact, comparative studies of IL-2 receptor antibody induction versus no 
induction in patients receiving tacrolimus-based immunosuppression are 
lacking7. In a prospective and randomized trial in pediatric renal transplantation, 
use of IL-2 receptor antibody did not improve clinical efficacy. There was no 
difference in patient survival, graft survival and biopsy-proven acute rejection8. 
The aim of this study is to evaluate the efficacy and safety of a tacrolimus-
based immunosuppressive regimen with and without induction therapy using 
daclizumab in our first cadaveric renal transplant recipients. 
Methods 
Trial design 
This was a single center and prospective study. Since 1st January 2001, 36 
sequential first cadaveric renal transplant recipients were put on induction 
treatment with daclizumab. This group was compared with 21 sequential first 
cadaveric renal transplant recipients between 1st June 1998 and 31st December 
2000, who did not receive induction therapy regarded as a historic control 
group. All patients were Chinese and received tacrolimus-based therapy. 
Follow-up outcome data were analyzed until 31st December 2006. The trial was 
approved by ethical committee and conducted in accordance with the 
Declaration of Helsinki. Written consent was obtained. 
Immunosuppressive regimens 
Tacrolimus was administered orally as capsules with loading dose of 0.3 mg/kg 
within 12 hours of surgery and then 0.15 mg/kg twice daily. Abbreviated 
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tacrolimus AUC0-12 monitoring was used. Calculation of tacrolimus AUC0-12 was 
by the formula: 16.2 + C2 * 2.4 + C4 * 5.9 [C2: 2-h post dose tacrolimus level; 
C4: 4-h post dose tacrolimus level]. Based on our previous pilot study in stable 
patients on tacrolimus, AUC0-12 value was kept at around 100-150 ng x h/ml in 
first three months and around 80-100 ng x h/ml after three months9. Whole 
blood levels of tacrolimus were monitored by means of IMx tacrolimus II assay 
(Abbott Laboratories, Abbott Park, IL, USA). 
Concomitant immunosuppressive therapy was identical in the two arms of the 
trial. A bolus dose of intravenous methylprednisolone 500 mg was given on 
day 1. This was followed by intravenous hydrocortisone 100 mg every six hours 
for three days and followed by oral prednisolone 30 mg daily. The dose of 
prednisolone was gradually tailed down after the first month at a rate of 2.5 mg 
every two weeks and then maintained at 5 mg daily. Azathioprine was given at 
a dose of 1.5 mg /kg daily since day 1. 
Patients in the study group received induction therapy. Daclizumab (Zenapax, 
Roche, NJ, USA) was given at 1 mg/kg infusion two hours before 
transplantation and then every 14 days for four more doses.   
If a rejection episode occurred, our protocol prescribed pulse methyl-
prednisolone therapy as first-line treatment with the dosage of 500 mg daily for 
three days. In case of steroid resistant rejection, appropriate antibody therapy 
was started. 
Clinical outcome parameters 
The primary endpoint was the incidence of acute rejection. Rejection was 
defined as any episode with the relevant clinical and laboratory signs and 
symptoms and all clinically apparent episodes of rejection were confirmed by 
core biopsy. Rejection was classified according to Banff 97 classification10 after 
assessment by local pathologists.   
The secondary endpoints were patient survival, graft survival, the course of 
renal function, the incidence of infection and malignancy, and the 
cardiovascular risk profile. Graft loss was defined as the need to resume long 
term dialysis, re-transplantation, transplant nephrectomy or death. Renal 
function parameters were serum creatinine and estimated creatinine clearance 
(CrCl) by means of Cockcroft-Gault formula and expressed in milliliter per 
minute11. The annualized change of CrCl (ml/min/year) was used to monitor the 
progression of renal function decline. Positive value means improvement or 
stabilization of renal function while negative value means decline in CrCl. The 
cardiovascular risk profile was assessed by the incidence of hypertension, 
hypercholesterolemia and diabetes mellitus. Hypercholesterolemia was defined 
as total cholesterol greater than 5.8 mM (224 mg/dl) or requiring lipid-lowering 
agent. New onset diabetes mellitus (NODM) was defined as fasting blood 
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glucose more than 7 mM (126 mg/dl) on two occasions at any time after 
transplantation in those patients with no previous history of diabetes mellitus. 
Statistical analysis 
The intention-to-treat population was used for analyses of both efficacy and 
safety and included all patients who received at least one dose of study 
medication. Values were expressed as mean (SD) or median (range). Baseline 
and demographic data were compared by Student’s t-test, Pearson’s chi-
squared test or Fisher’s exact test where appropriate. Pearson’s chi-squared 
test or Fisher’s exact test was used to compare the rates of adverse events 
between treatment groups. Kaplan-Meier Model and log-rank test were used to 
compare the patient survival, graft survival and rejection-free survival. The 
annualized change of CrCl for each patient was determined using simple linear 
regression. At least three estimates over two consecutive years of follow-up 
were required to calculate the annualized change of CrCl. A two-tailed P-value 
of <0.05 was considered to be statistically significant. 
Results 
Thirty six patients received tacrolimus/steroid/azathioprine+daclizumab 
(TSA+D arm) while 21 patients received tacrolimus/steroid/azathioprine (TSA 
arm). The mean follow-up duration was 56 +/- 12 months and 85 +/- 13 months 
in TSA+D arm and TSA arm respectively. The baseline characteristics were 
depicted in Table 3.1. No statistical significant differences were observed in 
baseline parameters in both groups of patients. 
Acute rejection 
A total of eight patients (four patients in each arm) were treated for acute 
rejection. All were confirmed by renal biopsy. The histological type of the 
rejection was depicted in Table 3.2. All patients responded to pulse steroid 
therapy except two patients in the TSA arm with type III rejection requiring graft 
nephrectomy for ruptured graft kidney. Fewer acute rejections were observed 
in the TSA+D arm: 11.1% (4/36) versus 19% (4/21). The rejection free survival 
was similar (P=0.37). 
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Table 3.1 Baseline characteristics of the patients with and without induction therapy.  
 TSA+D arm 
(n=36) 
TSA arm 
(n=21) 
P value 
Age (years) 41.6 +/- 9.2 44.1 +/- 6.3 0.28 a 
Male (n (%)) 
Pre-transplant diabetes mellitus(n(%)) 
19 (52.8) 
3 (8.3) 
12 (57.1) 
4 (19.0) 
0.75 b 
0.40 b 
HLA-AB (≥2 mismatch)(n(%)) 26 (72.2) 16 (76.2) 0.74 b 
HLA-DR ≥1 mismatch)(n(%)) 27 (75.0) 15 (71.4) 0.77 b 
PRA-T cell (%) 22.8 +/- 34.4 26.4 +/- 33.5 0.70a 
Donor age (years) 50.8 +/- 15.1 45.7 +/- 11.0 0.31a 
Cold ischemic time (hours)  10.0 +/- 6.4 10.4 +/- 5.4 0.84 a 
Anastomotic time (minutes) 46.1 +/- 7.7 48.1 +/- 11.4 0.44a 
Primary cause of renal failure (n (%)) 
   Chronic glomerulonephritis 
   Diabetes mellitus 
   Polycystic kidney disease 
   Others/unknown 
 
23 (63.9) 
2 (5.6) 
0 (0) 
11 (30.5) 
 
11 (52.4) 
2 (9.5) 
3 (14.3) 
5 (23.8) 
 
0.39b 
0.97b 
0.09b 
0.58b 
Values expressed as mean +/- standard deviation or number (percentage) 
a Student’s t test, b Pearson’s chi squared test. TSA: tacrolimus/steroid/azathioprine; TSA+D: 
tacrolimus/steroid/azathioprine+daclizumab. 
 
 
Tabel 3.2 Types of acute rejection, change of dose of tacrolimus over time and cardiovascular 
risk factors. 
 TSA+D arm 
(n=36) 
TSA arm 
(n=21) 
P value 
Episodes of acute rejection    
Borderline 1 0  
Type IA 0 0  
Type IB 3 1  
Type II A 0 1  
Type II B 0 0  
Type III 0 2  
Mean +/-SD tacrolimus dosage  (mg/kg/day)    
0-day 0.30 0.30 1 
6-month 0.08 +/- 0.03 0.10 +/- 0.05 0.25 
12-month 0.07 +/- 0.03 0.06 +/- 0.03 0.33 
18-month 0.06 +/- 0.02 0.06 +/- 0.02 0.76 
24-month 0.06 +/- 0.02 0.06 +/- 0.02 0.74 
36-month 0.06 +/- 0.02 0.06 +/- 0.02 0.80 
Cardiovascular risk factors, n (%)    
Hypertension 27 (75.0%) 16 (76.2%) 0.92 
Hypercholesterolemia 8 (22.2%) 1 (4.7%) 0.08 
NODM 4 (11.1%) 3 (14.3%) 0.73 
NODM: new onset diabetes mellitus; TSA: tacrolimus/steroid/azathioprine; TSA+D: tacrolimus/ 
steroid/azathioprine+daclizumab. 
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Patient survival 
Three patients in the TSA+D arm (8.3%) died with functioning grafts during the 
study. One patient died one year after renal transplantation because of acute 
myocardial infarction. One died of septicemia two months after kidney 
transplant. The remaining patient died of carcinoma of stomach 3.5 years after 
kidney transplant. On the other hand, one patient died of subarachnoid 
hemorrhage three years after transplant in the TSA arm. There was no 
significant difference in patient survival (P=0.62). 
Graft survival 
Total four patients had graft failure in the first year. Three of them belonged to 
the TSA arm while one patient belonged to the TSA+D arm. The patient in the 
TSA+D arm had graft thrombosis. One patient in the TSA arm had graft artery 
anastomotic leakage while the other two patients had renal graft rupture.  Both 
of them showed Type III acute rejection. The first-year graft survival rate, 
censored for death, in the TSA arm group was 14.3% while in the TSA+D arm, 
it was 2.7%. There was no significant difference between both groups 
(P=0.10). 
Dose of tacrolimus 
The change of dose of tacrolimus over time was shown in Table 3.2. The 
starting dose of tacrolimus in all patients was 0.3 mg /kg/day. In both treatment 
groups, the maintenance dose was 0.06 +/- 0.02 mg /kg/day. There was no 
significant difference between them. 
Renal function 
There was no significant difference of CrCl in both treatment groups starting 
from the first month after transplantation up to five years (Figure 3.1). The 
annualized change of CrCl in the TSA+D arm and the TSA arm was 1.12 +/- 
4.91 ml/min/year and -1.4 +/- 5.48 ml/min/year respectively. The difference 
between them was not statistically significant (P=0.1). There was no difference 
in the use of angiotensin converting enzyme inhibitors or angiotensin II receptor 
blockers between them (1/36 in the TSA+D arm vs. 2/21 in the TSA arm, 
P=0.55). 
Infection 
The episodes of bacterial urinary tract infection were more common in the TSA 
arm (10/21 in the TSA arm versus 9/36 in the TSA+D arm). However, the 
difference was not significant (P=0.08). The incidence of opportunistic infection 
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in both groups was also comparable (10/36 in the TSA+D arm vs. 7/21 in the 
TSA arm, P=0.66). Among the opportunistic infection, CMV infection was 
documented in 11.1% (4/36) in the TSA+D arm and 14.3% (3/21) in the TSA 
arm. There was also no significant difference between them (P=0.73). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Calculated creatinine clearance (Cockcroft-Gault formula) over time since 
transplantation. 
 
Malignancy 
Only two patients in the TSA+D arm had malignancy. One of them had 
carcinoma of thyroid and the other one had carcinoma of stomach. On the 
other hand, none of the patients in the TSA arm had malignancy during the 
follow up period. However, the difference was not statistically significant 
(P=0.53). 
Cardiovascular risk profile 
The incidence of hypertension, hypercholesterolemia, and NODM were shown 
in Table 3.2. There was no significant difference in these cardiovascular risk 
factors between the TSA+D arm and the TSA arm. 
Discussion 
This is a single center and prospective study to investigate the efficacy and 
safety of adding daclizumab to a tacrolimus-based therapy in Chinese first 
cadaveric renal transplant recipients. The incidence of biopsy-proven acute 
rejection was low in both treatment groups when compared with those reported 
in other studies combining IL-2 receptor antibody and cyclosporine-based 
Thesis_Cheung_v2.pdf
 Daclizumab in tacrolimus-based renal tx.⏐63 
therapy1,12. In this study, there was no significant difference in the incidence of 
acute rejection between both treatment arms. Induction with IL-2 receptor 
antibody might be of greater benefit for those patients with high immunological 
risk. Different studies had shown lower incidence of acute rejection in patients 
using IL-2 receptor antibody1,3. However, the study population was quite 
heterogeneous with different racial groups including African-Americans. It had 
been suggested that African-Americans might have stronger immune response 
than other racial groups, thus requiring more potent immunosuppressive 
regimens13-15. On the other hand, the population was homogeneous in our 
study. They were all Chinese patients receiving first graft kidneys. The 
immunological risks might be lower than the African-American population. This 
factor, together with the use of tacrolimus-based therapy, could explain the low 
risk of acute rejection in our study. As a result, daclizumab induction seems to 
confer no additional clinical efficacy as shown by the similar incidence of acute 
rejection in both treatment arms. However, the severity of acute rejection might 
be even worse in the treatment arm without daclizumab as shown by the 
presence of type III acute rejection with graft rupture. Further studies with more 
patients might be needed to show the impact of induction therapy on the 
severity of acute rejection. 
A retrospective study demonstrated that daclizumab was associated with 
improved patient and graft survival.3 However, we failed to prove this 
association in the present study. Concerning the renal function, calculated 
creatinine clearance using Cockcroft-Gault formula was used in our study. 
Equation derived from the Modification of Diet in Renal Disease (MDRD) study 
was not used because it had not been validated in Chinese population16-18. 
There was no significant difference in creatinine clearance between both 
groups up to five years. Moreover, there was also no difference in the 
annualized change of creatinine clearance. As a result, we failed to show better 
graft survival and long term renal graft function with daclizumab. 
A recent study suggested that even early and short exposure to induction 
treatment might create risk for late malignancy and infection-related 
complications19. However, many studies had demonstrated that use of 
daclizumab was safe and did not result in more infectious complications and 
malignancies1,3. This was similar to our results. The incidence of bacterial 
urinary tract infection and opportunistic infection were comparable between 
those with and without induction therapy. Although the incidence of malignancy 
was higher in patients with daclizumab, the difference between them was not 
statistically significant. Furthermore, there was no significant difference in 
cardiovascular risks between both treatment groups. 
One of the main drawbacks in this study was the small sample size. A two-
sided log rank test with an overall sample size of 57 patients achieves only 
20% power at a significance level of 0.05 to detect a difference of 9% between 
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89% and 80% - the percentage of patients without acute rejection in TSA+D 
arm and TSA arm respectively. Large randomized, controlled trials might be 
needed in order to demonstrate any difference between both treatment arms. 
However, we had a homogeneous group of patients in this study because all of 
them were Chinese following up in a single center with similar baseline 
characteristics. This would eliminate the influence of racial factors and different 
clinical protocols due to different centers.   
In conclusion, we found that daclizumab was safe to use but we did not 
demonstrate clinical superiority in a tacrolimus-based immunosuppressive 
regimen. There was no difference demonstrated for acute rejection, patient 
survival, graft survival or creatinine clearance. 
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Background 
Post-transplant diabetes mellitus (PTDM) after renal transplantation is associated with 
adverse outcome on patient and graft survival. Fasting blood glucose alone will 
underestimate diabetes and also ignores diagnosis of impaired glucose tolerance (IGT). 
IGT has great correlation with diabetes and cardiovascular risk. 
 
Methods 
In this cross-sectional study, we estimate the prevalence of abnormal glucose 
metabolism (AGM) using oral glucose tolerance test (OGTT) and identify its predictive 
factors. Patients who received kidney transplantation in our centre without pre-
transplant diabetes were recruited. OGTT was performed in patients with fasting 
glucose levels between 5.6 and 6.9 mmol/l for at least two occasions six months post-
transplantation.   
 
Results 
Of 119 patients recruited, 31 had OGTT performed. The prevalence of PTDM, IGT and 
IFG was 21.8 (26/119)%, 6.7 (8/119)% and 3.4 (4/119)% respectively. Thus the overall 
prevalence of AGM was 31.9%. Age (P=0.003), body mass index (P=0.032), hepatitis B 
seropositivity status (P=0.01), CMV infection (P=0.02) and acute rejection (P=0.002) 
were all associated with development of AGM. Using multivariate analysis, only older 
age at transplant (OR 1.09), history of acute rejection (OR 3.40) and hepatitis B 
seropositivity (OR 3.13) were significantly associated with development of AGM. 
 
Conclusion 
Abnormal glucose metabolism is common in our renal transplant recipients. 
Abstract 
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Introduction 
Post-transplant diabetes mellitus (PTDM) after solid organ transplantation is a 
well-known serious metabolic complication. It can adversely affect the patient 
and graft survival1. Moreover, it has been shown that development of PTDM is 
a major determinant of cardiovascular mortality and morbidity in renal 
transplant recipients2.  
The prevalence of PTDM varies widely among literature3,4. The main reason is 
that there is no consensus regarding the definition and diagnostic criteria. 
Clinical trials seldom included oral glucose tolerance test (OGTT) to determine 
the exact incidence of glycaemic abnormality in kidney transplant recipients. 
Diagnosis of PTDM has been clarified by the International Consensus 
Guidelines, which is based on American Diabetic Association (ADA) and World 
Health Organization (WHO) guidelines5-7. Early recognition leads to early 
appropriate treatment. Moreover, the detection of “pre-diabetic state” (impaired 
fasting glucose (IFG) and/or impaired glucose tolerance (IGT)) is also important 
because of the increased risk of development of diabetes and cardiovascular 
risks8. Fasting glucose is commonly used in clinical setting for diagnosis of 
diabetes when compared to OGTT because of its simplicity. However, it is less 
sensitive and specific than an OGTT in diagnosis9,10. Fasting glucose alone will 
underestimate diabetes9 and also ignores the diagnosis of IGT. IGT itself can 
only be diagnosed with OGTT and has been shown to have a great correlation 
with diabetes and cardiovascular risks11,12. 
The aim of this study was to show the prevalence of abnormal glucose 
metabolism (AGM = PTDM+IGT+IFG) after kidney transplantation when OGTT 
was used. In addition, the associated risk factors for its development were also 
studied. 
Subjects and Methods 
This was a cross-sectional study. All Chinese patients who received solitary 
living-related or cadaveric kidney transplantation from 1st July 1997 to 31st 
December 2005 in Queen Elizabeth Hospital, Hong Kong with follow up >6 
months were recruited.  
Patients with pre-transplant diabetes mellitus were excluded. The study was 
performed in accordance with the Declaration of Helsinki. A written consent 
was obtained from each patient. Demographic and clinical data were extracted 
from the patients’ records. 
Participants were initially classified into three categories: 1) PTDM with fasting 
blood glucose level ≥7.0 mmol/l for two occasions; 2) normal with fasting blood 
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glucose level <5.6 mmol/l and 3) fasting blood glucose level between 5.6 and 
6.9 mmol/l for at least two occasions six months after transplantation.  
For patients under the 3rd category, an OGTT was performed. After an 
overnight 8-h fast, fasting blood glucose was taken. Patients were then 
administered 75 g of glucose (113 ml of Polycal) with post-prandial samples 
taken two hours after administration of glucose. The results of the test were 
classified by ADA criteria (Table 4.1).  
 
Table 4.1 OGTT classification according to ADA criteria. 
OGTT criteria Baseline glucose (mmol/l) 2-hr glucose (mmol/l) 
Normal <5.6 <7.8 
Impaired fasting glucose (IFG) 5.6-6.9 - 
Impaired glucose tolerance (IGT) - 7.8-11.1 
Diabetes >6.9 >11 
 
Immunosuppressive Regimens  
Our patients were basically put on triple immunosuppressive therapy with either 
tacrolimus or Neoral cyclosporine, concomitantly with prednisolone and 
azathioprine therapy. All patients received 500 mg of methylprednisolone at 
induction. This was followed by intravenous hydrocortisone 100 mg every six 
hours for three days and followed by oral prednisolone 30 mg daily. The dose 
of prednisolone was gradually tapered after the first month at a rate of 2.5 mg 
every two weeks then maintained at 7.5 mg daily. Azathioprine was given at a 
dose of 1.5 mg/kg daily since Day 1 after transplant. Cyclosporine (CsA) was 
initially administered orally as a loading dose of 10mg/kg within 12 h of surgery 
and then 5 mg/kg b.i.d. An abbreviated formula based on limited sampling 
strategy was used in this study to estimate the cyclosporine area under 12-h 
concentration-time curve (AUC0-12). Calculation of cyclosporine AUC0-12 was 
based on the formula: 452.4 + C0 x 17.5 + C1.5 x 1.89 [C0: cyclosporine trough 
level; C1.5: 1.5-h post-dose cyclosporine level].13. The dose of cyclosporine was 
gradually titrated to maintain the abbreviated AUC0-12 at ~6000-8000 ng x h/ml 
in the first 3-month post-transplant and 4000-6000 ng x h/ml from 3-month 
post-transplant onwards14. On the other hand, tacrolimus was administered 
orally with loading dose of 0.3 mg/kg within 12-h of surgery and then 
0.15 mg/kg b.i.d. Abbreviated tacrolimus AUC0-12 monitoring was used. 
Calculation of tacrolimus AUC0-12 was by the formula: 16.2 + C2 x 2.4 + C4 x 5.9 
[C2: 2-h post-dose tacrolimus level; C4: 4-h post-dose tacrolimus level]. Based 
on a previous pilot study in stable patients on tacrolimus in our center, AUC0-12 
value was kept at ~100-150 ng x h/ml in first three months and ~80-100 ng x 
h/ml after three months15. Some of our patients have received interleukin-2 
receptor antagonist during induction therapy since 2001. Patient on 
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cyclosporine was given Basiliximab (Simulect, Norvatis, Switzerland) while 
patients on tacrolimus was given Daclizumab (Zenapax, Roche, NJ, USA). 
Basiliximab was given at a dose of 20 mg ~2 h before transplantation and the 
second dose was given four days after transplantation. Daclizumab was given 
at 1 mg/kg infusion ~2-h before transplantation and then every 14 days for four 
more doses. 
Acute rejection was defined as any episode with the relevant clinical and 
laboratory signs and symptoms and confirmed by renal biopsy. Episodes 
during which treatment against acute rejection was given and for which no 
biopsy could be performed due to contraindications were considered as acute 
rejection. There was clinical suspicion of rejection in the case of an 
unexplained rise or insufficient decrease of serum creatinine, with or without 
other signs, such as fever, graft tenderness, decreased renal perfusion on 
nuclear scan, or hypertension. Contraindications for biopsy were bleeding 
disorders or uncontrolled severe hypertension. Our protocol for treating acute 
cellular rejection was 500 mg methylprednisolone intravenously for three days. 
In case of steroid resistant rejection, appropriate antibody therapy was started. 
Statistical Analyses 
The statistical software SPSS (SPSS 13.0, Inc., Chicago, IL USA) was used to 
perform the analyses. Continuous data are expressed as means ± standard 
deviation (SD); categorical data are expressed as percentages. Continuous 
data were analyzed by independent sample t-test to detect the difference 
between groups; categorical data are analyzed by chi-square test. Associations 
between the clinical variables and the development of AGM were estimated 
using both univariate and multivariate logistic regression analyses. The 
multivariate model incorporated a backward and stepwise elimination method 
using variables with a P-value of <0.05 from the univariate analysis. A P-value 
of less than 0.05 was defined as statistically significant in this study. 
Results 
From a total of 147 patients receiving a kidney allograft between July 1997 and 
December 2005, 14 patients were excluded due to pre-transplant diabetes 
mellitus, four due to primary non-functioning grafts or surgical complications 
requiring graft nephrectomy and 10 due to patient death or graft loss (4/10 had 
PTDM). As a result, 119 renal transplant recipients were included in our study. 
The baseline demographic and clinical variables were depicted in Table 4.2. 
The median follow-up duration after kidney transplant was 62 (15-120) months. 
The mean age at transplantation was 39±11 years and 54.6% were male 
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patients. All enrolled patients did not have past history of gestational diabetes 
mellitus and none of them were hepatitis C carrier. All the patients were on 
prednisolone 7.5 mg daily. None of them were on thiazide diuretics. 
 
Table 4.2 Baseline demographic and clinical variables. 
Total number (n)  119 
Age ( years)  39 ± 11 
Waist circumference (cm) 81 ± 11 
Body weight (kg) 57.1 ± 10.9 
BMI (kg/m2) 22 ± 3 
Gender  Male (%) 
 Female (%) 
65 (54.6) 
54 (45.4) 
No. of Transplantation, n (%) 1st transplant 
 2nd transplant 
111 (93.3) 
8 (6.7) 
Mode of Transplantation, n (%) Cadaveric  
 Living related   
106 (89.1) 
13 (10.9) 
Hepatitis B carrier, n (%) Yes 
 No  
17 (14.3) 
102 (85.7) 
Hepatitis C carrier, n (%) Yes 
 No 
0 (0) 
119 (100) 
DM in first degree relatives, n (%) Yes 
 No 
30 (25.2) 
89 (74.8) 
Primary diagnosis, n (%) Chronic glomerulonephritis 
 Hypertension  
 Polycystic kidney disease 
 Obstructive uropathy 
 Others 
 Unknown 
80 (67.2) 
5 (4.2) 
4 (3.4) 
2 (1.7) 
8 (6.7) 
20 (16.8) 
Values expressed as mean ± SD or number (percentage) 
 
Of the 119 patients, 22 patients were classified as PTDM and 66 patients were 
normal based on fasting blood glucose level alone. The remaining 31 patients 
fulfilled our criteria of OGTT (fasting blood glucose level between 5.6 and 6.9 
mmol/l for at least two occasions six months after transplantation). Based on 
the results from OGTT, 4/31 (12.9%) patients were diagnosed IFG, 8/31 
(25.8%) patients were diagnosed IGT, 4/31 (12.9%) patients were diagnosed 
PTDM and 15/31 (48.4%) patients were normal.  
As a result, total 26 patients were classified as PTDM. Among them, seven 
patients were treated with diet only and 19 patients required medications. For 
patients requiring medical treatment, 13 patients required oral hypoglycemic 
agents alone while six required insulin therapy. 
The prevalence of PTDM, IGT and IFG in our study was 21.8 (26/119)%, 6.7 
(8/119)% and 3.4 (4/119)% respectively. Thus the overall prevalence of AGM 
was 31.9%. 
Table 4.3 showed the factors associated with development of AGM by 
univariate analysis. Age (P=0.003), body mass index (P=0.032), hepatitis B 
seropositivity status (P=0.01), CMV infection (P=0.02) and acute rejection 
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(P=0.002) were all associated with the development of AGM. The follow-up 
duration after transplantation was significantly longer in the patients with AGM 
than the normal patients. Using multivariate analysis, only older age at 
transplant (OR 1.09), history of acute rejection (OR 3.40) and hepatitis B 
seropositivity (OR 3.13) were associated with development of AGM (Table 4.4). 
 
Table 4.3 Comparison between patients who developed AGM and normal. 
 AGM 
n=38 
Normal 
n=81 
P-value♣ 
Age of recipient (yr) 44±10 37±11 0.003 
Gender, n (males %) 19(50.0) 46(56.8) 0.488 
Waist circumference (cm) 82.0±12.0 80.5±10.5 0.494 
Body weight at transplant (kg) 58.9±10.9 56.3±10.9 0.229 
Body mass index (kg/m2) 23±4 21±3 0.032 
Hepatitis B status (%) 10(26.3) 7(8.6) 0.010 
Family history of DM, n (%) 13(34.2) 17(21.0) 0.092 
Duration of dialysis (months) 65.5±52.6 57.6±44.8 0.398 
Time since transplantation (months) 74±24 53±21 0.015 
Hemoglobin A1c (%) 6.4±1.2 5.8±0.4 0.015 
Immunosuppressants, n (%) 
   Tacrolimus 
       Dosage (mg/kg/day) 
       AUC0-12(ng x h/ml) 
   Cyclosporine 
       Dosage (mg/kg/day) 
       AUC0-12(ng x h/ml) 
   Basiliximab 
   Daclizumab 
   Prednisolone dosage (mg/day)  
 
20(52.6) 
0.08±0.04 
114±29 
18(47.4) 
3.2±0.7 
4581±415 
7(18.4) 
11(28.9) 
7.5±0 
 
33(40.7) 
0.08±0.04 
106±19 
48(59.3) 
3.5±0.7 
4757±1244 
22(27.2) 
23(28.4) 
7.5±0 
 
0.224 
0.821 
0.297 
0.224 
0.308 
0.785 
0.301 
0.950 
1 
Use of Beta-blocker, n (%) 27(71.1) 52(64.2) 0.460 
Use of ACEI/ ARB, n (%) 2(5.3) 6(7.4) 0.663 
CMV infection, n (%) 10(26.3) 8(9.9) 0.020 
Acute rejection, n (%) 16(42.1) 13(16.0) 0.002 
Values expressed as mean ±SD or number (percentage). ACEI, angiotensin converting enzyme 
blockers; ARB, angiotensin II receptor blockers; CMV, cytomegalovirus. ♣ Continuous variables 
were analyzed with the use of t-tests, all categorical data were analyzed with the use of chi-square 
test. 
 
Table 4.4 Factors predicting development of AGM according to multivariate analysis. 
 Odds ratio 95% Confidence Interval P-value 
Age of recipients 1.09 1.02-1.10 0.008 
Acute rejection 3.40 1.32-8.77 0.011 
Hepatitis B seropositivity 3.13 1.01-9.89 0.050 
 
The types of acute rejection were shown in Table 4.5. All patients with acute 
rejection were given 500 mg methylprednisolone intravenously for three days. 
For the 16 patients in the AGM group, five developed AGM before episodes of 
acute rejection. The median time for the development of AGM after acute 
rejection in the remaining 11 patients was 49 (1-104) months. 
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Table 4.5 Types of acute rejection according to Banff 1997 classification30. 
Banff classification AGM 
n=16 
Normal 
n=13 
Borderline 5 2 
Type IA  2 4 
Type IB  3 3 
Type IIA  1 2 
Type IIB  1 0 
Type III  2 1 
No histology 2 1 
 
For patients who were finally classified as AGM (n=38), there was no significant 
difference between those sorted out before OGTT (n=22) and those diagnosed 
during OGTT (n=16) (Table 4.6). On the other hand, there was also no 
significant difference between the patients sorted out as normal in the 
beginning (n=66) and those diagnosed as normal during OGTT (n=15) (Table 
4.7). 
 
Table 4.6 Comparison between patients who were diagnosed as AGM before and during OGTT. 
 AGM before OGTT 
n=22 
AGM during OGTT
n=16 
P-value♣ 
Age of recipient (yr) 46±9 41±10 0.118 
Gender, n (males %) 10(45.5) 9(56.3) 0.511 
Waist circumference (cm) 80.2±10.7 84.3±14.2 0.351 
Body weight at transplant (kg) 58.8±12.3 59.0±8.9 0.948 
Body mass index (kg/m2) 23±4 22±3 0.582 
Hepatitis B status (%) 7(31.8) 3(18.8) 0.366 
Family history of DM, n (%) 6(27.3) 7(43.8) 0.290 
Duration of dialysis (months) 65.8±58.3 62.8±43.4 0.867 
Hemoglobin A1c (%) 6.6±1.4 6.1±0.8 0.295 
Immunosuppressants, n (%) 
      Tacrolimus 
            Dosage (mg/kg/day) 
            AUC0-12(ng x h/ml) 
      Cyclosporine 
            Dosage (mg/kg/day) 
            AUC0-12(ng x h/ml) 
      Basiliximab 
      Daclizumab  
 
12(54.5) 
0.08±0.04 
87±21 
10(45.5) 
3.3±0.9 
3860±1112 
3(13.6) 
7(31.8) 
 
8(50.0) 
0.08±0.04 
108±37 
8(50.0) 
3.2±0.5 
4403±39 
4(25.0) 
4(25.0) 
 
0.782 
0.930 
0.242 
0.782 
0.877 
0.551 
0.372 
0.647 
Use of Beta-blocker, n (%) 15(68.2) 12(75.0) 0.647 
Use of ACEI/ ARB, n (%) 1(4.5) 1(6.3) 0.816 
CMV infection, n (%) 8(36.4) 2(12.5) 0.099 
Acute rejection, n (%) 10(45.5) 6(37.5) 0.624 
Values expressed as mean ±SD or number (percentage). ACEI, angiotensin converting enzyme 
blockers; ARB, angiotensin II receptor blockers; CMV, cytomegalovirus. ♣ Continuous variables 
were analyzed with the use of t-tests, all categorical data were analyzed with the use of chi-square 
test. 
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Table 4.7 Comparison between patients classified as normal before OGTT and during OGTT. 
 Normal 
Before OGTT 
n=66 
Normal 
During OGTT 
n=15 
P-value♣ 
Age of recipient (yr) 37±11 39±10 0.377 
Gender, n (males %) 36(54.5) 10(66.7) 0.392 
Waist circumference (cm) 80.0±10.6 82.6±10.0 0.395 
Body weight at transplant (kg) 55.9±11.3 58.0±8.8 0.506 
Body mass index (kg/m2) 21±3 21±2 0.750 
Hepatitis B status (%) 5(7.6) 2(13.3) 0..474 
Family history of DM, n (%) 14(21.2) 3(20.0) 0.917 
Duration of dialysis (months) 55.9±45.8 60.5±37.4 0.719 
Immunosuppressants, n (%) 
      Tacrolimus 
            Dosage (mg/kg/day) 
            AUC0-12(ng x h/ml) 
      Cyclosporine 
            Dosage (mg/kg/day) 
            AUC0-12(ng x h/ml) 
      Basiliximab 
      Daclizumab 
  
 
25(37.9) 
0.08±0.04 
100±28 
41(62.1) 
3.4±0.7 
4370±983 
18(27.3) 
19(28.8) 
 
 
8(53.3) 
0.08±0.04 
94±18 
7(46.7) 
3.9±0.5 
4829±1102 
4(26.7) 
4(26.7) 
 
 
0.272 
0.965 
0.545 
0.272 
0.110 
0.571 
0.962 
0.869 
 
Use of Beta-blocker, n (%) 40(60.6) 12(80.0) 0.157 
Use of ACEI/ ARB, n (%) 4(6.1) 2(13.3) 0.332 
CMV infection, n (%) 6(9.1) 2(13.3) 0.619 
Acute rejection, n (%) 10(15.2) 3(20.0) 0.644 
Values expressed as mean ±SD or number (percentage). ACEI, angiotensin converting enzyme 
blockers; ARB, angiotensin II receptor blockers; CMV, cytomegalovirus. ♣ Continuous variables 
were analyzed with the use of t-tests, all categorical data were analyzed with the use of chi-square 
test. 
Discussion  
The incidence and prevalence of PTDM varies widely in literature because of 
the lack of standard definition for the condition. Many studies used fasting 
blood glucose alone or need for insulin and/or oral hypoglycemic agents for at 
least 30 days as definition of PTDM16,17. Moreover, heterogeneity between 
study groups on background parameters (age, ethnicity) and types and dosage 
of immunosuppressive regimen may also attribute to the great difference in 
incidence of PTDM among literature. The International Consensus Guidelines 
in 20036 attempted to bring consistency in the diagnosis and management of 
PTDM. Diagnosis was to be based on ADA and WHO criteria which included 
the OGTT for the diagnosis of diabetes.   
The ADA guidelines in 200610 highlight the increased sensitivity and specificity 
of the OGTT, compared to fasting glucose alone in diagnosing diabetes in the 
general population. Armstrong KA et al. have shown that the prevalence of 
PTDM is much higher with OGTT and fasting blood glucose alone will miss 
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65% of patients with diabetes in renal transplant recipients18. The ADA 
guidelines also recommend screening for pre-diabetes and diabetes in high-
risk patients such as transplant recipients. Early detection of IFG and IGT is 
very important due to the associated increased risk of developing both PTDM 
and cardiovascular disease. Early diagnosis can allow early education for 
lifestyle modification and appropriate intensive intervention can be given to 
reduce different diabetic complications. 
 
There are different criteria of defining IFG according to WHO and ADA 
guidelines. If ADA classification is used, more people will require OGTT and 
more people will be classified as IFG. The Decode study9 assessed the impact 
of sensitivity and specificity of variable cutoffs for IFG. If OGTT were performed 
in people with a fasting glucose level between 5.6-6.9 mmol/l, 46% of the 
population would require an OGTT. This would identify 93% of all people with 
diabetes and 69% of people with IGT. On the other hand, if OGTT were 
performed in people with a fasting glucose between 6.1-6.9 mmol/l, only 12% 
of the population would require an OGTT. This would only identify 82% of all 
people with diabetes and 29% of people with IGT. In our study, we recruited 
patients for OGTT according to ADA classification. Twenty-six percent (31/119) 
of patients required OGTT. Among those with OGTT, 51.6% (16/31) had AGM 
including IFG, IGT and PTDM.  
There is consistent evidence that PTDM is more common in older individuals. 
Cosio et al. reported that recipients >45 years old were 2.9 times more likely to 
become diabetic post-transplant when compared with younger recipients19. Our 
results also showed that older recipients at the time of transplant were 
significantly associated with the development of AGM. The odds ratio 
corresponding to an increase of one year of recipient’s age was 1.09. 
Calcineurin inhibitors are important factors for the development of PTDM. 
There is consistent evidence that tacrolimus is more diabetogenic than 
cyclosporine17,20. A meta-analysis has revealed that the odds ratio for 
development of PTDM in renal transplantation with tacrolimus was 5.03 (95% 
confidence interval 2.04-12.36)21. However, the above findings were not shown 
in our study. This can be explained by the use of limited sampling strategy and 
abbreviated AUC for drug monitoring and titration, resulting in lower tacrolimus 
dose used in our center22. Patients receiving tacrolimus experienced a delay in 
the restoration of glucose metabolism when compared with patients on 
cyclosporine. This delay could be caused by slow recovery of insulin secretion, 
possibly the result of a high exposure to tacrolimus23. The target abbreviated 
AUC0-12 in our patients was ~80-100 ng x h/ml after three months, 
corresponding a tacrolimus trough level at ~6 ng/ml22. Maintaining a low 
tacrolimus trough level may diminish the development of impaired glucose 
metabolism23. The mean age of our patients was 39 years. On the other hand, 
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the United States Renal Data System Annual Report for 2007 showed an older 
recipient age. Sixty-two percent were >45 years. Our patients were young and 
had a low body mass index, thus counteracting the diabetogenic effect of 
tacrolimus and reducing the difference between tacrolimus- and cyclosporine-
based therapy. However, the overall prevalence of AGM in our patients is 
31.9%. All the patients were on prednisolone 7.5 mg daily during the study and 
they were relatively lean. The dosage of maintenance steroids might be high if 
expressed in milligram per body weight. This can explain the relatively high 
prevalence of AGM in our patients. In a recent comparative cohort study24, 321 
patients were recruited with 301 of them had OGTT 10 weeks after kidney 
transplantation. The incidence of PTDM and IGT/IFG was 13% and 18% 
respectively, which was significantly lower when compared with a historical 
cohort. The major explanation of this beneficial change in glucose tolerance is 
probably related to the lower doses of steroids used in the early post-
transplantation period. They found that 1-mg increase in daily prednisolone 
was associated with an 11% increased risk of PTDM in the multivariate model. 
There is limited evidence that PTDM is associated with at least one acute 
rejection episode (64% vs. 27%, P<0.01)25. It may be related to higher 
cumulative corticosteroid dose for the treatment of acute rejection. Kasiske et 
al. have proposed that early acute rejection may explain the relationship 
between graft loss and onset of diabetes. Acute rejection predisposes to graft 
loss and tends to prompt an increase in intensity of immunosuppressive agents 
that in turn exacerbates the risk of PTDM20. In our center, rejection episodes 
were treated with 500 mg methylprednisolone intravenously for three days and 
temporary increment of oral prednisolone. As a result, the cumulative dosage 
of steroid was much higher in patients treated with acute rejection. In fact our 
results also showed that acute rejection was significantly associated with the 
development of AGM. 
Chronic hepatitis C infection is associated with an increased incidence of 
PTDM in liver transplantation.26 A meta-analysis has also shown a significant 
relationship between anti-HCV seropositive status with development of PTDM 
after renal transplantation with adjusted odds ratio 3.97 4. All patients in our 
study were hepatitis C seronegative, thus the association of AGM with HCV 
status could not be verified. In Hong Kong, chronic HCV infection is of minor 
epidemiological significance. On the other hand, chronic hepatitis B infection is 
endemic with a prevalence rate of 8.8%27. The association of hepatitis B status 
with PTDM in renal transplant recipients is rarely addressed in the literature. A 
study by Hirakauva EY et al. showed that there was no difference in prevalence 
of PTDM in patients infected with HBV in renal transplant recipients28. There 
are limited data concerning the prevalence of hepatitis B carrier in renal 
transplant recipients. In our study, the prevalence of hepatitis B seropositive 
status was 14.5%. To the best of our knowledge, this was the first published 
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single centre observational study which revealed that hepatitis B seropositive 
status was a predictive factor for development of AGM after renal 
transplantation although it is only marginally significant (O.R.: 3.13, P=0.05). In 
populations with a low prevalence of HBV infection, this association may not be 
demonstrable. In fact, hepatitis B carrier is found to be significantly associated 
with development of gestational diabetes in Chinese women in Hong Kong29. 
The authors postulate that hepatitis B carrier status can aggravate pregnancy-
induced hepatic insulin resistance leading to gestational diabetes. Similarly 
hepatitis B virus may also worsen steroid-induced insulin resistance in 
susceptible individuals. Further studies are necessary to evaluate the 
association, pathophysiological mechanisms and prognostic implications of 
hepatitis B status with AGM in renal transplant recipients. 
A limitation in our study might be the underestimation of patients with pre-
transplant diabetes mellitus. In the pre-transplant examination, the diagnosis of 
diabetes mellitus was based on routine fasting blood glucose only. Lack of 
mandatory use of OGTT might include patients with diabetes in our study and 
overestimate the prevalence of AGM after transplantation. 
In conclusion, the prevalence of AGM including IFG, IGT and PTDM in our 
renal transplant recipients was 31.9%. Older patients at time of transplant, 
history of acute rejection and hepatitis B seropositivity status were all 
independent predictive factors of development of AGM. A large scale 
prospective study with longer duration of follow up is necessary to assess 
whether the use of OGTT in renal transplant recipients can risk stratify each 
patient for the development of PTDM and cardiovascular disease. 
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Abstract 
Objective 
To investigate the prevalence of metabolic syndrome in Chinese renal transplant 
recipients, using two different sets of diagnostic criteria.  
 
Design 
Cross-sectional study.  
 
Setting 
Regional hospital, Hong Kong. 
 
Patients 
All Chinese patients who received solitary living–related or cadaveric kidney 
transplantation from 1 July 1997 to 31 December 2005 in our hospital with follow-up of 
more than six months were recruited. The diagnosis of metabolic syndrome was made 
according to the National Cholesterol Education Program–Adult Treatment Panel III 
(NCEP-ATPIII) criteria and the International Diabetes Federation criteria.  
 
Results 
Using the modified (Asian) NCEP-ATPIII criteria, a total of 39 (32%) of 121 patients had 
metabolic syndrome, which included 20/69 (29%) of the males and 19/52 (37%) of the 
females. Using the International Diabetes Federation criteria, metabolic syndrome was 
diagnosed in 26% of the patients, 22% in males and 31% in females. In our patients, the 
most common component of metabolic syndrome was hypertension and the least 
common was low high-density-lipoprotein–cholesterol level. Low high-density-
lipoprotein–cholesterol levels were significantly more common in female patients.  
 
Conclusion 
This study shows that there is a high prevalence of metabolic syndrome in our Chinese 
renal transplant recipients. 
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Introduction 
The metabolic syndrome (MS) is a cluster of interrelated common clinical 
entities, which include: obesity, insulin resistance, glucose intolerance, 
hypertension, and dyslipidaemia. It has been well recognised that MS is closely 
associated with atherosclerotic cardiovascular disease in the general 
population1. A community-based population study demonstrated that 
established cardiovascular disease risk factors are associated with the 
development of new-onset kidney disease2. Moreover, MS increases the risk of 
chronic kidney disease among US adults3. Recently it has been found that MS 
is also common in renal transplant recipients4. As in the general population, in 
renal transplant recipients, MS is associated with an increased risk of renal 
dysfunction and cardiovascular mortality4-6. However, most of the published 
studies were based on Caucasians, there being a lack of data in Chinese renal 
transplant recipients. Interestingly, in the general population, the prevalence of 
MS differs widely among ethnic groups and according to the definition used7-9. 
In the present study, we investigated the prevalence of MS in Chinese renal 
transplant recipients using different diagnostic criteria. 
Methods 
Patients 
This was a cross-sectional study. All Chinese patients who received solitary 
living–related or cadaveric kidney transplantation from 1 July 1997 to 31 
December 2005 in Queen Elizabeth Hospital, Hong Kong with follow-up of 
more than six months were recruited. The study was performed in accordance 
with the Declaration of Helsinki. Written consent was obtained from each 
patient. Demographic and clinical data were extracted from patient records. 
Immunosuppressive regimens  
Our patients were basically put on triple immunosuppressive therapy with either 
tacrolimus (Prograf, Astellas, Japan) or cyclosporine A (Neoral, Novartis, 
Switzerland), prednisolone and azathioprine. All patients received 500 mg of 
methylprednisolone at induction, followed by intravenous hydrocortisone 
100 mg every six hours for three days and then oral prednisolone 30 mg daily. 
The dose of prednisolone was gradually tapered after the first month at a rate 
of 2.5 mg every two weeks and maintained at 7.5 mg daily. Azathioprine was 
given at a dose of 1.5 mg/kg daily since day 1 after the transplant. 
Cyclosporine was initially administered orally as a loading dose of 10 mg/kg 
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within 12 hours of surgery and continued as 5 mg/kg twice daily. In this study, 
an abbreviated formula based on a limited sampling strategy was used to 
estimate the cyclosporine area under 12-hour concentration-time curve 
(AUC0-12). Calculation of cyclosporine AUC0-12 depended on the formula: 452.4 
+ C0 x 17.5 + C1.5 x 1.89 (C0: cyclosporine trough level; C1.5: 1.5-hour postdose 
cyclosporine level).10 The dose of cyclosporine was gradually titrated to 
maintain an abbreviated AUC0-12 of around 6000-8000 ng x h/ml in the first 
three months post-transplant and 4000-6000 ng x h/ml thereafter11. On the 
other hand, tacrolimus was administered orally with a loading dose of 
0.3 mg/kg within 12 hours of surgery and then 0.15 mg/kg twice daily. 
Abbreviated tacrolimus AUC0-12 monitoring was used. Calculation of tacrolimus 
AUC0-12 depended on the formula: 16.2 + C2 x 2.4 + C4 x 5.9 (C2: 2-hour 
postdose tacrolimus level; C4: 4-hour postdose tacrolimus level). Based on a 
previous pilot study in stable patients on tacrolimus in our centre, the AUC0-12 
value was kept at around 100-150 ng x h/ml in the first three months and 
around 80-100 ng x h/ml thereafter.12 Since 2001, some of our patients did 
receive an interleukin-2 receptor antagonist during induction therapy; patients 
on cyclosporine were given basiliximab (Simulect, Novartis, Switzerland) while 
those on tacrolimus were given daclizumab (Zenapax, Roche, NJ, US). 
Basiliximab was given at a dose of 20 mg around 2-hour pre-transplantation 
and a second dose after four days. Daclizumab was given as a 1 mg/kg 
infusion around two hours before transplantation and then every 14 days for 
four doses. 
 
Acute rejection was defined as any episode with the relevant clinical and 
laboratory signs and symptoms and all such episodes were confirmed by renal 
biopsy. Our protocol for treating acute cellular rejection entailed 500 mg 
methylprednisolone given intravenously for three days. In case of steroid-
resistant rejection, appropriate antibody therapy was started. 
Measurements 
Subjects came back to our centre at 8:00 am after an 8-to-12–hour overnight 
fast. Fasting blood samples were drawn to determine serum creatinine, 
triglyceride, and high-density-lipoprotein (HDL) cholesterol and plasma glucose 
concentrations. Low-density lipoprotein (LDL) cholesterol concentration was 
calculated using the Friedewald formula.13 Hypertension was defined as (i) the 
administration of antihypertensive agents and/or a history of this disorder; (ii) a 
systolic blood pressure greater than 130 mmHg; or (iii) a diastolic blood 
pressure greater than 85 mmHg. Weight, height, and waist circumference 
(midway between the iliac crest and the 10th rib) were also measured. 
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Post-transplant diabetes mellitus (PTDM) was defined as a fasting blood 
glucose of more than 7 mM (126 mg/dl) on two occasions at any time after 
transplantation or requiring use of oral hypoglycaemic agents and/or insulin, in 
patients with no previous history of diabetes mellitus. 
Diagnostic criteria for metabolic syndrome 
The diagnosis of MS was made according to the National Cholesterol 
Education Program–Adult Treatment Panel III (NCEP-ATPIII) criteria14 and the 
International Diabetes Federation (IDF) criteria15. The five thresholds used 
were: (i) serum triglyceride level ≥1.69 mmol/l (≥150 mg/dl) or specific 
treatment for this lipid abnormality, (ii) serum HDL-cholesterol level 
<1.04 mmol/l (<40 mg/dl) in men or <1.29 mmol/l (<50 mg/dl) in women or 
specific treatment for this lipid abnormality, (iii) systolic blood pressure 
≥130 mm Hg and/or diastolic blood pressure ≥85 mm Hg (high blood pressure) 
or use of antihypertensive medication, (iv) fasting plasma glucose level 
≥100 mg/dl (≥5.6 mmol/l) or use of antidiabetic medication, and (v) waist girth 
>102 cm for men or >88 cm for women (original NCEP-ATPIII criteria) and 
waist girth ≥90 cm for men or ≥80 cm for women (modified NCEP-ATPIII 
criteria for Asians). Because the original cut-off for abdominal obesity in the 
NCEP definition (waist circumference >102 cm for men and >88 cm for women) 
were shown to be inappropriate for Asian populations and the number of 
subjects who met these criteria was extremely low7,8,16, we used Asian cut-off 
limits7,8,15,16.  
National Cholesterol Education Program–Adult Treatment Panel 
III criteria 
Subjects who had three or more of the risk factors were judged as having MS 
(MS group), and having two or less risk factors were judged as not having the 
condition (non-MS group). 
International Diabetes Federation criteria 
Subjects with central obesity (defined as waist circumference ≥90 cm for men 
or ≥80 cm for women in Chinese) plus two or more of the risk factors were 
judged as having MS. 
Statistical analysis 
The Statistical Package for the Social Sciences (Windows version 15.0; SPSS 
Inc, Chicago [IL], US) was used to perform the analyses. Continuous data were 
expressed as means and standard deviations and categorical data as 
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percentages. Continuous data were analysed by independent sample t tests to 
detect the differences between groups and categorical data by the Chi-square 
test. A P-value of <0.05 was considered as statistically significant. 
Results 
Demographic and transplant characteristics of patients with and 
without metabolic syndrome (according to the National 
Cholesterol Education Program–Adult Treatment Panel III criteria 
for Asians) 
Table 5.1 shows the background data for renal transplant patients with or 
without MS. The mean follow-up duration after kidney transplantation was 63 
(standard deviation, 29) months. Using the modified (Asian) NCEP-ATPIII 
criteria, a total of 39 (32%) of 121 patients had MS. Compared to the non-MS 
group, in those with MS, the mean age was greater (P=0.010), PTDM and 
hypertension were more prevalent (P=0.013 and P=0.002 respectively), and 
body mass index and waist circumference were greater (P<0.001 in both 
cases). The MS group also had higher mean serum triglyceride levels 
(P=0.026), and more severe proteinuria (P=0.038). Other clinical variables did 
not differ significantly. Both groups were receiving similar doses of steroids 
during the study and the proportions receiving tacrolimus or cyclosporine were 
also similar (P=0.452). In all, 15 patients in this cohort were taking on lipid-
lowering agents. 
Percentage of patients with metabolic syndrome according to 
diagnostic criteria  
Using the modified (Asian) NCEP-ATPIII criteria, 39 (32%) of 121 patients had 
MS including 20 (29%) of 69 males and 19 (37%) of 52 females. Using the 
original NCEP-ATPIII criteria, MS was diagnosed in 18% of patients: 16% of 
the males and 21% of the females. Using the IDF criteria, MS was diagnosed in 
26% of patients: 22% of the males and 31% of the females (Table 5.2). 
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Table 5.1 Demographic and transplant characteristics of patients with / without metabolic 
syndrome (MS) by modified (Asian) National Cholesterol Education Program-Adult 
Treatment Panel III criteria. 
 MS 
n=39 
Non-MS 
n=82 
P-value♣ 
Age of recipient (years) 42±10 38±10 0.010* 
Male 20 (51) 49 (60) 0.379 
Donor source 
      Living     
      Cadaveric 
 
3 (8) 
36 (92) 
 
9 (11) 
73 (89) 
0.572 
Diabetes Mellitus 
Pre-transplant 
Post-transplant 
 
11(28) 
12 (31) 
 
1(1) 
10 (12) 
 
<0.001* 
0.013* 
Duration of Transplant, (years) 5.1±2.1 5.3±2.3 0.633 
Waist circumference (cm) 90.3±9.6 78.1±10.0 <0.001* 
Body mass index (kg/m2) 25±5 21±3 <0.001* 
Weight gain at 1-year post transplant  (kg) 6±7 3±6 0.017* 
Hepatitis B status  5(13) 13(16) 0.661 
Calcineurin inhibitors 
      Tacrolimus 
      Cyclosporine 
 
19 (49) 
20 (51) 
 
34 (41) 
48 (59) 
 
0.452 
 
Use of interleukin-2 receptor antagonist 20 (51) 44 (54) 0.807 
Prednisolone dosage (mg) 7.5 7.5 1.000 
Use of ACEI or ARB 4 (10) 5 (6) 0.415 
Triglyceride (mM) 2.0±1.1 1.5±1.1 0.026* 
HDL cholesterol (mM) 1.5±0.5 1.7±0.5 0.370 
Fasting glucose (mM) 5.6±0.8 5.2±0.8 0.188 
Hypertension 39 (100) 64 (78) 0.002* 
SCr at 6 months(uM) 160±60 162±66 0.792 
SCr at 12 months(uM) 151±55 158±55 0.510 
Proteinuria (g/day) 0.81±1.44 0.29±0.71 0.038* 
Albuminuria (mg/day) 62±76 52±75 0.680 
CMV infection 7 (18) 11 (13) 0.512 
Acute rejection 7 (18) 20 (24) 0.426 
Values are expressed as mean ±SD or number (percentage). MS, metabolic syndrome; ACEI, 
angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; CMV, 
cytomegalovirus; HDL, high-density lipoprotein; SCr, serum creatinine; ♣ Continuous variables 
were analyzed with the use of t-tests, all categorical data were analyzed with the use of chi-square 
test. 
 
 
Table 5.2 Percentage of patients with metabolic syndrome according to different diagnostic 
criteria. 
                                                          Prevalence of metabolic syndrome (%) 
 n 1 2 3  
Male  69 29 16 22  
Female  52 37 21 31  
Total 121 32 18 26  
1. Modified (Asian) NCEP-ATP III criteria – Waist girth >80cm in women or >90cm in men; 2. 
Original NCEP-ATP III criteria – Waist girth ≥88cm in women or ≥102cm in men; 3. IDF criteria – 
Waist girth ≥80cm in women or ≥90cm in men. NCEP-ATP III denotes National Cholesterol 
Education Program-Adult Treatment Panel III, and IDF International Diabetes Federation. 
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Prevalence of metabolic syndrome and its components as defined 
by the modified (Asian) National Cholesterol Education Program–
Adult Treatment Panel III criteria criteria 
In our Chinese renal transplant recipients, the most common component of MS 
was hypertension and the least common was low HDL-cholesterol. Low HDL-
cholesterol was significantly more common in female patients (14% vs. 2%, 
P=0.009). However, there was no significant difference in the occurrence of 
other MS components between males and females (Table 5.3). 
 
Table 5.3 Crude prevalence of metabolic syndrome and its components as defined by the 
modified (Asian) National Cholesterol Education Program-Adult Treatment Panel III 
criteria. 
Component Total 
(n=121) 
Men 
(n=69) 
Women 
(n=52) 
P value 
 
Central obesity (%) 37 33 42 0.312 
Low HDL-cholesterol (%)  7   2 14  0.009* 
High TG (%) 42 42 42 0.975 
Hypertension (%) 86 84 89 0.490 
Hyperglycemia (%) 36 38 35 0.729 
Metabolic syndrome (%) 32 29 37 0.379 
HDL denotes high-density lipoprotein, and TG triglyceride. 
Discussion  
In the general population, the prevalence of MS differs widely among ethnic 
groups depending on the definition of MS used7-9. In a US study, its prevalence 
was 24.7 to 26.7% using the original NCEP-ATPIII criteria3,9. By contrast, in a 
Japanese population its prevalence was 12.4% using the same NCEP criteria 
and 21.2% according to the modified (Japanese) criteria17. de Vries et al.4 
applied the consensus definition (NCEP-ATPIII) of MS to the kidney transplant 
population in the Netherlands. They reported that 63% of Caucasian renal 
transplant patients had MS. Porrini et al5 reported that 37.7% of Spanish renal 
transplantation recipients had MS using modified NCEP criteria, while 
Armstrong et al.18 reported that 50% of Australian renal transplant recipients 
had MS according to the original NCEP criteria. These various reports suggest 
that MS is more prevalent in Caucasian renal transplant recipients than the 
general Caucasian population. However, there was only a slight difference in 
the prevalence of MS between the general population and renal transplant 
patients in Japan19. This discrepancy may therefore be related to differences in 
lifestyle, eating habits, or the prevalence and degree of obesity among 
Japanese and Caucasian populations. In the InterASIA study, Gu et al.7 
showed that 15.1% of the Chinese adults aged 35-74 years had MS by the 
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modified NCEP (Asian) criteria. In another study involving a Hong Kong 
Chinese working population, the crude prevalence of MS ranged from 8.9 to 
13.4% depending on the criteria used20. In the present study, we showed that 
MS was more prevalent in our Chinese renal transplant recipients than that 
reported in the literature for the general population. To the best of our 
knowledge, this is the first study showing the prevalence of MS in Chinese 
renal transplant recipients. 
 
In our study, body mass index and waist circumference of the MS group were 
significantly greater than in the non-MS group. As in the general population, 
being overweight was a major clinical feature of MS in renal transplant 
recipients. Insulin resistance is the central pathophysiological feature 
underlying MS21. In renal transplant recipients, factors other than obesity may 
contribute to insulin resistance. High-dose immunosuppressive therapy in the 
early post-transplant period, namely steroids and calcineurin inhibitors, may 
play a major role. Indeed, early high-dose steroid usage, together with acute 
rejection, have been associated with insulin resistance22,23. In our study, all 
patients received the same immunosuppressive regimen as well as the same 
amount of maintenance steroids. Thus, we were unable to assess the 
relationship between steroid dosage and the occurrence of MS. However, 
acute rejection was not particularly associated with subsequent development of 
MS. Similarly, none of our patients were on a calcineurin inhibitor-free regimen, 
and thus we could not evaluate their role in the occurrence of MS. Hjelmesaeth 
et al.23 have demonstrated an association between cytomegalovirus (CMV) 
disease and insulin resistance, possibly via inducing release of cytokines such 
as tumour necrosis factor–alpha24,25. Our data, however, could not demonstrate 
any independent relationship between CMV disease and the development of 
MS. 
 
Our study revealed that MS was more prevalent in the female patients (37% vs. 
29%), which was consistent with the general adult population in China7. This 
difference might be due to a higher prevalence of low HDL-cholesterol in 
women compared to men, which may be due to different cut-off values used in 
men and women. de Vries et al.4 also reported that patients with MS were more 
often female. In contrast, some reports have shown that MS was more 
common in male renal transplant recipients5,19, indicating that in renal 
transplant recipients, gender predisposition of MS may differ widely between 
ethnic groups3,7-9,16,17. 
 
In our study, PTDM was more prevalent in the MS group, consistent with a 
previous report by Porrini et al.5 In their longitudinal study, they showed that 
MS was a prominent risk factor for PTDM. Obesity and dyslipidaemia, which 
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are components of MS, are associated with insulin resistance, one of the most 
important causative elements in the pathophysiology of type 2 diabetes26,27. 
Our approach to treating dyslipidaemias in renal transplant recipients is 
consistent with that advocated by the NKF-K/DOQI working group28. There is a 
particular emphasis given to the high cardiovascular risks associated with 
kidney transplantation. Based almost entirely upon adverse results and benefits 
with therapy in the general population, three subgroups of renal allograft 
recipients with distinct lipid profiles are distinguished for particular attention. 
These are: (1) those with triglyceride levels >5.65 mmol/l (>500 mg/dl); (2) 
those with LDL levels >2.59 mmol/l (>100 mg/dl); and (3) those with LDL levels 
≤2.59 mmol/l (≤100 mg/dl), triglycerides levels >2.26 mmol/l (>200 mg/dl) and 
non-HDL cholesterol levels >3.36 mmol/l (>130 mg/dl). They were all treated 
with lipid-lowering agents after failure of control with lifestyle modification.  
 
In the present study, the diagnosis of MS was made according to the NCEP-
ATPIII criteria and IDF criteria, as they are easily applicable in a clinical setting 
and widely used in different studies. Our study showed that the prevalence of 
MS was differed according to the criteria used, being slightly lower by IDF 
criteria (which recognises central obesity as an essential component). At 
present, there is no consensus on which diagnostic criteria for MS are best 
suited for renal transplant recipients. Further longitudinal studies of 
cardiovascular disease and renal allograft function are needed to clarify this 
issue. 
 
It has been reported that MS is a risk factor for renal dysfunction in the general 
population2,3. In heart transplantation, Valantine et al.29 suggested that a 
‘metabolic milieu’ may modify the process of chronic transplant dysfunction. In 
longitudinal studies, de Vries et al.4 and Porrini et al.5 suggested that MS is 
associated with impaired renal allograft function. Different mechanisms have 
been proposed for the association between MS and impaired renal function. 
Obesity may contribute to renal dysfunction in many ways—excess excretory 
load, renal sodium retention, hyperinsulinaemia, insulin resistance, or renal 
lipotoxicity30-33. Moreover, obesity is associated with worsening proteinuria in 
renal transplant recipients18. Finally, glucose intolerance, hypertension and 
dyslipidaemia (all components of MS), directly damage the kidneys through 
renal or systemic atherosclerosis34-37. Our series did not demonstrate a 
significant difference in renal function between patients with and without MS, 
probably because they were from a cross-sectional study and the sample size 
was small. 
 
In conclusion, our present study showed a high prevalence of MS in our 
Chinese renal transplant recipients, more so in females than males. Prevalence 
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varied according to the different diagnostic criteria used. By the IDF criteria, 
which cites central obesity as an essential component, its prevalence was 
slightly lower. 
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Abstract 
Background and aim 
Tacrolimus has a narrow therapeutic window and a wide interindividual variation in its 
pharmacokinetics. Cytochrome P450 3A (CYP3A) and the adenosine triphosphate-
binding cassette B1 (ABCB1) gene encoding protein, multidrug resistance-1 (MDR1) or 
P-glycoprotein play an important role in the tacrolimus disposition. Therefore this study 
evaluates whether CYP3A and ABCB1 polymorphisms are associated with the area 
under the time tacrolimus concentration curve (AUC0-12) calculated using a two time 
point sample strategy.  
 
Materials and methods 
The CYP3A and ABCB1 genotypes are determined by real-time polymerase chain 
reaction (PCR) fluorescence resonance energy transfer (FRET) assays in 103 Chinese 
renal transplant recipients and consequently related to their dose-normalized AUC0-12 
(dnAUC0-12).  
 
Results 
A significant allele-dependent effect (Kruskal Wallis; P<0.001) is observed between the 
CYP3A5*3 polymorphism and the dnAUC0-12. Multiple regression analysis showed that 
the CYP3A5*3 polymorphism is the most significant independent variable and explained 
35% of the dose requirement variability in relation to tacrolimus use. Regarding the 
ABCB1 G2677T/A and C3435T polymorphisms, a trend is observed between the 
different genotypes and the dnAUC0-12.  
 
Conclusion 
The CYP3A5*3 polymorphism may be an important factor in determining the dose 
requirement for tacrolimus and genotyping can help determine the initial daily dose 
needed by individual patients for adequate immunosuppression. 
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Introduction 
The calcineurin inhibitor tacrolimus that is used worldwide for primary 
immunosuppression following renal transplantation has a narrow therapeutic 
index, which makes close therapeutic drug monitoring necessary to prevent 
both sub-therapeutic blood levels as well as toxic blood levels. Subtherapeutic 
tacrolimus blood levels increase the risk of transplant rejection1-3, while toxic 
tacrolimus blood levels may lead to severe side effects such as nephrotoxicity 
and neurotoxicity4-6. The high interindividual variability in tacrolimus 
pharmacokinetics complicates the realization of this narrow therapeutic 
index7,8. Although tacrolimus trough (C0) levels have been shown to provide a 
reliable indication of the total drug exposure9, their usefulness in differentiating 
graft rejection episodes from nephrotoxicity has been questioned2,10. A more 
accurate estimation of the tacrolimus exposure by making 12 hour 
pharmacokinetic profiles may lead to a lower incidence of acute rejection like in 
the case of cyclosporine11,12. Since obtaining complete 12 hour 
pharmacokinetic profiles for every renal transplant patient is not feasible in 
clinical practice, parameters have been examined that strongly correlate with 
the 12 hour pharmacokinetic profile. Recent studies showed higher correlations 
with the 12 hour pharmacokinetic profiles of tacrolimus when a limited sampling 
point sample strategy is used instead of C0 levels alone13-17. Additionally, the 
two time point sample strategy used in the present study is able to calculate 
reliable the area under the time tacrolimus concentration curve or AUC0-12 in 
renal transplant patient groups.15,17 The cytochrome P450 (CYP) 3A iso-
enzymes mainly represented by CYP3A4 and CYP3A5 have been identified as 
the major enzymes responsible for the disposition of tacrolimus.18 Although a 
number of CYP3A4 polymorphisms have been identified  (website Human 
Cytochrome P450 (CYP) Allele Nomenclature Committee101), these are rare 
and therefore do not contribute significantly to CYP3A4 expression variability. 
The single nucleotide polymorphism (SNP) CYP3A5 6986G or *3 displays a 
sequence variability in intron 3 that creates a cryptic splice site and encodes an 
aberrantly spliced mRNA with a premature stop codon, leading to the absence 
of protein expression. This CYP3A5*3 polymorphism occurred homozygously 
in 90% of the Caucasians, 73% of the Chinese and in 30% of the African-
American population19-21. Although several studies22-31 have described the 
association between the CYP3A5*3 polymorphism and tacrolimus C0 levels, the 
present study examines the associations with the CYP3A polymorphisms using 
a more accurate approach to determine the tacrolimus exposure in renal 
transplant patients. Tacrolimus is also a substrate for the adenosine 
triphosphate-binding cassette B1 (ABCB1) gene encoding protein multidrug 
resistance-1 (MDR1) or P-glycoprotein. ABCB1 is an ATP-dependent efflux 
pump that contributes to the protection of the body from environmental toxins 
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and drugs like tacrolimus by limiting their absorption from the gut lumen or 
increasing their biliary and urinary excretion32. Three partly linked 
polymorphisms in the ABCB1 gene located on exons 12, 21 and 26 have been 
studied widely and these polymorphisms account for the major haplotypes 
encountered in Caucasians. Whereas two of these ABCB1 polymorphisms, 
C1236T and C3435T, result in silent mutations, the ABCB1 G2677T/A 
polymorphism in exon 21 is non-synonymous and results in an amino acid 
exchange (Ala893Ser/Thr). A number of studies already have reported that 
there seems to be no association between the ABCB1 polymorphisms and 
tacrolimus dose-normalized trough (dnC0) levels25-27,30,31,33 or the dose-
normalized area under the time tacrolimus concentration curve (dnAUC0-12)34,35. 
However, some studies found a correlation between individual ABCB1 
polymorphisms23,24,36 or the ABCB1 1236C-2677G-3435C haplotype37 and a 
higher tacrolimus dose. The present study evaluates in Chinese renal 
transplant recipients the impact of CYP3A and ABCB1 polymorphisms on the 
dnAUC0-12 which is calculated according to a two time point sampling strategy. 
Furthermore, we described two new real-time polymerase chain reaction (PCR) 
fluorescence resonance energy transfer (FRET) assays to determine the 
genotype for the CYP3A5 A6986G and ABCB1 C1236T polymorphism. 
Patients and methods 
Study population 
A total of 103 Chinese renal transplant recipients who received tacrolimus as 
part of the immunosuppressive therapy and had regular follow-up in Queen 
Elizabeth Hospital or Tuen Mun Hospital in Hong Kong were included in this 
retrospective study. There was no change in the daily tacrolimus dose for at 
least two weeks. Patients were advised to avoid St. John’s wort and grapefruit 
juice which may affect the tacrolimus concentration. None of the patients 
included were taking medication known to have interaction with tacrolimus, 
such as calcium channel blockers, anti-epileptics, anti-mycotics and macrolide 
antibiotics. Additionally, patients who suffered from gastrointestinal disease, 
liver disease or other disorders that may alter the absorption of tacrolimus were 
excluded. Apart from tacrolimus and steroids, these patients were normally put 
on azathioprine, however some patients preferred to use mycophenolic acid on 
advice of their private physician. The dosage of azathioprine was 
1.5 mg/kg/day while the dosage of mycophenolic acid was 0.5 gram twice daily. 
The initial tacrolimus dosage, administrated twice daily, was 0.3 mg/kg/day for 
all patients. The daily tacrolimus dose was then adjusted according to the 
AUC0-12 value, which was kept at around 100-150 ng×hr/ml in the first three 
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months. After three months the target AUC0-12 value was decreased to around 
80-100 ng×hr/ml for long term maintenance. These AUC0-12 values were based 
on our previous pilot study15 and the experiences obtained in our 
transplantation centers. The steroid regimen for the first month was 30 mg/day 
of oral prednisolone, progressively tapered by 2.5 mg every two weeks until a 
daily maintenance dose of 5 mg. Demographic as well as clinical data were 
collected at the time of the tacrolimus blood sample collection. 
Tacrolimus concentration determination 
Tacrolimus blood concentrations were determined 2 (C2) and 4 (C4) hours 
after the morning tacrolimus administration in ethylene diamine tetra-acetic acid 
(EDTA) whole blood using a semi-automated microparticle enzyme 
immunoassay (MEIA) on an Imx II clinical analyser (Abbott Laboratories, 
Abbott Park, IL, USA). The Imx  II does not cross-react enormously with the 
most important tacrolimus metabolite produced by CYP3A5, 13-O-demethyl 
tacrolimus, which has a minor immunosuppressive effect. Furthermore, a few 
metabolites show significant cross reactivity with the antibody but were present 
at low concentrations compared to tacrolimus27. The two tacrolimus blood 
concentrations determined were used to calculate the AUC0-12 according to the 
equation based strategy as described by our group15: AUC0-12 = 16.2 + 2.4 × 
C2 + 5.9 × C4. The dnAUC0-12 was calculated by dividing the AUC0-12 by the 
corresponding 24 hour dose on a milligrams per kilogram basis. 
Ethics 
The study was performed in accordance to the Declaration of Helsinki and its 
amendments. The protocol was approved by the Medical Ethics Committee of 
the Queen Elizabeth Hospital in Hong Kong and written informed consent for 
participation in this study was obtained from all patients. 
DNA isolation 
Genomic DNA was extracted from 103 Chinese renal transplant recipients by 
using 200 μl EDTA anti-coagulated blood for isolation with a QIAamp blood 
mini kit (Qiagen, Leusden, the Netherlands) according to the manufacturers’ 
instructions. 
Genotyping of CYP3A and ABCB1 gene polymorphisms 
Real-time PCR FRET assays were used for genotyping the CYP3A4 A-392G, 
CYP3AP1 G-44A, ABCB1 G2677T/A and C3435T polymorphisms with the 
same primers and probes as described in the original publications38-41. The 
real-time PCR FRET assays for the CYP3A5 A6986G and ABCB1 C1236T 
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polymorphisms were designed, optimised and validated in our laboratory. The 
presence of the expected polymorphisms was confirmed by sequencing the 
different allelic variants of CYP3A5 and ABCB1 according to a direct sequence 
procedure on a capillary sequencer ABI Prism 3100® using the Bridge version 
1.1 sequence kit (both products from Applied Biosystems, Fostercity, USA). 
Genotyping for the CYP3A5 A6986G polymorphism was performed using the 
primers F16: 5’-TTT gCC TCT TTg TAC TTC TTC ATC-‘3 (sense; 172835-858) 
and R16: 5’- Tag TTg TAC gAC ACA Cag CAA CC-‘3 (anti-sense; 173335-313) 
to amplify a 501 bp part from the CYP3A5 gene which covers the A6986G 
polymorphism in intron 3 (Genbank acces no: AF280107). Detection was 
carried out using the anchor probe CYP316R640: 5’-CCC TgT TTg gAC CAC 
ATT ACC CTT-‘3 (sense; 173214-237) which was labelled at the 5‘ end with 
LCRed 640 and phosphorylated at the 3‘- end to block extension and the 
sensor probe CYP3A5A16: 5’-gAg CTC TTT TgT CTT TCA ATA TCT CT-‘3 
(sense; 173187-212) which is complementary to the CYP3A5 6986A or *1 
allele with the polymorphic nucleotide indicated underlined. This 3‘-fluorescein 
labelled anchor probe binds with a distance of one base 5’ to the detection 
probe. The PCR mixture contained 3.3 μl sterile water; 2.0 mmol/l MgCl2; 1.0 μl 
LC Faststart DNA Master Hybridisation Probes (Roche Diagnostics GmbH, 
Mannheim, Germany), 0.60 μmol/l of each primer, and 0.20 μmol/l of both 
anchor and sensor probe (TIB MOLBIOL, Berlin, Germany). After adding 1.0 μl 
containing 50-100 ng genomic DNA to the PCR mixture, the total volume is 
10 μl. The PCR protocol included the following steps: a) denaturation for ten 
minutes at 95°C b) 45 cycles at 95°C for ten seconds; 55°C for ten seconds 
and 72°C for 20 seconds (all 20°C/second). After amplification was completed, 
a melting curve was recorded by cooling to 45°C (20°C/second) holding at 
45°C for two minutes and then heating slowly to 75°C at 0.1°C/second. 
Moreover, genotyping for the ABCB1 C1236T polymorphism is performed 
using the primers F35: 5’-gTT CCT ATA TCC TgT gTC TgT gAA T-‘3 (sense; 
208-32) and R35: 5’-AgT CTA gCT CgC ATg ggT CAT C-‘3 (anti-sense; 
448-27) to amplify a 241 bp part from the ABCB1 gene which covers the 
C1236T polymorphism in exon 12 (Genbank access no: M29432). Detection of 
the ABCB1 C1236T polymorphism was carried out using the anchor probe 
A35: 5'-gCC ACC gTC TgC CCA CTC TgC AC-3 (anti-sense; 343-321) which 
is labelled at the 3’- end with fluorescence and binds with a distance of one 
base 5’ to the sensor probe. This 5’ LCRed640 labelled sensor probe P35: TTC 
Agg TTC AgA CCC TTC AAg (anti-sense; 319-299) which is phosphorylated at 
the 3’ end to block extension from the anchor probe and is complementary to 
the ABCB1 1236T polymorphism which is indicated underlined. The PCR 
mixture for the ABCB1 C1236T polymorphism contained: 2.95 μl sterile water; 
2.0 mmol/l MgCl2; 1.0 μl LC Faststart DNA Master Hybridization Probes; 
(Roche Diagnostics GmbH, Mannheim, Germany) 0.5 μM of each primer and 
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0.225 μmol/l of both sensor and anchor probe (TIB MOLBIOL, Berlin, 
Germany). After adding 1.0 μl containing 50-100 ng genomic DNA to the PCR 
mixture, the total volume was 10 μl. The PCR protocol included the following 
steps: denaturation for 10 minutes at 95°C; 45 cycles at 95°C for 5 seconds, 
55°C for 10 seconds and 72°C for 20 seconds (all 20°C/second). After 
amplification was completed, a melting curve was recorded by heating to 95°C 
(20°C/second) holding at 95°C for 20 seconds; subsequently cooling to 40°C 
(20°C/second) holding at 40°C for 20 seconds and then heating slowly to 85°C 
at 0.2°C/second. All PCR and melting curve analysis were performed on the 
LightCycler (Roche Diagnostics, Almere, the Netherlands). 
Statistical analysis 
Statistical analysis of the data was performed with use of SPSS 12.0 software 
for windows (Chicago, IL, USA). To examine the population homogeneity of the 
patients, the genotype frequencies of the CYP3A and ABCB1 polymorphisms 
were tested against Hardy-Weinberg equilibrium by the Pearson’s goodness-
of-fit test. For analysis of the dnAUC0-12 (ng×hr/ml per mg/kg) and the daily 
tacrolimus dose (mg/kg/day), two groups were compared using the non 
parametric Mann-Whitney test while the non parameteric Kruskal Wallis test 
was used to compare several groups. Stepwise multiple regression analyses 
was used to calculate the relative contribution of several genetic and non-
genetic factors on the variability in the daily tacrolimus dose requirement. The 
genetic factors examined are the CYP3A5*3 polymorphism and three ABCB1 
polymorphisms while the non-genetic factors examined are gender, age, serum 
creatinine concentration, time since transplantation and steroid dosing. P 
values less than 0.05 were considered statistically significant. All values are 
expressed as median and range unless stated otherwise. 
Results 
Demographic characteristics of patients 
Table 6.1 illustrates the characteristics of the 103 Chinese renal transplant 
patients that fulfilled the inclusion criteria and were enrolled in our study. 
Real-time PCR FRET assays for CYP3A5 A6986G and ABCB1 
C1236T genotyping 
The melting point of the sensor probe covering the CYP3A5 A6986G 
polymorphism was 57°C when hybridised to the CYP3A5 6986G/G or *3/*3 
genotype and 62°C when hybridised to the CYP3A5 6986A/A or *1/*1 
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genotype. A heterozygous sample contained both type of targets and thus 
generated both peaks (Figure 6.1A). In addition, for the ABCB1 C1236T 
polymorphism, the melting point of the sensor probe was 56.5°C when 
hybridised to the ABCB1 1236CC genotype and 62°C when hybridised to the 
ABCB1 1236TT genotype. A heterozygote sample for the ABCB1 C1236T 
polymorphism showed both melting peaks (Figure 6.1B). The presence of the 
expected polymorphisms was confirmed by sequencing6 these different allelic 
variants of CYP3A5 and ABCB1 gene. The resulting characterised 
heterozygote samples were used as controls in each run performed. 
 
Table 6.1 Demographic characteristics of the renal transplant recipients  
Demographic characteristics  
Gender (male/female) 58/45 
Age (years, mean ± SD, (range)) 43.1 ± 11.1 (21-77) 
Weight (kg, mean ± SD, (range)) 62.5 ± 11.4 (37.4-87.8) 
Primary kidney disease   
   Glomerulonephritis  
   Chronic pyelonephritis  
   Diabetic nephropathy  
   Hypertensive nephropathy  
   Polycystic kidney disease  
   Obstructive Uropathy 
   Unknown  
   Other  
57 
1 
10 
9 
2 
3 
18 
3 
Transplantation number 
   First  
   Second  
 
97 
6 
Tacrolimus dose (mg/kg body weight/day, mean ± SD, (range)) 0.067 ± 0.032 (0.01-0.18) 
Tacrolimus conc. 2 hour post dose (ng/ml, mean ± SD, (range)) 13.5 ± 4.30 (5.7-29.4) 
Tacrolimus conc. 4 hour post dose (ng/ml, mean ± SD, (range)) 8.7 ± 2.60 (2.3-16.4) 
AUC0-12 (ng × hr/ml, mean, (range)) 100.3 (47.8-183.5) 
DnAUC0-12 (ng × hr/ml per mg/kg body weight, mean, (range)) 1940 (300-11125) 
Use of azathiopurine/mycophenolate mofetil 78/25 
Current steroid dose (mg, mean ± SD, (range)) 6.98 ± 2.37 (4-25) 
Time since transplantation (days, mean, (range)) 977 (133-4982) 
Haemoglobin (mmol/l, mean ± SD, (range)) 12.8 ± 2.0 (8.5-19) 
Haematocrit fraction (mean ± SD, (range)) 0.38 ± 0.058 (0.25-0.57) 
ALAT (U/l, mean ± SD, (range)) 22 ± 18 (8-147) 
Serum albumin (g/l, mean ± SD, (range)) 43 ± 3.2 (34-50) 
Serum creatinine (µmol/l, mean ± SD, (range)) 156 ± 76 (62-462) 
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Figure 6.1 Genotyping of CYP3A5 A6986G and ABCB1 C1236T with allele specific fluorescent 
probes by derivative melting curve plots. The derivative melting curves are read in 
channel 2 for the detection of the CYP3A5 and the ABCB1 fragments. 
 A. The derivative melting curve is plotted for a sample homozygous for the CYP3A5 
6986G or *3 allele (1; Tm 57°C); a sample homozygous for the CYP3A5 6986A or *1 
allele (2; Tm 62°C) and a heterozygous sample (3; Tm 57°C and 62°C). B. The 
derivative melting curve is plotted for a sample homozygous for the ABCB1 1236C 
allele (1; Tm 56.5°C); a sample homozygous for the ABCB1 1236T allele (2; Tm 62°C) 
and a heterozygous sample (3; Tm 56.5°C and 62°C). Melting analysis of a no 
template control was also performed for both assays (4). 
The allele distribution of the different CYP3A and ABCB1 
polymorphisms 
Table 6.2 shows both the different genotypes and the allele frequencies of the 
CYP3A and ABCB1 polymorphisms. In our population, we found no 
homozygous or heterozygous variant allele for the CYP3A4*1B polymorphism, 
which confirmed its very low frequency in the Chinese population. The allele 
frequencies found for the CYP3A5, CYP3AP1 and ABCB1 polymorphisms are 
in line with the literature20,22,25. The distribution of all polymorphisms examined 
is not significantly different from that predicted with the Hardy-Weinberg 
equilibrium (each P>0.05). The genetic linkage of CYP3AP1 G-44A with 
CYP3A5 A6986G as already described by previous studies42,43, was also 
confirmed in our study. 
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Table 6.2 Allelic distribution of CYP3A, CYP3AP1 and ABCB1 variants in 103 Chinese renal 
transplant recipients 
SNP wt/wt wt/m m/m Allele frequency (%) 
CYP3A4 
   A-392G 
 
103 (100%) 
 
0 (0%) 
 
0 (0%) 
A 
100 
G 
0 
 
CYP3A5  
   A6986G 
 
10 (10%) 
 
38 (37%) 
 
55 (53%) 
A 
28 
G 
72 
 
CYP3AP1 
   G-44A 
 
9 (9%) 
 
40 (39%) 
 
54 (52%) 
G 
28 
A 
72 
 
ABCB1, exon 12 
   C1236T 
 
8 (8%) 
 
52 (50%) 
 
43 (42%) 
C 
33 
T 
67 
 
ABCB1, exon 21 
   G2677T/A 
 
26 (25%) 
GT: 32 (31%) 
GA: 16 (15%)
TT: 19 (19%)
TA: 10 (10%)
G 
48 
T 
39 
A 
13 
ABCB1, exon 26 
   C3435T 
 
46 (45%) 
 
43 (42%) 
 
14 (13%) 
C 
66 
T 
34 
 
 
Effect of CYP3A and ABCB1 polymorphisms on tacrolimus dose 
requirements and pharmacokinetic profiles  
Table 6.3 shows a significant decrease in the dnAUC0-12 which strongly 
depends on whether the patients were carrier of none, one or two CYP3A5*1 
alleles (2143, 1228 and 920 ng×hr/ml per mg/kg; Kruskal Wallis, P<0.001), 
respectively. Consequently, the daily tacrolimus dose was 80% higher in 
homozygous carriers of a CYP3A5*1 allele compared to homozygous carriers 
of the CYP3A5*3 allele (0.09 mg/kg/day versus 0.05 mg/kg/day; Kruskal Wallis, 
P<0.001). This allele-dependent effect of the CYP3A5*3 polymorphism is also 
illustrated in Figure 6.2. Additionally, a significant correlation is found between 
the allelic variants of the CYP3AP1 G-44A polymorphism and both the dnAUC0-
12 and the daily tacrolimus dose. Likely, this is caused by a very high linkage 
(>98%) between CYP3A5*3 and CYP3AP1 -44A (only two patients differed in 
genotype) in our study. 
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Figure 6.2 Influence of the CYP3A5 A6986G genotype on the pharmacological parameters 
recorded in 103 renal transplant recipients. A. The boxplot of the dose-normalized 
(dn)AUC0-12 (ng×hr/ml per mg/kg body weight) clustered according to CYP3A5 
A6986G genotype. B. The boxplot of the distribution of the daily tacrolimus dose 
(mg/kg body weight) clustered according to CYP3A5 A6986G genotype. P values for 
the pairwise comparisons of each genotype are given. Open circles indicate an outlier 
value at more than 1.5 boxlengths above the box, while asterics indicate an extreme 
value at more than 3 box lengths above the box. 
 
 
Regarding the ABCB1 polymorphisms, we examined both the individual 
ABCB1 polymorphisms and the ABCB1 haplotypes present in the renal 
transplant patients. Table 6.3 shows the genetic effect of the three individual 
ABCB1 polymorphisms on both the dnAUC0-12 and the daily tacrolimus dose. 
Individuals carrying the 2677TT or 3435TT genotype showed no significant 
difference in the dnAUC0-12 compared to individuals carrying the 2677GG or 
3435CC genotype. However, as is shown in Table 6.3, individuals carrying the 
2677TT or 3435TT genotype required a significantly higher daily tacrolimus 
dose than individuals carrying the 2677GG or 3435CC genotype (0.066 
mg/kg/day versus 0.053 mg/kg/day and 0.073 mg/kg/day versus 0.051 
mg/kg/day; Mann-Whitney, P=0.033 and P=0.044), respectively. In contrast to 
ABCB1 G2677T/A and C3435T, the allelic variants of the ABCB1 C1236T 
polymorphism showed no significant difference on the dnAUC0-12 and the daily 
tacrolimus dose. Additionally, we analysed the correlation between the ABCB1 
haplotypes and the dnAUC0-12 as well as the daily tacrolimus dose.  
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Table 6.3 Influence of CYP3A, CYP3AP1 and ABCB1 genotypes on the daily tacrolimus dose 
and the dose-normalized (Dn)AUC0-12. 
Genotype Allelic status (n) Dose 
(mg/kg/day) 
DnAUC0-12 
(ng×hr/ml 
per mg/kg) 
CYP3A5 *1/*1 (10)  0.090 (0.05-0.18)a  920 (300-1981)a 
A6986G *1/*3 (38)  0.070 (0.04-0.15)a  1228 (589-2266)a 
 *3/*3 (55)  0.050 (0.01–0.10)a  2143 (827-11125)a 
CYP3AP1 G/G   (9)  0.090 (0.05-0.18)a  929 (300-1981)a 
G-44A A/G (40)  0.070 (0.04-0.15)a  1298 (589-2265)a 
 A/A (54)  0.050 (0.01–0.10)a  2156 (827-11125)a 
ABCB1 C/C   (8)  0.060 (0.03-0.15)  1484 (875-5166) 
C1236T C/T (52)  0.060 (0.01-0.18)  1494 (300-11125) 
 T/T (43)  0.063 (0.01-0.15)  1651 (589-7579) 
ABCB1 G/G (26)  0.053 (0.03-0.09)b  1887 (891-6166) 
G2677T/A G/T (32)  0.070 (0.01-0.18)  1365 (300-7579) 
 G/A (16)  0.050 (0.01-0.15)  1864 (676-11125) 
 T/A (10)  0.056 (0.05-0.13)  1765 (805-2870) 
 T/T (19)  0.066 (0.02-0.15)b  1473 (589-4532) 
ABCB1 C/C (46)  0.052 (0.01-0.15)b  1882 (676-11125) 
C3435T C/T (43)  0.063 (0.03-0.18)  1466 (300-6166) 
 T/T (14)  0.073 (0.02-0.15)b  1332 (589-4532) 
CYP3A5 – ABCB1 *3/*3 – GG (17)  0.048 (0.03-0.08)  2097 (1056-6166) 
A6986G – G2677T/A *3/*3 – GA/GT/TA (26)  0.050 (0.01-0.10)  2369 (827-11125) 
 *3/*3 – TT (12)  0.063 (0.02-0.09)  1694 (1237-4532) 
 *1/*3 – GG (8)  0.068 (0.04-0.09)  1346 (913-2168) 
 *1/*3 – GA/GT/TA (24)  0.073 (0.05-0.15)c  1271 (691-1973)c 
 *1/*3 – TT (6)  0.104 (0.05-0.15)c  788 (589-2266)c 
 *1/*1 – GG (1)  0.0787  891 
 *1/*1 – GA/GT/TA (8)  0.110 (0.05-0.18)c  878 (300-1981)c 
 *1/*1 – TT (1)  0.0800  1106* 
CYP3A5 – ABCB1 *3/*3 – CC (28)  0.046 (0.01-0.08)  2120 (1056-11125) 
A6986G – C3435T *3/*3 – CT (21)  0.059 (0.03-0.10)  2179 (827-6166) 
 *3/*3 – TT (6)  0.055 (0.02-0.09)  1845 (1322-4532) 
 *1/*3 – CC (15)  0.069 (0.04-0.15)c  1106 (870-2168)c 
 *1/*3 – CT (16)  0.073 (0.05-0.13)c  1271 (691-1882)c 
 *1/*3 – TT (7)  0.098 (0.05-0.15)c  841 (589-2266)c 
 *1/*1 – CC (3)  0.090 (0.08-0.13)c  891 (676-950)c 
 *1/*1 – CT (6)  0.11 (0.05-0.18)c  977 (300-1981)c 
 *1/*1 – TT (1)  0.800  1106 
Values are indicated as median (range), a P<0.001 (Kruskal Wallis); b P<0.05 (Mann-Whitney), 
c P<0.05 (Bonferroni), when the designated CYP3A5 - ABCB1 genotype combination is compared 
to the reference genotype combination, which is CYP3A5 - ABCB1 G2677T/A *3/*3 – GG and 
CYP3A5-ABCB1 C3435T *3/*3 – CC, respectively. 
 
 
Table 6.4 illustrates that in contrast to the two individual ABCB1 
polymorphisms, no significant difference or trend was observed between the 
ABCB1 haplotypes and the dnAUC0-12 as well as the daily tacrolimus dose. 
Moreover, using stepwise multiple regression analysis to examine the relative 
contribution of the non-genetic and genetic factors to the daily tacrolimus dose 
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variability, the CYP3A5*3 polymorphism appears to be the most significant 
independent variable when considering the daily tacrolimus dose as a 
dependent variable. The CYP3A5*3 polymorphism can explain 35.3% 
(P<0.001) of the variation in the daily tacrolimus dose observed in the renal 
transplant recipient population. Furthermore, gender (9.9%; P<0.001) and the 
ABCB1 C3435T polymorphism (3.7%; P<0.009) have a significant contribution 
in the variation of the daily tacrolimus dose. The two ABCB1 polymorphisms 
C1236T and G2677T/A, ABCB1 haplotypes and the non-genetic factors: age, 
serum creatinine concentration, time since transplantation and steroid dosing 
have no significant contribution on the variation of the daily tacrolimus dose. 
 
Table 6.4 ABCB1 haplotypes in correlation to tacrolimus dose and dose-normalized (Dn)AUC0-12 
 
C1236T 
 
G2677T/A 
 
C3435T 
 
n 
Frequency 
(%) 
Dose 
(mg/kg/day) 
DnAUC0-12 
(ng×hr/ml 
per mg/kg) 
CC GG CC 4 3.9  0.064 (0.03-0.08)  1484 (1301-5166) 
CC GA CC 4 3.9  0.054 (0.03-0.15)  1862 (875-3948) 
CT GG CC 11 10.7  0.070 (0.03–0.09)  1073 (891-4002) 
CT GG CT 2 1.9  0.034  4519 
CT GT CC 2 1.9  0.067  1650 
CT GT CT 15 14.6  0.070 (0.03–0.18)  1227 (300-4702) 
CT GT TT 2 1.9  0.056  2156 
CT GA CC 11 10.7  0.050 (0.01-0.13)  1846 (676-11125) 
CT TA CC 1 1.0  0.050  1918 
CT TA CT 8 7.8  0.056 (0.05-0.13)  1765 (805-2870) 
TT GG CC 9 8.7  0.050 (0.03-0.08)  1919 (1438-3717) 
TT GT CC 2 1.9  0.021  4814 
TT GT CT 11 10.7  0.080 (0.05-0.10)  1325 (837-2309) 
TT GA CC 1 1.0  0.039  2933 
TT TA CC 1 1.0  0.072  1106 
TT TT CT 7 6.7  0.063 (0.05-0.08)  1685 (1237-2626) 
TT TT TT 12 11.7  0.075 (0.02-0.15)  1277 (589-4532) 
 
 
Figure 6.3 suggests that a combined analysis of the CYP3A5*3 and ABCB1 
G2677T/A or ABCB1 C3435T polymorphism may be helpful to identify those 
individuals that require a strong aberrant daily tacrolimus dose, although the 
contribution of the individual ABCB1 polymorphisms on the daily tacrolimus 
dose variation is not significant or minor compared to the CYP3A5*3 
polymorphism. 
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Figure 6.3 The boxplot of the distribution of the daily tacrolimus dose (mg/kg) clustered according 
to the combination of CYP3A5 A6986G and ABCB1 G2677T/A genotypes. B. The 
boxplot of the distribution of the daily tacrolimus dose (mg/kg body weight) clustered 
according to the combination of CYP3A5 A6986G and ABCB1 C3435T genotypes. A 
P value is given for comparison of several groups of both CYP3A5 and ABCB1 
genotype combinations. Open circles indicate an outlier value at more than 1.5 
boxlengths below/above the box, while asterics indicate an extreme value at more 
than 3 box lengths above the box. 
Discussion 
Although most centres still use C0 levels for monitoring tacrolimus there are 
conflicting data about the correlation with the systemic tacrolimus exposure. 
Several studies reported a reasonable squared correlation between C0 levels 
and AUC0-12 of tacrolimus44-46, while other studies found very poor 
correlations13-16,47,48. Recently, Scholten et al.17 reported a reduction of the 95% 
prediction interval by 50%, when a two point sampling strategy was used 
consisting of a C0 level and a second sample obtained between two and four 
hour post dose. Moreover, Scholten et al.17 evaluated the predictive 
performance of the two time point sample strategy used in the present study 
and confirmed its suitability. It is known that several non-genetic factors can 
modulate the post-operative CYP3A phenotype, especially in the early period 
after transplantation49. Therefore, it is important to demonstrate with close drug 
monitoring of tacrolimus that steady state blood concentrations have been 
achieved in order to examine the genotype-phenotype associations more 
accurately. Therapeutic drug monitoring of tacrolimus can be performed 
accurately using complete AUC0-12 or an AUC0-12 calculated by a limited 
sampling strategy. In the present study a limited sampling strategy is used to 
calculate the AUC0-12 in 103 Chinese renal transplant recipients. To the best of 
our knowledge, two recent studies34,35 previously examined, in Japanese renal 
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transplant recipients, the association between the CYP3A5*3 and the ABCB1 
C3435T polymorphism and the pharmacokinetic parameters; (dn)C0, 
(dn)AUC0-12, (dn)Cmax, Tmax and t1/2. Although several studies found a significant 
effect of CYP3A5*3 polymorphism22-24,26-31,35 on tacrolimus levels or dosages, 
the number homozygous carriers of the CYP3A5*1 polymorphism was limited 
in these studies. Recently, Zhang et al.25 correlated the different genotypes of 
the CYP3A5*3 and ABCB1 C3435T polymorphism of 118 Chinese renal 
transplant recipients with their corresponding C0 levels and daily tacrolimus 
dosages respectively, one week, one month and three months after 
transplantation. Our findings showed in line with the results of Zhang et al.25 a 
strong significant genetic effect between the CYP3A5*3 polymorphism and 
both the dnAUC0-12 and the daily tacrolimus dose. After a mean time of 2.5 
years post transplantation, carriers of the CYP3A5*3 polymorphism still require 
a remarkable lower daily tacrolimus dose compared to carriers of the 
CYP3A5*1 polymorphism. An estimation of the contribution of the different 
CYP3A and ABCB1 polymorphisms in the variation of the daily tacrolimus dose 
is performed by Haufroid et al.27. They found that the CYP3A5*3 polymorphism 
is with a relative contribution of 38% the most significant independent variable 
when considering the daily tacrolimus dose as dependent variable, which is in 
line with the findings observed in the present study. The significant contribution 
of the gender in the variation of the daily tacrolimus dose is also found by 
Kuypers et al.14 although they examined the influence of several non-genetic 
variables within the first year after transplantation. However, no significant 
contribution is observed for the time since transplantation in the variation of the 
daily tacrolimus dose in contrast to the findings observed by Haufroid et al.27. 
Despite the ABCB1 G2677T/A and C3435T polymorphisms showed a 
significant genetic effect after correlating these ABCB1 polymorphisms with the 
daily tacrolimus dose, no significant contribution is found using multiple 
regression analysis for the two individual ABCB1 polymorphisms or ABCB1 
haplotype. Our findings seem therefore in contrast to several other studies 
which reported that carriers of the 3435CC allele23,24,36 and 1236C-2677G-
3435C or 2677GG-3435CC haplotype required a higher daily tacrolimus 
dose37. However, the significant genetic effect for ABCB1 polymorphisms or 
haplotypes found in these studies is like in our study not as pronounced as it is 
for the CYP3A5*3 polymorphism. The minor influence of the ABCB1 
polymorphisms compared to the CYP3A5*3 polymorphism on the tacrolimus 
pharmacokinetics combined with the differences regarding pharmacokinetic 
parameter used (C0 or AUC0-12), the genetic (single SNP versus haplotype) 
analyses that were performed, the number of transplant patients included, and 
the difference in inclusion criteria for the transplant recipients may explain the 
differences in genotype-phenotype associations found by these studies. Also 
after combining the CYP3A5*3 polymorphism with the ABCB1 G2677T/A or 
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C3435T polymorphism, the extra part of the variation in dnAUC0-12 and daily 
tacrolimus dose that can be clarified above the CYP3A5*3 polymorphism is 
marginal. 
Highlights 
• The calcineurin inhibitor tacrolimus, an immunosuppressant used in 
transplantation therapy, has unpredictable drug levels and therefore 
requires close therapeutic drug monitoring in order to minimize the risk of 
under- or overimmunosuppression. 
• Tacrolimus is metabolized by the cytochrome P450 3A (CYP3A) iso-
enzymes, which is quantitatively the most important metabolic route of 
tacrolimus. Additionally, tacrolimus is also a substrate for the adenosine 
triphosphate-binding cassette B1 (ABCB1) gene encoding protein multidrug 
resistance-1 (MDR1) or P-glycoprotein. 
• The present study used a two time point sampling strategy to calculate the 
area under the time tacrolimus concentration curve (AUC0-12) and 
correlated these dose-normalized AUC0-12 with the corresponding CYP3A 
and ABCB1 genotypes in 103 Chinese renal transplant recipients. 
• Several single nucleotide polymorphisms (SNPs) recently identified in 
CYP3A and ABCB1 gene may elucidate the interindividual differences in 
the tacrolimus pharmacokinetics. 
• The CYP3A5*3 allele, which results in the absence of the functional 
CYP3A5 protein, has been strongly associated with a higher dnAUC0-12 
and consequently a lower daily tacrolimus dose. The different genotypes of 
the ABCB1 G2677T/A and C3435T SNPs showed a weaker association 
with the dnAUC0-12 as well as the daily tacrolimus dose. 
• Multiple regression analysis demonstrates that the CYP3A5*3 allele is the 
most important independent variable among several genetic and non-
genetic variables examined in the renal transplant recipients. 
• Knowing the impact of the CYP3A5*3 allele on the tacrolimus disposition, 
genotyping prior transplantation may help to assess the initial daily dose 
needed by individual patients for adequate immunosuppression. 
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Outlook and conclusion 
Tacrolimus has a narrow therapeutic index which requires close monitoring of 
the drug concentration in order to achieve an optimal efficiency and minimizing 
the risks of acute rejection and drug overdose. The polymorphisms present in 
CYP3A and ABCB1 can explain their variability in expression and activity and 
thus clarify the interindividual differences in the tacrolimus pharmacokinetics. 
The majority of studies that examined the CYP3A and ABCB1 genotype-
phenotype association were based on tacrolimus C0 levels, despite the fact that 
an AUC0-12 is the best way to determine the tacrolimus exposure. To the best of 
our knowledge only two studies reported an association between the 
CYP3A5*3 polymorphism and both the different pharmacokinetic parameters of 
tacrolimus and the daily tacrolimus dose. Furthermore, several studies reported 
an association between CYP3A5*3 polymorphism and the tacrolimus C0 levels 
obtained within the early period after transplantation. However, non-genetic 
parameters have then also a large impact on the tacrolimus concentration in 
this period. The present study calculated an AUC0-12 according to a two time 
point sampling strategy for 103 Chinese renal transplant patients with a wide 
time interval starting on at least three months post-transplantation. Our results 
clearly point out that the CYP3A5*3 polymorphism is strongly allele-dependent 
associated with both the dnAUC0-12 and the daily tacrolimus dose in renal 
transplant recipients. A weaker significant association is found for the ABCB1 
G2677T/A and ABCB1 C3435T polymorphisms. Multiple regression analysis 
demonstrates that the CYP3A5*3 polymorphism is the most important 
independent variable among several genetic and non-genetic variables 
examined in the renal transplant recipients. Therefore, CYP3A5 genotyping 
prior transplantation may contribute to determine the initial tacrolimus dose 
required for individual patients. 
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Abstract 
Background and aim 
Tacrolimus, an immunosuppressant used after organ transplantation, has a narrow 
therapeutic range and its pharmacokinetic variability complicates its daily dose 
assessment. P-glycoprotein (P-gp), encoded by the adenosine triphosphate-binding 
cassette B1 (ABCB1) and the cytochrome (CYP) 3A4 and 3A5 enzymes appear to play 
a role in the tacrolimus metabolism.  
 
Materials and methods 
In the present study, two different renal transplant recipients groups are used to 
examine the influence of ABCB1 and CYP3A polymorphisms on the daily tacrolimus 
dose and several pharmacokinetic parameters. In total 63 Caucasian renal transplant 
recipients divided into 26 early [median (range) of the days since transplantation –16 
(3-74)] and 37 late post-transplant recipients [median (range) of the days since 
transplantation –1465 (453-4128)] were genotyped for ABCB1 and CYP3A 
polymorphisms. The pharmacokinetic parameters of tacrolimus were determined for all 
renal transplant recipients and correlated with their corresponding genotypes.  
 
Results 
A significant difference in allele frequencies of the CYP3A4*1B (P=0.028) and 
CYP3A5*1 (P=0.022) alleles was observed between the early and late post-transplant 
recipient groups. Significant higher dose-normalized trough levels (dnC0), dose-
normalized area under the curve (dnAUC0-12), and dose-normalized maximum 
concentration (dnCmax) were observed for carriers of the CYP3A5*3 variant allele in both 
renal transplant patient groups. Except for the daily tacrolimus dose (P=0.025) no 
significant differences were observed for carriers of the CYP3A4*1B variant allele. 
Neither the individual ABCB1 polymorphisms nor the ABCB1 haplotypes were 
associated with any pharmacokinetic parameter. 
 
Conclusion 
We noticed that patients carrying a CYP3A5*1 allele require a twofold higher tacrolimus 
dose compared to homozygous carriers of the CYP3A5*3 variant allele to maintain the 
target dnAUC0-12. Therefore, genotyping for the CYP3A5*3 variant allele can contribute 
to a better and more individualized immunosuppressive therapy in transplant patients. 
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Introduction 
The immunosuppressant tacrolimus is used worldwide in transplant patients 
although its narrow therapeutic window and high pharmacokinetic variability 
complicate the establishment of a dosage regime1,2. Therefore, close 
therapeutic drug monitoring for tacrolimus is required to prevent the risk of sub-
therapeutic or toxic blood concentrations. Sub-therapeutic tacrolimus blood 
concentrations increase the risk of transplant rejection enormously3-5, while 
high tacrolimus blood concentrations may lead to severe side effects such as 
nephrotoxicity, neurotoxicity and hyperglycemia6-8. Tacrolimus is similar to 
numerous other clinically used drugs, a substrate for P-glycoprotein (P-gp) and 
cytochrome P450 3A (CYP3A) enzymes. P-gp is encoded by the adenosine 
triphosphate (ATP)-binding cassette B1 (ABCB1) gene and co-expressed with 
the CYP3A enzymes in the liver and intestines. CYP3A4 and CYP3A5 are the 
most important members of the CYP3A subfamily9,10. The differences in 
expression levels and activity of ABCB1 and CYP3A may explain the 
interindividual variations in the tacrolimus pharmacokinetics. P-gp is an ATP-
dependent membranous transporter that contributes to the protection of the 
body from environmental toxins and drugs such as tacrolimus by limiting their 
absorption from the intestine and promoting the efflux into bile and urine11. 
Three partly linked polymorphisms in the ABCB1 gene located on exons 12, 21 
and 26 were studied extensively. Two of these ABCB1 polymorphisms, 
C1236T and C3435T, result in silent mutations while the ABCB1 G2677T/A 
polymorphism in exon 21 is non-synonymous and results in an amino acid 
exchange (Ala893Ser/Thr). A number of studies found no association between 
the ABCB1 genotypes and tacrolimus trough (C0) concentrations12-17 or the 
pharmacokinetic parameters: area under the time/ tacrolimus concentration 
curve (AUC0-12), the maximum concentration (Cmax), the time that the maximum 
concentration is reached (Tmax) and the half-life time (t1/2)18,19. However, some 
other studies found an association between the tacrolimus C0 concentrations, 
the daily tacrolimus dose and individual ABCB1 polymorphisms20,21 or the 
ABCB1 haplotypes22. Homozygotes for the CYP3A4*1B and CYP3A5*3 variant 
allele carry at position –392 an A and at position 6986 a G, respectively. 
Moreover, homozygotes for the CYP3A4*1B variant allele show an altered 
CYP3A4 enzyme activity while homozygotes for the CYP3A5*3 variant allele 
show no CYP3A5 enzyme activity. A number of studies demonstrated the 
impact of the CYP3A5*3 variant allele on tacrolimus C0 concentrations12-17,23-25, 
the pharmacokinetic parameters: AUC0-12, Cmax, Tmax, t1/218,19 and the daily 
tacrolimus dose in different transplant patient groups. However, the influence of 
CYP3A4*1B and ABCB1 C1236T variant alleles on these pharmacokinetic 
parameters of tacrolimus was never examined. In the present study, a 
complete 12-h pharmacokinetic profile is recorded for all transplant patients to 
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examine the association between the CYP3A4 A-392G, CYP3A5 A6986G, 
CYP3AP1 G-44A polymorphisms and the three ABCB1 polymorphisms 
C1236T, G2677T/A, C3435T on the pharmacokinetic parameters in an early 
and a late post-transplant recipient group. Furthermore, the influence of several 
clinical parameters was determined on the variation in pharmacokinetic 
parameters in the two renal transplant recipient groups. 
Patients and methods 
Study population 
In total 63 Caucasian renal transplant recipients (of whom a complete 12-h 
time-tacrolimus concentration curve was performed) were divided into two 
different groups. Group I included early post-transplant patients with a short 
median time since transplantation [16 (3-74) days], while group II included late 
post-transplant patients with a long median time since transplantation [1465 
(453-4128) days]. Moreover, in group I eight patients used calcium channel 
blockers which are known to interact with tacrolimus, whereas patients included 
in group II used no medication known to interfere with tacrolimus. In addition, 
patients that suffer from gastrointestinal, liver disease or other disorders that 
may alter the absorption of tacrolimus were disqualified for inclusion in both 
groups. Prior to the blood sample collection, there had been no tacrolimus dose 
change for at least three days in the two groups. After overnight fasting the 
blood samples were collected immediately before (C0) and 0.5 (C0.5), 1 (C1), 
2 (C2), 3 (C3), 4 (C4), 5 (C5), 7.5 (C7.5) and 12 (C12) hours after the morning 
tacrolimus administration. Patients were not allowed to take food until one hour 
after ingesting the tacrolimus dose and were advised to avoid grapefruit juice 
after transplantation to prevent alterations in the tacrolimus metabolism. 
Demographic as well as clinical data were determined at the time of recording 
the 12 hour time tacrolimus concentration curve. 
Ethics 
The study was performed in accordance to the Declaration of Helsinki and its 
amendments. The protocol was approved by the local Medical Ethics 
Committee, and written informed consent for participation in this study was 
obtained from all patients. 
Tacrolimus concentration determinations  
The tacrolimus blood concentrations were determined in ethylenediaminetetra-
acetic acid (EDTA)-added whole blood samples, using a method based on a 
microparticle enzyme immunoassay with a monoclonal antibody (IMX II assay 
and a high-pressure liquid chromotography (HPLC) tandem mass spectrometry 
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(MS/MS) assay. The immunoassay IMX II is linear from 1.5 to 30 microg/l. The 
repeatability of a low (5 microg/l) tacrolimus concentration is 6.7%; medium 
(11 microg/l) tacrolimus concentration 7.2% and the high (22 microg/l) 
tacrolimus concentration 6,6%. The limit of quantification was 1.5 microg/l. 
Additionally, the HPLC tandem MS/MS assay is linear from 1 to 300 microg/l. 
Intra-assay precision was 3.4%, 2,2% and 3.0% and accuracy was 102%, 94% 
and 94% at 3.04, 6.23 and 13.0 microg/l (n=6), respectively. Inter-assay 
precision was 8.2%, 5,2%, 4,6% and accuracy was 102%, 94% and 93% (n=9), 
respectively. The limit of quantification was 1.0 microg/l. The laboratory is a 
participatory in an International Tacrolimus Proficiency Testing Scheme. 
The tacrolimus C0 concentration and the peak blood concentration (Cmax) 
during the time interval assessed were determined directly from the time versus 
tacrolimus blood concentration data. Additionally, the area under the 
time/concentration curve (AUC0-12) was calculated from the time versus 
tacrolimus concentration plot using the linear trapezoidal rule in MWPharm 
3.50 (Mediware, Groningen, the Netherlands). Dose-normalized (dn)C0, dose-
normalized (dn)AUC0-12 and dose-normalized (dn)Cmax were calculated by 
dividing the C0, AUC0-12 and Cmax, respectively, by the corresponding morning 
dose on a milligram per kilogram basis. 
DNA isolation 
Genomic DNA isolation of 63 renal transplant recipients was performed by 
using 200 μl EDTA-anti-coagulated blood sample with a QIAamp blood mini kit 
(Qiagen, Leusden, the Netherlands) according to the manufacturers’ 
instructions. 
Genotyping of ABCB1 and CYP3A gene polymorphisms 
Real-time polymerase chain reaction (PCR)-fluorescence resonance energy 
transfer (FRET) assays were used for genotyping, ABCB1 G2677T/A, ABCB1 
C3435T, CYP3A4 A-392G and CYP3AP1 G-44A using the same primers and 
probes as in other studies26-29. In Table 7.1 the sequences of the primers and 
the probes are illustrated. Regarding the ABCB1 C1236T and CYP3A5 
A6986G polymorphisms real-time PCR-FRET assays were performed as 
described earlier30. Although it is known that CYP3A5 A6986G polymorphism 
influences CYP3A5 activity, in the present study the known linkage between 
the G-44A polymorphism in the pseudo-enzyme CYP3AP1 and CYP3A5 
A6986G polymorphism was also determined. For each polymorphism, 
heterozygote samples were sequenced according to a direct sequence 
procedure on a capillary sequencer ABI Prism 3100® using the Bridge version 
1.1 sequence kit (both products from Applied Biosystems, Fostercity, USA) and 
for each assay control samples with known genotypes were run in parallel with 
study samples. 
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Statistical analysis 
Statistical analysis of the data was performed with the use of the statistical 
software SPSS 11.0 for Windows (Chicago, IL, USA). Correlations between 
pharmacokinetic parameters and clinical variables were evaluated using 
stepwise multiple regression analysis. To examine the population homogeneity 
of the patients, the genotype frequencies of the ABCB1 and CYP3A 
polymorphisms were tested against Hardy-Weinberg equilibrium by the 
Pearson’s goodness-of-fit test31. Allele frequencies of the early and late post-
transplant recipient groups were compared using the χ2 test. For analysis of the 
daily tacrolimus dose (mg/kg/day), dnC0 (ng/ml per mg/kg), dnAUC0-12 
(ng×hr/ml per mg/kg), and dnCmax (ng/ml per mg/kg), groups were compared 
using non-parametric statistical tests. To compare two groups we used the 
Mann-Whitney test, and to compare several groups the Kruskal Wallis test. 
P-values less than 0.05 were considered statistically significant. All values are 
expressed as median and range unless stated otherwise. 
Results 
Influence of clinical and genetic parameters on the variation in 
pharmacokinetic tacrolimus parameters   
The characteristics of the early post-transplant (group I) as well as the late 
post-transplant (group II) recipients who were enrolled in our study are shown 
in Table 7.2.  
 
Table 7.2 Demographic characteristics of the two renal transplant recipients groups. 
Demographic characteristics Group I Group II 
Gender (male/female) 18/8 24/13 
Age (years, mean ± SD)  43.0 ± 13.2  51.3 ± 10.9 
Body Mass Index (kg/m2, mean ± SD)  23.3 ± 4.40  25.6 ± 3.42 
Transplantation number First 
      Second 
      Third or more 
 20 
 5 
 1 
 30 
 6 
 1 
Use of azothiopurine/MMF/rapamycine  1  29 
Time since transplantation (days, median, (range)) 16 (3-74) 1465 (453–4128) 
Haemoglobin (mmol/l, mean ± SD; ref. ♂ 8.2-11.0, ♀ 7.3-9.7)  5.43 ± 1.08  8.52 ± 0.83 
Haematocrit (mean ± SD; ref. ♂ 0.41-0.52, ♀ 0.36-0.48)  0.25 ± 0.07  0.41 ± 0.04 
ALAT (U/l, mean ± SD; ref. ♂ <45, ♀ <35)  34 ± 34  24 ± 13 
Serum albumin (g/l, mean ± SD; ref. 34-45)  30.7 ± 3.86  37.0 ± 3.84 
Serum creatinine (μmol/l, mean ± SD; ref. ♂ 71-110, ♀ 53-97)  331 ± 293  128 ± 29 
Creatinine clearancea (ml/min, mean ± SD; ref. 90-140)  37.5 ± 28.4  58.0 ± 26.6 
ref. the reference values applied in the Clinical Chemistry and Haematology Laboratory of the 
University Hospital Maastricht. ♂ male, ♀ female, MMF is mycophenolate mofetil, a creatinine 
clearance is determined with the Cockcroft-Gault equation. 
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The influence of different clinical (gender, age, body mass index (BMI), 
haemoglobin, haematocrit, ALAT, serum albumin, serum creatinine, creatinine 
clearance) and genetic (CYP3A4 A-392G, CYP3A5 A6986G, ABCB1 C1236T, 
G2677T/A, C3435T) parameters was examined on the variation in the 
tacrolimus pharmacokinetic parameters in all post-transplant recipients. Table 
7.3 illustrates the influence of independent clinical and genetic parameters on 
the variability of pharmacokinetic tacrolimus parameters. In the early post-
transplant recipient group the time since transplantation and the haemoglobin 
concentration correlated significantly with dnC0, dnAUC0-12 and dnCmax whereas 
the CYP3A5 A6986G polymorphism and the body mass index (BMI) were 
found to have a significant influence on the variability of dnC0, dnAUC0-12 and 
dnCmax in the late post-transplant recipient group. The clinical and genetic 
parameters: age, haematocrit, ALAT, serum creatinine, creatinine clearance 
and the polymorphisms CYP3A4 A-392G, ABCB1 C1236T, ABCB1 G2677T/A 
and ABCB1 C3435T show no significant correlation with any of the 
pharmacokinetic parameters in both renal transplant recipient groups. 
 
Tabel 7.3 Influence of independent clinical and genetic parameters on the pharmacokinetic 
parameters of an early (group I) and a late (group II) post-transplant recipient group. 
Group Dependent parameter Independent parameter Partial r2 aP value 
I Tacrolimus dose CYP3A5 A6986G polymorphism 0.531  < 0.001 
  Model r2: 0.531   
I DnC0 Time since transplantation 0.613  < 0.001 
  Haemoglobin 0.079  < 0.001 
  Model r2: 0.692   
I DnAUC0-12 Time since transplantation 0.528  < 0.001 
  Haemoglobin 0.092  < 0.001 
  Model r2: 0.620   
I DnCmax Time since transplantation 0.405  < 0.001 
  Haemoglobin 0.230  < 0.001 
  Model r2: 0.635   
II Tacrolimus dose CYP3A5 A6986G polymorphism 0.354  < 0.001 
  Model r2: 0.354   
II DnC0 CYP3A5 A6986G polymorphism 0.175  0.010 
  Body mass index (BMI) 0.157  0.001 
  Gender 0.086  < 0.001 
  Model r2: 0.418   
II DnAUC0-12 CYP3A5 A6986G polymorphism 0.190  0.007 
  Body mass index (BMI) 0.145  0.001 
  Model r2: 0.335   
II DnCmax CYP3A5 A6986G polymorphism 0.226  0.003 
  Body mass index (BMI) 0.109  0.001 
  Serum Albumin 0.077  < 0.001 
  Model r2: 0.412   
P value belonging to the partial r2. DnC0, dose-normalized trough level, dnAUC0-12, dose-normalized 
area under the curve, DnCmax dose-normalized maximum concentration. Tested independent 
parameters were gender, age, body mass index (BMI), haemoglobin, haematocrit, ALAT, serum 
albumin, serum creatinine, creatinine clearance (Cockcroft-Gault), CYP3A4 A-392G, CYP3A5 
A6986G, ABCB1 C1236T, G2677T/A, C3435T. 
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Allele distribution of the different ABCB1 and CYP3A 
polymorphisms 
Table 7.4 and 7.5 show the genotype frequencies of the different CYP3A and 
CYP3AP1 polymorphisms that were determined for the 26 early and 37 late 
post-transplant recipients. The genotype frequencies of the two renal transplant 
recipient groups were not significantly different from that predicted by the 
Hardy-Weinberg equation. 
 
Table 7.4 Influence of ABCB1, CYP3A and CYP3AP1 allelic variants on the pharmacokinetic 
tacrolimus parameters of the early post-transplant recipients. 
Genotype N 
No 
Allelic 
status 
Dose 
 
DnC0 
 
DnAUC0-12 
 
DnCmax 
 
CYP3A4 21 *1A/*1A 0.28 (0.04-0.80)a 90 (40-1329) 1782 (824-15721) 383 (89-1535) 
A-392G 5 *1A/*1B 0.50 (0.43-0.79)a 59 (32-107) 1275 (922-1796) 216 (184-338) 
 0 *1B/*1B ----- ----- ----- ----- 
CYP3A5 1 *1/*1 0.78 32 922 184 
A6986G 9 *1/*3 0.50 (0.35-0.80)a 59 (40-107)a 1220 (824-1796)a 216 (89-380)a 
 16 *3/*3 0.25 (0.04-0.59)a 118 (45-1329)a 1975 (839-15721)a 435(90-1535)a 
CYP3AP1 1 G/G 0.78 32 922 184 
G-44A 10 G/A 0.49 (0.12-0.80)a 60 (40-107)a 1248 (824-1796)a 236 (89-381)a 
 15 A/A 0.25 (0.04-0.59)a 123 (45-1329)a 2030 (839-15721)a 454 (90-1535)a 
Tacrolimus dose (mg/kg/day), dnC0, dose-normalized trough concentration (ng/ml per mg/kg), 
dnAUC0-12 (ng × hr/ml per mg/kg) dose-normalized area under the curve, dnCmax dose-normalized 
maximum concentration (ng/ml per mg/kg). Values are indicated as median and (range), a P<0.05; 
(Mann-Whitney). 
 
Table 7.5 Influence of ABCB1, CYP3A and CYP3AP1 allelic variants on the pharmacokinetic 
tacrolimus parameters of the late posttransplant recipients. 
Genotype N 
No 
Allelic 
status 
Dose 
 
DnC0 
 
DnAUC0-12 
 
DnCmax 
 
CYP3A4 36 *1A/*1A 0.05 (0.02-0.14) 276 (70-669) 4642 (1355-11994) 775 (294-1729) 
A-392G  1 *1A/*1B 0.067 121 2766 504 
  0 *1B/*1B ----- ----- ----- ----- 
CYP3A5  0 *1/*1 ----- ----- ----- ----- 
A6986G  5 *1/*3 0.10 (0.05-0.14)a 87.4 (70-248)a 1663 (1355-4057)a 461 (294-646)a 
 32 *3/*3 0.04 (0.02-0.11)a 287 (118-669)a 4808 (2227-11994)a 814 (465-1729)a 
CYP3AP1  0 G/G ----- ----- ----- ----- 
G-44A  8 G/A 0.07 (0.02-0.14)a 161 (70-669)a 2990 (1355-11994)a 544 (294-1729)a 
 29 A/A 0.04 (0.02-0.11)a 283 (118-640)a 4761 (2227-11504)a 810 (465-1493)a 
Tacrolimus dose (mg/kg/day), dnC0, dose-normalized trough concentration (ng/ml per mg/kg), 
dnAUC0-12 (ng×hr/ml per mg/kg) dose-normalized area under the curve, dnCmax dose-normalized 
maximum concentration (ng/ml per mg/kg). Values are indicated as median and (range), a P<0.05; 
(Mann-Whitney). 
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Effect of ABCB1 and CYP3A polymorphisms on the daily 
tacrolimus dose and the pharmacokinetic parameters 
In the present study, we found that neither the individual ABCB1 
polymorphisms nor the ABCB1 haplotypes were associated with the daily 
tacrolimus dose and the pharmacokinetic parameters; dnC0, dnAUC0-12 and 
dnCmax.  
Table 7.4 shows a trend between the heterozygote carriers of the CYP3A4*1B 
variant allele in both the daily tacrolimus dose and the pharmacokinetic 
tacrolimus parameters compared to the homozygote carriers of the 
CYP3A4*1A allele. However, except for the daily tacrolimus dose (0.28 vs. 0.50 
mg/kg/day; Mann-Whitney, P=0.025), no significant differences were found 
between the pharmacokinetic parameters for tacrolimus and the different 
CYP3A4 A-392G genotypes in the early post-transplant recipient group.  
Additionally, Table 7.4 demonstrates a significant decrease in the pharmaco-
kinetic tacrolimus parameters dnC0, 118 vs. 59 ng/ml per mg/kg; dnAUC0-12 
1975 vs 1220 ng×hr/ml per mg/kg; and dnCmax 435 vs. 216 ng/ml per mg/kg 
when renal transplant recipients were carriers of none or one CYP3A5*1 allele. 
Consequently, the daily tacrolimus dose was significantly higher in 
heterozygous carriers of the CYP3A5*3 variant allele compared to homozygous 
carriers of the CYP3A5*3 variant allele (0.50 vs. 0.25 mg/kg/day; Mann-
Whitney, P=0.001). Regarding the late post-transplant recipients included in 
group II, a similar genetic effect is found for CYP3A5*1 allele in association 
with the pharmacokinetic tacrolimus parameters and the daily tacrolimus dose, 
as is shown in Table7.5. Because there is only one heterozygous carrier of the 
CYP3A4*1B variant allele among the late post-transplant group, no statistical 
analyses could be performed between the CYP3A4*1B genotypes and the 
pharmacokinetic tacrolimus parameters. Although we observed a significant 
difference in the daily tacrolimus dose as well as in the dnC0, dnAUC0-12 and 
dnCmax for only the CYP3A5*3 variant allele, it is not clear whether the 
CYP3A4*1B variant allele has, similarly to the CYP3A5*3 variant allele, an 
important contribution to the pharmacokinetic variability of tacrolimus, 
particularly, knowing that in this study all individuals carrying a CYP3A4*1B 
variant allele also carry at least one CYP3A5*1 allele. To examine the influence 
of the CYP3A4*1B variant allele solely, we selected those renal transplant 
recipients in group I who were heterozygous for the CYP3A5*1 allele. One 
renal transplant patient was heterozygous for the CYP3A4*1B variant allele 
and homozygote for the CYP3A5*1 allele. Five renal transplant patients were 
carriers of both one CYP3A4*1B variant allele and one CYP3A5*1 allele. 
Additionally, another four renal transplant recipients were homozygous for the 
CYP3A4*1A allele and heterozygous for one CYP3A5*1 allele. Figure 7.1 
illustrates that renal transplant recipients who were heterozygous for the 
CYP3A4*1B and CYP3A5*3 variant allele show no significantly higher daily 
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tacrolimus dose or lower dnAUC0-12 compared to patients that were only 
heterozygous for the CYP3A4*1B variant allele. 
 
A                                                             B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Box plot of the distribution of (A) the dose-normalized (Dn)AUC0-12 (ng×hr/ml per 
mg/kg) and (B) the tacrolimus dose (mg/kg/day) clustered according to the 
combination of CYP3A4 A-392G and CYP3A5 A6986G genotypes. P values are given 
for the pairwise comparisons of each genotype combination. 
Discussion 
In the early post-transplant recipient group, the time since transplantation and 
the haemoglobin concentration contributes significantly to the variability of the 
pharmacokinetic tacrolimus parameters dnC0, dnAUC0-12 and dnCmax while in 
the late post-transplant recipient group the CYP3A5 A6986G polymorphism 
and the BMI have an important influence on the variability of different 
pharmacokinetic tacrolimus parameters. Previously, Haufroid et al.12 reported a 
significant contribution of the CYP3A5 A6986G polymorphism and the time 
since transplantation on the variation of tacrolimus C0 concentrations and the 
tacrolimus dose requirement. Additionally, we also demonstrated in a stable 
Chinese renal transplant recipient population that the CYP3A5 A6986G 
polymorphism is the most significant independent variable when considering 
the daily tacrolimus dose as a dependent variable30. Kuypers et al.32 found 
higher tacrolimus peak concentrations for female renal transplant recipients 
compared to their male counterparts and a significantly higher tacrolimus AUC0-
12 in female recipients six months after transplantation. Furthermore, Kuypers 
et al.32 found lower tacrolimus trough concentrations with increasing age.  
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Although some earlier studies20-22 reported a weak significant association 
between ABCB1 genotypes or haplotypes with tacrolimus C0 concentrations of 
the transplant patients, no differences were found between either the different 
ABCB1 polymorphisms or the ABCB1 haplotypes and the pharmacokinetic 
tacrolimus parameters in the two renal transplant recipient groups. Recently, 
Fredericks et al.33 reported, after examining 206 stable renal transplant 
recipients that the individual ABCB1 polymorphisms and ABCB1 haplotypes 
show a relatively minor association with the tacrolimus pharmacokinetics which 
implies that genotyping for ABCB1 polymorphisms seems to be of minor 
importance for predicting the daily tacrolimus dose regime. CYP3A enzymes 
are responsible for the most important metabolic route of tacrolimus, namely its 
demethylation to 13-O-demethyltacrolimus34-37. Because of the lack of CYP3A5 
activity caused by the CYP3A5*3 variant allele, transplant patients who were 
homozygous for the CYP3A5*3 variant allele required an almost twofold lower 
daily tacrolimus dose and achieved even a higher dnC0, dnAUC0-12 and dnCmax 
compared with the transplant recipients who carry at least one CYP3A5*1 
allele. Although in the present study a trend was observed between the 
different CYP3A4 A-392G genotypes and the pharmacokinetic tacrolimus 
parameters, the contribution of this CYP3A4*1B variant allele seemed limited. 
After selecting two renal transplant recipient groups - one group with the 
genotype combination CYP3A4 *1A/*1A – CYP3A5 *1/*3 and the other with the 
genotype combination CYP3A4 *1A/*1B – CYP3A5 *1/*3 - no significant 
differences were observed between these groups and the daily tacrolimus dose 
as well as the dnC0, dnAUC0-12 and dnCmax. This may indicate that the influence 
of the CYP3A4 *1B variant allele is restricted and that at least most of the 
genetic effect is being caused by the CYP3A5 A6986G polymorphism. On the 
other hand, Hesselink et al. reported that the CYP3A4*1B variant allele has a 
significant influence on the daily tacrolimus dose though they observed a 80% 
overlap between the CYP3A4*1B and CYP3A5*1 allele15. Although tacrolimus 
is a substrate of CYP3A4, our findings with a limited number of patients 
suggest that if there is an influence of this CYP3A4*1B polymorphism, it is 
probably caused by the strong linkage between CYP3A4*1B and CYP3A5*1. In 
conclusion, it appears that carriers of CYP3A5*1 allele included, in either the 
early or the late post-transplant recipient group, show a twofold lower dnC0, 
dnAUC0-12 and dnCmax for tacrolimus compared  with homozygous carriers of a 
CYP3A5*3 variant allele. Thus carriers of a CYP3A5*1 allele require a twofold 
higher tacrolimus dose compared with homozygous carriers of a CYP3A5*3 
variant allele. Therefore, we conclude that genotyping for the CYP3A5*3 
variant allele is of great value to determine the initial and maintenance oral 
tacrolimus dose. By doing so the risk of under- or over-immunosuppression in 
individual renal transplant recipients will be minimized. 
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Abstract 
Dried blood spot (DBS) sampling and high-performance liquid chromatography-tandem 
mass spectrometry (HPLC-MS), have been developed in monitoring tacrolimus levels. 
Our center favors the use of limited sampling strategy and abbreviated formula to 
estimate the AUC0-12. However, it is inconvenient for patients because they have to wait 
in the center for blood sampling. We investigated the application of DBS method in 
tacrolimus level monitoring using limited sampling strategy and abbreviated AUC 
estimation approach. Duplicate venous samples were obtained at each time point (C0, 
C2 and C4). To determine the stability of blood samples, one venous sample was sent to 
our laboratory immediately. The other duplicate venous samples, together with 
simultaneous fingerprick blood samples, were sent to the University of Maastricht in the 
Netherlands. Thirty six patients were recruited and 108 sets of blood samples were 
collected. There was a highly significant relationship between AUC0-12 estimated from 
venous blood samples and fingerprick blood samples (r2=0.96, P<0.0001). Moreover, 
there was excellent correlation between whole blood venous tacrolimus levels in the two 
centers (r2=0.97; P<0.0001). The blood samples were stable after long distance 
transport.  DBS sampling can be used in centers using limited sampling and abbreviated 
AUC0-12 strategy as drug monitoring. 
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Introduction 
Tacrolimus has a narrow therapeutic index with wide interpatient and 
intrapatient variation in pharmacokinetics1. As a result, therapeutic drug 
monitoring (TDM) is essential. TDM is usually performed using 
ethylenediamine tetraacetic acid (EDTA) anticoagulated blood, obtained by 
venous sampling by physicians, nurses or phlebotomists. 
Dried blood spot sampling (DBS) is common for screening of metabolic 
disorders in newborns2. Moreover, its use in TDM has been reported for 
several drugs such as antimalarials and antiretrovirals3,4. Recently a method for 
measurement of tacrolimus level, based on DBS and high-performance liquid 
chromatography-tandem mass spectrometry (HPLC-MS), has been 
developed5. Preliminary results showed that DBS is promising for routine 
tacrolimus monitoring of stable renal transplant recipients6. 
The gold standard of determining the drug exposure is the estimation of the 
area under concentration-time curve (AUC0-12). AUC0-12 should be estimated 
from six or more concentration-time points. However, its routine clinical use is 
limited by the need for multiple blood sampling. Patients need to stay in centers 
for long time and it is also inconvenient to the clinical staff. Majority of the 
published data use whole blood trough level (C0) for dose monitoring and 
titration of tacrolimus therapy. It has been shown that C0 has a poor correlation 
with AUC0-12 7-8. Our center favors the use of limited sampling strategy and 
abbreviated formula to estimate the AUC0-12, which allows better prediction of 
drug exposure9. However, it is inconvenient for the patients because they have 
to stay in the center for at least two hours waiting for blood sampling. 
Moreover, blood sampling in center may involve a long journey and absence 
from work duty. The potential advantage of DBS is that the patients can stay at 
home. They can obtain capillary blood themselves with an automatic lancet and 
the drop of blood is applied to sampling paper. After drying, the paper with the 
blood spot sample is sent by mail to the laboratory for analysis. 
This is a collaborative study with the Department of Clinical Pharmacy, 
University of Maastricht in the Netherlands. In this study, we investigated the 
application of DBS method in tacrolimus level monitoring using limited sampling 
strategy and abbreviated AUC0-12 estimation approach. Moreover, we also 
studied the stability of blood samples after storage and long distance transport. 
Methods 
The study was approved by the ethical committee. Stable kidney transplant 
recipients who received tacrolimus-based immunosuppressive therapy and had 
follow up in Queen Elizabeth Hospital, Hong Kong were recruited in the study. 
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Written consent was obtained from each patient. Blood samples for the 
measurement of whole blood tacrolimus levels were collected. Limited 
sampling strategy and abbreviated AUC0-12 estimation were used in our 
center for tacrolimus monitoring. Calculation of tacrolimus AUC0-12 was by the 
formula: 16.2 + C2 * 2.4 + C4 * 5.9 [C2: 2-h postdose tacrolimus level; C4: 4-h 
postdose tacrolimus level]9. Based on our previous pilot study in stable 
patients on tacrolimus, AUC0-12 value was kept at around 100-150 ng x h /ml 
in first three months and around 80-100 ng x h /ml after three months. Some 
centers also found very high coefficients of correlation between 3 time-point 
strategy and the complete AUC0-12 9-13. The regression equation using 3 
time-point derived in our group was: 13.3 + 1.2 x C0 + 2.4 x C2 + 5.6 x C4 9. 
Thus C0 was also obtained in this study. 
For each patient, duplicate venous samples were obtained at each time point 
(C0, C2 and C4). To determine the stability of blood samples after long distance 
transport, one venous sample was sent to our laboratory immediately for 
measurement of whole blood tacrolimus level using HPLC-MS14. The other 
duplicate venous samples, together with simultaneous drawn fingerprick blood 
samples, were sent to the Department of Clinical Pharmacy, University of 
Maastricht in the Netherlands for measurement of tacrolimus levels by HPLC-
MS5. 
Fingerprick blood samples were collected using spring-loaded lancets and 
collected from the fingertip. The first drop was discarded and the next drop 
collected to fill an 8-mm pre-marked circle on the sampling paper (no. 
10,535,097, obtained from Whatman Schleicher & Schuell, Dassel, Germany). 
The procedure was performed by the patients. Volume of the blood drops was 
approximately 30 ul and blood spots of about 9-10-mm diameter were 
produced. The blood spots were allowed to dry at room temperature for three 
hours and packed in sealable plastic minibags. The samples were then stored 
at room temperature and sent to the laboratory in University of Maastricht by 
airmail. The transit time from Hong Kong to Maastricht was approximately 24 
hours. On arrival in the laboratory, the blood spots were inspected. 
Requirements are complete, homogenous, and symmetric filling of the 8-mm 
circle and dark-red color on both sides of the paper. Paper disks with a 
diameter of 7.5 mm were punched out with an electromagnetic driven hole 
puncher. DBS sampling and assay were compared with venous sampling and 
our routine assay in venous blood. 
Statistical analysis 
MedCalc statistical package (MedCalc Software, Mariakerke, Belgium) was 
used for data analysis. Data was expressed as mean +/- standard deviation or 
median (range) where appropriate. Whole blood tacrolimus levels and 
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estimated abbreviated AUC from different assays were compared using linear 
regression analyses. Passing-Bablok regression analysis and the Bland-Altman 
method were also used15,16. A P-value of less than 0.05 was considered to be 
statistically significant. 
Results 
Thirty six patients were recruited in this study and 108 sets of blood samples 
were collected (C0, C2 and C4 for each patient). The mean age of patients was 
46.8 +/- 8.6 (range 29.8-62.6) years. All patients had isolated kidney 
transplantation. The median interval between transplant and blood sampling 
was 38 months (range: two months to ten years). The duration of storage of 
DBS samples before analysis was 40 +/- 14 (range: 16-78) days.  
Fingerprick sampling was well tolerated and accepted by the patients. None of 
the patient complained of serious discomfort. They found the sampling easy to 
perform. Of the 108 fingerprick samples collected, only two samples were 
unsuitable for analysis due to the incomplete filling of the pre-drawn circle. No 
samples were lost during delivery. 
Comparison of venous HPLC-MS (Hong Kong) tacrolimus levels 
with venous HPLC-MS (Netherlands) tacrolimus levels (n=106) 
Linear regression analysis showed a highly significant relationship between 
venous blood tacrolimus levels using HPLC-MS (Netherlands) and venous 
blood tacrolimus levels using HPLC-MS (Hong Kong) (r2=0.97, P<0.0001).  
The Passing-Bablok regression equation was: Venous tacrolimus levels 
(Netherlands) (ug/l) = 1.06 (95% CI 1.03 to 1.09) * Venous tacrolimus levels 
(Hong Kong) (ug/l) – 0.33 (95% CI -0.59 to -0.06). There is a small but 
significant difference from the line of identity. A Bland-Altman analysis showed 
that venous tacrolimus levels (Netherlands) tends to be higher than the venous 
tacrolimus levels (Hong Kong) and the mean difference was 1% of mean 
tacrolimus levels. The 95% limits of agreement were 19.2% to -17.3%. 
Comparison of fingerprick HPLC-MS tacrolimus levels with 
venous HPLC-MS (Netherlands) tacrolimus levels (n=106) 
Linear regression analysis showed a highly significant relationship between 
venous blood tacrolimus levels using HPLC-MS (Netherlands) and fingerprick 
blood samples (r2=0.96, p<0.0001) (Figure 8.1).  
The Passing-Bablok regression equation was: Venous tacrolimus levels 
(Netherlands) (ug/l) = 0.95 (95% CI 0.89 to 1.00) * Fingerprick tacrolimus levels 
(ug/l) – 0.39 (95% CI -0.83 to 0.04). There is no significant difference from the 
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line of identity. A Bland-Altman analysis showed that fingerprick tacrolimus 
levels tends to be slightly higher than the venous tacrolimus levels and the 
mean difference was 11% of the mean tacrolimus levels. The 95% limits of 
agreement were 36.1% to -14.1% (Figure 8.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 Linear regression analysis: Fingerprick tacrolimus level versus venous blood 
tacrolimus level measured in the same center 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2  Bland Altman analysis of the difference (% of average) between fingerprick 
tacrolimus level and venous blood tacrolimus level measured in the same center. 
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Comparison of fingerprick HPLC-MS tacrolimus AUC0-12 with 
venous HPLC-MS (Netherlands) tacrolimus AUC0-12 : 2 time-point 
sampling strategy (n=36) 
Linear regression analysis showed a highly significant relationship between 
AUC0-12 estimated from venous blood samples using HPLC-MS (Netherlands) 
and fingerprick blood samples (r2=0.96, P<0.0001) (Figure 8.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3 Linear regression analysis: Fingerprick tacrolimus AUC0-12 versus venous blood 
tacrolimus AUC0-12 using 2 time-point strategy measured in the same center. 
 
 
The Passing-Bablok regression equation was: Venous tacrolimus AUC0-12 
(Netherlands) (hr*ug/l) = 0.98 (95% CI 0.90 to 1.08) * Fingerprick tacrolimus 
AUC0-12 (hr*ug/l) – 5.93 (95% CI -17.33 to 2.98). There is no significant 
difference from the line of identity. A Bland-Altman analysis showed that 
fingerprick tacrolimus AUC0-12 tends to be higher than the venous tacrolimus 
AUC0-12 and the mean difference was 7.8% of mean tacrolimus AUC0-12. The 
95% limits of agreement were 25.1% to -9.4% (Figure 8.4). 
Thesis_Cheung_v2.pdf
138⏐Chapter 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4  Bland Altman analysis of the difference (% of average) between fingerprick 
tacrolimus AUC0-12 and venous blood tacrolimus AUC0-12 measured in the same 
center. 
 
Comparison of fingerprick HPLC-MS tacrolimus AUC0-12 with 
venous HPLC-MS (Netherlands) tacrolimus AUC0-12 : 3 time-point 
sampling strategy (n=36) 
Linear regression analysis showed a highly significant relationship between 
AUC0-12 estimated from venous blood samples using HPLC-MS (Netherlands) 
and fingerprick blood samples (r2=0.96, P<0.0001).  
 
The Passing-Bablok regression equation was: Venous tacrolimus 
AUC0-12(Netherlands) (hr*ug/l) = 0.97 (95% CI 0.90 to 1.06) * Fingerprick 
tacrolimus AUC0-12 (hr*ug/l) – 5.24 (95% CI -15.99 to 2.97). There is no 
significant difference from the line of identity. A Bland-Altman analysis showed 
that fingerprick tacrolimus AUC0-12 tends to be higher than the venous 
tacrolimus AUC0-12 and the mean difference was 8.3% of mean tacrolimus 
AUC0-12. The 95% limits of agreement were 25.7% to -9%. 
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Discussion 
This study has shown that the tacrolimus levels measured from fingerprick 
blood samples using HPLC-MS has an excellent correlation with those 
obtained from venous blood sampling using the same method in the same 
center (r2=0.96; P<0.0001). The difference between them is small (11% of the 
mean tacrolimus level). It is of limited clinical significance in view of the 
relatively wide range of target tacrolimus level used in most centers.  
Our group has validated the use of limited sampling strategy (C2 and C4) and 
abbreviated formula to estimate the AUC0-12 which allows better prediction of 
drug exposure. In this study, we found that the AUC0-12 estimated from 
fingerprick samples had a high correlation with those estimated from venous 
blood sampling using same method in the same center (r2=0.96; P<0.0001). 
Moreover, the mean difference between the two methods was 7.8% of mean 
tacrolimus levels. This difference is of limited clinical significance. Similar 
results were also found when 3 time-point sampling strategy was used for 
estimating abbreviated AUC0-12. 
We found that there was excellent correlation between whole blood venous 
tacrolimus levels using HPLC-MS in the two centers (r2=0.97; P<0.0001). The 
mean difference between the venous tacrolimus levels measured in the two 
centers was 1% only. The assay was reproducible and the blood samples 
remained stable after storage and long distance journey. 
Our results demonstrate that it is justifiable to use dried blood spot sampling as 
an alternative for conventional venous sampling. We have shown that self-
administered fingerprick blood sampling for tacrolimus levels is practical to 
implement. It is highly convenient for patients, especially those who have follow 
up in transplant centers where limited sampling strategy is used for drug 
monitoring.  
In conclusion, there was no significant difference between the abbreviated 
AUC0-12 estimated from venous blood samples and fingerprick blood samples. 
The blood samples were stable after storage and long distance transport. 
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Many studies have issued differences in clinical outcome of renal 
transplantation between recipients treated by cyclosporine versus tacrolimus. 
However, firm data about these items in a Chinese population is lacking. 
Moreover, although many randomized controlled trials comparing cyclosporine 
versus tacrolimus in de novo renal transplant recipients have been performed, 
none of these studies have compared the allocation of the treatment groups for 
paired kidneys, i.e. randomization of both kidneys of the same donor over the 
two treatment arms. In this thesis some of these questions are addressed. 
Efficacy 
A recent meta-analysis comparing the efficacy of tacrolimus and cyclosporine 
in renal transplant recipients1 showed a significant lower rate of graft loss at six 
months (odds ratio 0.56, 95% confidence interval 0.36-0.86) in tacrolimus-
treated patients, and this effect persisted up to three years. Moreover, there 
was a lower acute rejection rate (odds ratio 0.69, 95% confidence interval 
0.60-0.79) and steroid resistant rejection rate (odds ratio 0.49, 95% confidence 
interval 0.37-0.64) in tacrolimus-treated recipients at one year. The ELITE-
Symphony trial, a large randomized controlled trial comparing low-dose 
tacrolimus (target trough level 3-7 ng/ml) with standard-dose cyclosporine 
(target trough level 150-300 ng/ml for three months, 100-200 ng/ml thereafter), 
low-dose cyclosporine (target trough level 50-100 ng/ml) and low-dose 
sirolimus (target trough level 4-8 ng/ml), was published in 2007 2. In this trial, 
patients randomized towards the low-dose tacrolimus group had a significant 
better graft survival (odds ratio for graft failure 0.54) and lower acute rejection 
rate (odds ratio 0.48) compared to the other treatment groups. However, only a 
small proportion of the patients in the meta-analysis were from Chinese/Asian 
descent1. There was even no Asian center participated in the ELITE-Symphony 
trial2. Therefore, it remains unclear whether the improvement in efficacy of 
tacrolimus over cyclosporine is also present in Chinese renal transplant 
population. 
As shown in Chapter 2, we performed a paired kidney study in 66 Chinese 
deceased renal transplant recipients who were randomized towards tacrolimus- 
or cyclosporine- based immunosuppressive therapy. The odds ratio for acute 
rejection was 0.55 in tacrolimus-treated recipients. However, the difference in 
acute rejection rate between both treatment groups was not statistically 
significant. This was probably due to the small number of patients included and 
an overall modest rejection rate (21%) which was numerically comparable to 
the meta-analysis1. In an extension study (not yet published) involving 76 
recipients with a mean follow-up of more than six years, the difference in acute 
rejection rate became statistically significant (tacrolimus 18.4% versus 
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cyclosporine 42.1%). Because of the small number of patients included in our 
trial, no difference in graft survival could be expected. 
Using paired kidney design in our study can allow us to exclude the donor-
related bias and investigate the relative impact of tacrolimus and cyclosporine 
more directly. Moreover, in order to assure optimal drug exposure, abbreviated 
AUC approach was employed for therapeutic drug monitoring of both 
cyclosporine and tacrolimus in our center. Although many centers prefer the 
concept of C2 monitoring for cyclosporine microemulsion nowadays, its ability 
to improve efficacy is still not generally accepted3. A summary of the relative 
efficacy of tacrolimus- and cyclosporine micro-emulsion-based immuno-
suppression on rejection and graft survival is shown in Table 9.1. 
 
 
Table 9.1 Comparison of the efficacy of tacrolimus-based immunosuppression versus 
cyclosporine-microemulsion-based immunosuppression. 
 Tacrolimus Cyclosporine microemulsion 
Acute rejection ↓  
Steroid-resistant rejection ↓  
Recurrent rejection ↓  
Rescue of CNI-resistant acute rejection + - 
Graft survival at 5 years ↑  
CNI=calcineurin inhibitor 
 
Renal function 
Differences between cyclosporine and tacrolimus in renal function have been 
summarized recently4. An overview of the main statements are given in 
Chapter 1 Table 1.4. 
Kaplan et al. performed an analysis on a database with patients who received 
paired kidneys from the same donor, and were treated by either cyclosporine or 
tacrolimus upon discharge5. Serum creatinine was significantly lower in the 
tacrolimus group. However, there are few drawbacks in this study. First of all, it 
is not a randomized controlled trial. Moreover, patients were not treated 
according to fixed criteria and that it is not known if the patients were kept on 
the drugs they received upon discharge. 
In chapter 2, we also investigated the difference in renal function between 
paired kidneys from the same donor, of which one kidney was transplanted in a 
patient receiving cyclosporine and the other in a patient receiving tacrolimus in 
the same center. Donor and center bias can be excluded and differences in 
renal function can be attributed directly towards the immunosuppressive drugs. 
Dosage of both drugs was adjusted according to the estimated abbreviated 
Thesis_Cheung_v2.pdf
144⏐Chapter 9 
AUC0-12. Patients treated with tacrolimus had a significant better creatinine 
clearance from 6-month after transplant onward and a lesser decline in 
creatinine clearance. An extension of this study showed that the improved 
creatinine clearance was sustained up to 6-year follow-up. The results could be 
explained by the lower nephrotoxicity of tacrolimus and/or less efficacy of 
cyclosporine in the suppression of the immune response, resulting in more 
(subclinical) rejection, eventually leading towards chronic allograft dysfunction. 
The superiority of low-dose tacrolimus in maintaining renal function after kidney 
transplant was also confirmed in a recently published ELITE-Symphony Study2. 
It has been shown that patients receiving the tacrolimus regimen had the 
highest GFR at 12-month follow-up. 
Interleukin-2 receptor antagonist 
Several multicenter, randomized, placebo-controlled studies have consistently 
demonstrated that in combination with cyclosporine, the interleukin-2 (IL-2) 
receptor antagonists (basiliximab or daclizumab) could result in a significant 
30–40% reduction in the incidence of biopsy-proven acute rejection6-10. On the 
other hand, randomized comparative studies of IL-2 receptor antagonists 
induction versus no induction in patients receiving tacrolimus-based 
immunosuppression are lacking. As a result, a single center prospective study 
to investigate the efficacy and safety of adding daclizumab to a tacrolimus-
azathioprine-prednisolone-based therapy in Chinese first deceased renal 
transplant recipients was performed (Chapter 3). In this immunological low-risk 
renal transplant population, the incidence of acute rejection was 19% in the 
standard group versus 11% in the daclizumab group (P=0.37). 
Although IL-2 receptor antagonists are widely applied in tacrolimus-based 
immunosuppression, few data support the use of IL-2 receptor antagonists in 
immunological low-risk renal transplant recipients. Considering some of the 
largest clinical trials using tacrolimus-based immunosuppressive therapy, the 
biopsy-proven acute rejection rate shown in the control arm (tacrolimus, 
mycophenolate mofetil and corticosteroids) in the Zenapax trial (364 patients)11 
and the Carmen study (538 patients)12 was 12% and 16.5% respectively, which 
is comparable to the 12% acute rejection rate in the ELITE-Symphony trial (401 
patients on tacrolimus, mycophenolate mofetil, corticosteroids, and 
daclizumab)2. The additional benefit of adding IL-2 receptor antagonists to 
these regimens seems to be limited. 
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Hyperglycemia after transplantation 
The incidence of post-transplant hyperglycemia differs considerably, mainly 
depending on the definition used and the ethnicity of the study population. 
Interpretation is often hampered by the fact that many patients have a period of 
transient hyperglycemia in the early phase after transplantation. 
Nowadays use of criteria of the American Diabetes Association (ADA)/World 
Health Organization (WHO) has been advocated13. The detection of 
“prediabetic state” (impaired fasting glucose (IFG) and/or impaired glucose 
tolerance (IGT)) is also important, because of the increased risk of 
development of diabetes and cardiovascular risks14. Fasting glucose is 
commonly used in clinical setting for diagnosis of diabetes when compared to 
Oral Glucose Tolerance Test (OGTT) because of its simplicity. However, it is 
less sensitive and specific than an OGTT in diagnosis15,16. Armstrong KA et al. 
have shown that the prevalence of post- transplant diabetes mellitus (PTDM) is 
much higher with OGTT and fasting blood glucose alone will miss 65% of 
patients with diabetes in renal transplant recipients17. Moreover, fasting glucose 
alone will also ignore the diagnosis of IGT. IGT itself can only be diagnosed 
with OGTT and has been shown to have a great correlation with diabetes and 
cardiovascular risks18,19. Clinical trials seldom included OGTT to determine the 
exact incidence of glycemic abnormality in kidney transplant recipients.  
Recently, a randomized trial designed by Vincenti et al. was published. Both 
tacrolimus and cyclosporine were compared with PTDM or IFG within first six 
months post-transplant as primary end-point20. The difference in incidence and 
severity of abnormal glucose metabolism (AGM) between the tacrolimus and 
cyclosporine were confirmed. However, there was a high frequency of AGM in 
both arms (33.6% in tacrolimus group versus 26% in cyclosporine group). This 
might be related to the lack of standardization of steroid dosages in the trial. On 
the basis of the knowledge of the pathophysiology of AGM, one could have 
predicted that the incidence of AGM will be high and more patients on 
tacrolimus than on cyclosporine will develop AGM in clinical setting with high 
dosages of steroids. Moreover, WHO/ADA criteria were applied at three and six 
months without defining the dosage of steroids and levels of tacrolimus at 
these time points in the study. Given the considerable effect of steroids and 
tacrolimus on insulin resistance and insulin secretion respectively, use of 
WHO/ADA criteria gives clinical useful information only when applied in a 
controlled setting such as in the maintenance phase without infection or 
rejection, and with stable defined low dosages of steroids and tacrolimus 
levels21. In Chapter 4, we estimated the prevalence of AGM (PTDM + IFG + 
IGT) in a cross sectional study by using ADA criteria. The overall prevalence of 
AGM was 31.9% (38% in tacrolimus treated patients and 27% in cyclosporine 
treated patients). Although numerically different, this difference was not 
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statistically significant between the tacrolimus- and cyclosporine-treated 
groups. Limited sampling strategy and abbreviated AUC was used for drug 
monitoring and titration in our center. The target abbreviated AUC0-12 for 
tacrolimus was around 80-100 ng x h/ml after three months, corresponding a 
tacrolimus trough level at around 6 ng/ml. As has been shown by van 
Duijnhoven et al., decreasing the tacrolimus trough level from 9.5 to 6.4 ng/ml 
improves insulin secretion with ±30%22. Another study also confirmed that the 
impairment in insulin secretion could be predicted by a tacrolimus trough level 
≥10.8 ng/ml, corresponding to an AUC0-12 ≥200 ng x h/ml. As a result, 
maintaining a low tacrolimus trough level may diminish the development of 
impaired glucose metabolism23. On the other hand, the overall high prevalence 
of AGM is probably related to the use of maintenance steroids (7.5 mg) in all of 
our patients. Steroids have a very strong effect on glucose metabolism, e.g. to 
maintain normoglycemia in a patient using 10 mg of prednisolone, insulin 
output has to be increased by 250%24. 
 
There are many other differences between tacrolimus and cyclosporine. It is 
well established that tacrolimus-treated patients have a better cardiovascular 
risk profile due to lower lipids and lower blood pressure25,26 and that the renal 
function is better preserved in tacrolimus-treated patients (as discussed 
above). It is unknown whether these positive effects are offset by the increased 
incidence of AGM.  
Hyperglycemia after transplantation is most probably a symptom of an 
underlying metabolic syndrome uncovered by immunosuppression. High risk 
patients for AGM should be given OGTT before transplantation21. Patients 
identified as high-risk group may benefit from pre-transplant lifestyle 
intervention such as exercise training and reducing obesity. Only by using 
tacrolimus in combination with steroids will more patients develop AGM than 
with other agents in combination with steroids. Two large European 
randomized trials showed that steroid avoidance is possible in a tacrolimus-
based immunosuppressive regimen, with a low incidence of PTDM11,12. In low 
risk patients, tacrolimus has benefits over cyclosporine in terms of better 
cardiovascular risk profile and better preservation of renal function. For high 
risk patients, there are two main options: steroid-free tacrolimus-based (with an 
unproven increased chance of worse long-term graft survival) or steroid + 
cyclosporine-based (with the proven increased cardiovascular risk profile and 
worse preservation of renal function)27. 
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Metabolic syndrome 
In the general population, the prevalence of metabolic syndrome (MS) differs 
widely among ethnic groups and depends according to the definition of MS 
used28-30. de Vries et al. applied the consensus definition (NCEP-ATPIII) of MS 
to the kidney transplant population in the Netherlands and reported that 63% of 
Caucasian renal transplant patients had MS31. Porrini et al. reported that 37.7% 
of Spanish renal transplantation recipients had MS by the modified NCEP 
criteria32 while Armstrong et al. reported that 50% of Australian renal transplant 
recipients had MS by the original NCEP criteria33. All these reports of 
Caucasian renal transplant recipients suggested that MS is more prevalent in 
renal transplant recipients compared with the general population. On the other 
hand, it was demonstrated that there was only a slight difference in the 
prevalence of MS between the general population and renal transplant patients 
in Japan34. This discrepancy may be related to the difference in lifestyle, eating 
habits, or the prevalence and degree of obesity between Japanese and 
Caucasian populations. In Chapter 5, we showed that MS was more prevalent 
in our Chinese renal transplant recipients when compared with the general 
population as shown in the literature35,36.  
In our study, body mass index and waist circumference of the MS group were 
significantly greater than those of the non-MS group. Similar to the general 
population, overweight is a major clinical feature of MS in renal transplant 
recipients. Weight gain after renal transplantation has particularly been linked 
with physical inactivity37. Insulin resistance is the central pathophysiological 
feature underlying MS38. In renal transplant recipients, factors other than 
obesity, especially the use of corticosteroids, may contribute to an increase in 
insulin resistance. Moreover, chronic corticosteroid use, will induce the 
accumulation of truncal fat39. This process will also amplify MS. As a result, 
steroid-withdrawal/avoidance will counteract the development of MS. 
In Chapter 5, we showed that PTDM was more prevalent in the MS group, 
which was consistent with the previous report by Porrini et al.32. They showed 
that MS was a prominent risk factor for PTDM in their longitudinal study. 
Obesity and dyslipidaemia, which are components of MS, are associated with 
insulin resistance, one of the most important causative elements in the 
physiopathological process of type 2 diabetes40,41. 
It has been reported that MS is a risk factor for renal dysfunction in the general 
population42,43. In heart transplantation, Valantine et al. suggested that a 
‘metabolic milieu’ may modify the process of chronic transplant dysfunction.44 
De Vries et al.31 and Porrini32 suggested that the presence of MS is associated 
with impaired renal allograft function in renal transplantation recipients in 
longitudinal studies. Different possible mechanisms have been proposed for 
the association between MS and impaired renal function. Obesity can 
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contribute to renal dysfunction in many ways: excess excretory load, renal 
sodium retention, hyperinsulinaemia, insulin resistance, or renal lipotoxicity45-48. 
Moreover, obesity is associated with worsening of proteinuria in renal 
transplant recipients33. Glucose intolerance, hypertension and dyslipidaemia, 
components of MS, can directly damage the kidneys through renal or systemic 
atherosclerosis49-52.  
Apart from renal allograft dysfunction, MS is also associated with 
atherosclerotic events53. Factors contributing to MS are closely interconnected 
and define a very high-risk population for atherosclerotic events. Clustering of 
both traditional and non-traditional risk factors in renal transplant recipients with 
MS contribute to the greater incidence of atherosclerotic events in this 
population. Cardiovascular mortality is the most important cause of graft loss in 
addition to renal graft dysfunction. It is therefore conceivable that people with 
the highest susceptibility to consequences of MS were already deceased 
before the start of this cross-sectional study. As a result, the study may have 
suffered from a healthy survivor bias. Further longitudinal and intervention 
studies are needed to assess the full impact of the metabolic syndrome on 
long-term renal allograft loss and atherosclerotic events in our Chinese renal 
transplant recipients. Moreover, physical activity levels in renal transplant 
recipients remain low, even after succesful transplantation and are therefore an 
important cause of increase in weight gain. Exercise capacity and muscle 
strength in renal transplant recipients are significantly lower compared to 
healthy controls and comparable to patients undergoing hemodialysis54. These 
findings underscore the importance of exercise training and increasing physical 
activity levels in renal transplant recipients. 
Pharmacogenetics 
Tacrolimus is well known for its large inter- and intra-individual variation in the 
dosage requirement to reach target levels. Therefore, therapeutic drug 
monitoring (TDM) is necessary. The common practice is that a peri-operative 
standard dose (generally 0.2 mg/kg/day) is started and the dose is adjusted 
according to the measured levels. By knowing the pre-transplant factors that 
can explain at least part of this variation, the starting dose can be individualized 
and better adjusted in the early phase after transplantation, with a lower 
chance of under- or over-immunosuppression. At a later stage, one can have 
better prediction when TDM is necessary, e.g. at the introduction of a factor 
known to influence the absorption and/or metabolism of tacrolimus.  
The absorption and metabolism of tacrolimus are regulated by enzyme 
systems, especially ABCB1 (MDR-1) and cytochrome P450 (CYP) subtypes 
3A4 and 3A5. Part of the described variation could be explained by differences 
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in activity of these enzyme systems. Indications for this are the well-known 
pharmacokinetic interactions of tacrolimus with other drugs that are 
metabolized by these enzyme systems. 
Mutations within the genes of these enzyme systems result in single nucleotide 
polymorphisms (SNPs) possibly resulting in a different activity of that enzyme 
system. 
There has been conflicting pubished data about the influence of the 
polymorphisms of the ABCB1 (MDR-1) system on the pharmacokinetics of 
tacrolimus. A number of studies have already reported that there seems to be 
no association between the ABCB1 polymorphisms and tacrolimus dose-
normalized trough levels (dnC0)55-59 or the dose-normalized area under the time 
tacrolimus concentration curve (dnAUC0-12)60,61. However, some studies found 
a correlation between individual ABCB1 polymorphisms and a higher tacrolimus 
dose62-64. Because of differences in design and study populations it might be 
that a polymorphism, that has a minor influence on the tacrolimus blood 
concentrations, demonstrates contrasting results among these studies. 
Moreover, there are several SNPs that may occur together, resulting in 
different haplotypes. The correlation of these haplotypes with the 
pharmacokinetics of tacrolimus has not yet been described extensively. In one 
study, a correlation between the ABCB1 1236C-2677G-3435C haplotype and a 
higher tacrolimus dose was found65. An overview of published data on the 
correlation of the main SNPs in the ABCB1 system on tacrolimus blood levels 
are given in Table 9.2. 
 
In this thesis, we studied the correlation of these polymorphisms with 
1. the 2-point limited sampling dnAUC0-12 in stable Chinese transplant 
recipients (Chapter 6)  
2. the 9-point dnAUC0-12 in 2 groups of Caucasian transplant recipients: early 
and late after transplantation (Chapter 7) 
 
In Chapter 7, 63 Caucasian renal transplant recipients were described who had 
a complete 9-point 12-hour AUC of tacrolimus: 26 patients within three months 
after transplantation (median 16 days, early phase group) and 37 patients over 
one year after transplantation (median 1465 days, late phase group). They 
were typed for three SNPs in the ABCB1 system. Neither the individual ABCB1 
polymorphisms nor the ABCB1 haplotypes were associated with any 
pharmacokinetic parameter.  
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Table 9.2 ABCB1 genetic polymorphism and effects on dose-normalized concentrations of 
tacrolimus. 
Patient  
population 
N Genotype 
Exon Mutation 
Effect of mutation of 
dose-normalized 
blood concentration
Reference 
Adult renal  103 Exon 21 
Exon 26 
g2677G>(T,A) 
g3435C>T 
Neutral 
Neutral 
Chapter 6 
Adult renal  63 Exon 21 
Exon 26 
g2677G>(T,A) 
g3435C>T 
Neutral 
Neutral 
Chapter 7 
Adult renal  206 Exon 12 
Exon 21 
Exon 26 
Haplotype 
g1236C>T 
g2677G>(T,A) 
g3435C>T 
Exons 12.21,26
Neutral 
Increased 
Increased 
Increased 
73 
Adult renal  180 Exon 26 g3435C>T Increased 64 
Adult renal  118 Exon 26 g3435C>T Neutral 55 
Adult renal  92 Exon 26 g3435C>T Increased 74 
Adult lung  91 Exon 12 
Exon 21 
Exon 26 
Haplotype 
g1236C>T 
g2677G>(T,A) 
g3435C>T 
Exons 12,21,26
Increased 
Increased 
Increased 
Increased 
75 
Adult lung  83 Exon 21 
Exon 26 
g2677G>(T,A) 
g3435C>T 
Minimal 
Minimal 
63 
Adult renal  81 Exon 1 
Exon 12 
Exon 21 
Exon 26 
Haplotype 
g-129T>C 
g1236C>T 
g2677G>(T,A) 
g3435C>T 
Exons 12,21,26
Neutral 
Increased 
Increased 
Neutral 
Increased 
65 
Adult renal  73 Exon 21 
Exon 26 
Haplotype 
g2677G>(T,A) 
g3435C>T 
Exons 21,26 
Neutral 
Neutral 
Neutral 
58 
Adult renal  64 Exon 26 g3435C>T Neutral 56 
Pediatric 
cardiac 
 63 Exon 21 
Exon 26 
g2677G>(T,A) 
g3435C>T 
Increased 
Increased 
62 
Adult liver  50 Exon 26 g3435C>T Increased 76 
Adult renal  50 Exon 12 
Exon 21 
Exon 26 
Haplotype 
g1236C>T 
g2677G>(T,A) 
g3435C>T 
Exons 12,21,26
Neutral 
Neutral 
Neutral 
Neutral 
57 
Adult renal  44 Exon 1b 
Exon 2 
Exon 11 
Exon 21 
Exon 26 
Cumulative 
g-129T>C 
g61A>G 
g1199G>A 
g2677G>(T,A) 
g3435C>T 
Neutral 
Neutral 
Neutral 
Neutral 
Neutral 
Increased 
77 
Adult renal  39 Exon 26 g3435C>T Neutral 60 
Adult renal  30 Exon 21 
Exon 26 
g2677G>(T,A) 
g3435C>T 
Neutral 
Neutral 
61 
Adult renal  24 Exon 21 
Exon 26 
g2677G>(T,A) 
g3435C>T 
Neutral 
Neutral 
78 
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In Chapter 6, 103 Chinese renal transplant recipients were studied at a mean 
of nearly three years after transplant. By a two-point limited sampling algorithm, 
dnAUC0-12 was calculated and correlated with SNPs in the ABCB1 system and 
the ABCB1 haplotypes. Individuals carrying the 2677TT or 3435TT genotype 
has a significantly lower dnAUC0-12. No correlation was found between ABCB1 
system haplotype and dnAUC0-12. In multiple regression analysis the 2677TT 
and 3435TT genotype was not shown to be significant if the CYP3A 
polymorphism was included. Therefore, the published correlation of SNPs of 
the ABCB1 system with dnAUC of tacrolimus might be related to genetic 
linkage of the ABCB1 system with other polymorphisms, such as the CYP3A 
system. 
Polymorphism in CYP3A5 such as CYP3A5*1 is associated with a higher dose 
(and lower blood levels) of tacrolimus. The frequency of these alleles depends 
on the population studies: the CYP3A5*1 allele is present in 15% of the 
Caucasian, 45% of the African-American66, and 25% of the Chinese 
population67. 
Since many genetic differences exist between races, it is important to examine 
whether the described polymorphisms are related to differences in 
pharmacokinetic and dosing of tacrolimus within the Chinese transplant 
population. In Chapter 6, a strong significant genetic effect between CYP3A5*3 
polymorphism and both the dnAUC0-12 and the daily tacrolimus dose is 
demonstrated in Chinese stable renal transplant recipients. In fact, the 
CYP3A5*3 polymorphism may explain 35.3% of the variation in the daily 
tacrolimus dose observed in the renal transplant recipients. In Chapter 7, a 
study involving Caucasian population, significantly higher dnC0, dnAUC0-12 and 
dnCmax is demonstrated in carriers of the CYP3A5*3 allele in both early and late 
post renal transplant recipient groups than in patients homozygous for 
CYP3A5*1. Since the CYP3A5*1 allele was over-represented in the early 
phase group, we concluded that a complete pharmacokinetic profile is more 
frequently requested for renal transplant recipients carrying this allele, 
suggesting that these patients have more difficulties in achieving and 
maintaining tacrolimus concentrations compared to homozygous carriers of the 
CYP3A5*3 variant. This might be of importance for the Chinese population in 
which the CYP3A5*1 allele has a much higher prevalence than in the 
Caucasian population. In Chapter 2, the incidence of acute rejection in the 
tacrolimus-treated Chinese recipients was 15%. This is comparable with the 
acute rejection rate in tacrolimus-mycophenolate mofetil-corticosteroids-treated 
Caucasian renal transplant recipients11,12. Possible explanations for not finding 
a higher rejection rate (as a consequence of lower dnAUC in CYP3A5*1 
patients) might be the higher starting dose of 0.3 mg/kg/day (instead of 
0.2 mg/kg/day as commonly used in Caucasians) and the increase in 
tacrolimus dose early post-transplant based on the tacrolimus blood levels. 
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Genotyping for CYP3A5 to predict the ideal initial dose of tacrolimus remains 
the most promising option for a pharmacogenetic strategy. However, recently 
Hesselink et al. did not found an association between CY3A5 genotype and 
risk of acute rejection in tacrolimus-treated renal transplant recipients in a 
randomized controlled trial (CYP3A5 genotype is not associated with a higher 
risk of acute rejection in tacrolimus-treated renal transplant recipients)68. 
Application of dried blood spot in renal transplantation 
Dried blood spot sampling (DBS) is commonly used for screening of metabolic 
disorders in newborns69. Its use in therapeutic drug monitoring (TDM) has been 
reported for medications such as antimalarials and antiretrovirals70,71. Recently, 
it has been shown that self-administered fingerprick testing for cyclosporine 
blood levels is practical to implement72. However, literature concerning its use 
in tacrolimus monitoring in renal transplant recipients is scarce. In Chapter 8, 
we investigated the application of DBS and high-performance liquid 
chromatography tandem-mass spectrometry (HPLC-MS) in tacrolimus 
monitoring. We found that there is an excellent correlation between the drug 
levels and the estimated abbreviated AUC0-12 obtained from venous blood 
sampling and fingerprick blood samples (r2=0.96, P<0.0001). Moreover, we 
showed that the assay is reproducible and the blood samples remain stable 
despite of storage and long-distance journey. DBS sampling is especially 
convenient for patients who have follow-up in transplant centers where limited 
sampling strategy is used for drug monitoring because the patients do not need 
to stay in transplant centers for at least two hours waiting for blood sampling. 
They can stay at home and perform the blood sampling themselves. In 
addition, home fingerprick sampling is proving useful for the more intensive 
follow-up of patients taking medication which would interact with the 
immunosuppressive agents. Use of fingerprick testing at home could provide a 
significant advantage to the physician by allowing the drug levels to be 
available at clinic visits, if samples were provided to the laboratory by the 
patients in advance. This approach would reduce the number of scheduled 
visits solely for venepuncture, with benefits for both the patients and clinic staff. 
Furthermore, our patients found the sampling easy to perform after careful 
instructions. Only two out of the 108 blood samples were unsuitable for 
analysis due to inadequate volume of blood. Thus it is justifiable to use DBS 
sampling as an alternative for conventional venous sampling in TDM in renal 
transplant recipients. However, this technique is not suitable for all patients and 
a careful assessment is required to ensure that the patients are happy with the 
procedure and are considered reliable to take the samples at appropriate time. 
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Conclusion 
The most challenging topic in renal transplantation nowadays is how to improve 
the long-term renal graft survival. Because many of the studies are performed 
in non-Chinese population, it is important to perform studies in the Chinese 
renal transplant recipients. In this thesis, it has been shown that tacrolimus is 
also more effective than cyclosporine in preserving renal function and 
prolongation of graft survival in a Chinese transplant population. Addition of 
IL-2 receptor antagonist seems to confer no additional benefit in terms of 
efficacy to them. 
 
PTDM and metabolic syndrome has been shown to affect both the long-term 
renal allograft function and cardiovascular events after renal transplantation. 
Previous studies revealed a higher incidence of PTDM in tacrolimus-treated 
patients. However, the risk of development of diabetes with tacrolimus can be 
diminished by avoidance or early withdrawal of steroid and tacrolimus level 
reduction. MS is becoming an increasing problem after renal transplantation. 
Potential factors related to MS are physical inactivity and use of corticosteroids. 
Therefore, these factors have to be aggressively dealt with. 
 
TDM is the gold standard for monitoring and titration of tacrolimus in order to 
ensure adequate immunosuppression but avoid nephrotoxicity and other side 
effects. Pharmacogenetics had generated considerable enthusiasm in 
transplantation medicine recently. Pharmacogenetic studies have led to a 
further understanding of the genetic basis of the variable pharmacokinetics of 
immunosuppressants. We show that patients expressing CYP3A5 require 
higher dose of tacrolimus to reach target concentrations than CYP3A5 non-
expressors. Genetic screening of transplant recipients for CYP3A5 expression 
may help to guide individual tacrolimus dosing. However, further prospective 
and intervention study involving genetic profile and transplant outcome is 
required in order to achieve the aim of personalized medicine.  
Application of DBS in tacrolimus monitoring may provide a convenient yet 
accurate alternative for those who cannot come back to transplant center for 
blood sampling. 
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Samenvatting 
In dit proefschrift worden enkele vraagstellingen besproken samenhangend 
met het gebruik van immunosuppressiva in een groep Chinese ontvangers van 
een niertransplantatie. 
Tacrolimus en Cyclosporine: effectiviteit en nierfunktie 
In hoofdstuk 2 staan de resultaten beschreven van onze studie naar verschillen 
in klinische uitkomstparameters van 66 postmortale Chinese niertransplantaties 
behandeld met cyclosporine of tacrolimus. De effectiviteit van deze twee 
immuunsuppressiva zijn weliswaar vaker onderzocht, maar die studies hebben 
als nadeel dat er tussen beide onderzoeksgroepen ook verschillen bestaan in 
de herkomst van de donornier. Daarnaast werden die studies vaak in 
verschillende centra uitgevoerd. In onze studie is dit vermeden door 
randomisatie van beide nieren van dezelfde donor naar de twee behandelings-
armen en het transplanteren in één transplantatiecentrum. Zo’n studie werd 
niet eerder verricht. Tevens werd de dosering geoptimaliseerd van zowel 
cyclosporine als tacrolimus door deze te baseren op verkorte AUC (area under 
the curve)-berekeningen en niet op alleen dalspiegels. De resultaten van de 
studie tonen een halvering van het relatieve risico op het optreden van acute 
rejectie in patiënten die met tacrolimus werden behandeld. Dit verschil was in 
deze studie statistisch niet significant, mogelijk samenhangend met het relatief 
geringe aantal geincludeerde patiënten en het gematigde rejectiepercentage. 
In een - nog niet gepubliceerde - vervolgstudie waarin 76 patiënten gedurende 
tenminste zes jaar vervolgd werden, was het acute rejectie percentage wel 
statistisch significant verschillend: tacrolimus 18.4% t.o.v. cyclosporine 42.1%. 
 
Tevens werd in deze studie aangetoond dat patiënten die behandeld werden 
met tacrolimus – i.p.v. cyclosporine - vanaf zes maanden na transplantatie een 
betere nierfunktie hebben en dat de nierfunktie ook minder verslechterde 
(Hoofdstuk 2). Essentieel hierbij is dat door de direkte vergelijking van de 
funktie van beide nieren van één donor donor- en centrumbias uitgesloten zijn 
en dat de verschillen in nierfunktie direkt toe te schrijven zijn aan verschillen in 
het gebruikte immunosuppressivum. In de nog niet gepubliceerde vervolgstudie 
werd aangetoond dat dit verschil tot zes jaar follow-up blijft bestaan. 
Mogelijke verklaringen voor het gevonden verschil zijn een lagere nefrotoxiciteit 
van tacrolimus en/of verminderde efficiëntie van cyclosporine in het vermijden 
van (subklinische) rejectie, eventueel leidend tot chronische transplantaat 
disfunktie. 
Een recente grote studie, de ELITE-Symphony studie, bevestigt de betere 
nierfunktie in tacrolimus-behandelde patiënten op 1 jaar na transplantatie. 
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Interleukin-2 receptor antagonist 
Het is aangetoond dat het toevoegen van interleukine-2 receptor antagonist 
(basiliximab of daclizumab) aan een cyclosporine-bevattend immuun-
suppressief schema het optreden van biopsie-bewezen rejectie met 30-40% 
wordt gereduceerd. Dit was nog niet onderzocht in gerandomiseerde studies bij 
het gebruik van een tacrolimus-bevattende immuunsuppressief schema. In 
hoofdstuk 3 is een prospectieve studie beschreven naar de effectiviteit en 
veiligheid van het toevoegen van daclizumab aan Chinese ontvangers van een 
1e postmortale niertransplantatie behandeld met tacrolimus, azathioprine en 
prednisolon. De incidentie van het optreden van acute rejectie was niet 
significant verschillend tussen beide groep: 19% in de controle-groep en 11% 
indien daclizumab was toegevoegd. Er waren ook geen verschillen in het 
optreden van infecties, cardiovasculaire bijwerkingen en transplantaat- en 
patiëntoverleving. Geconcludeerd werd, dat niet aangetoond is dat het 
toevoegen van daclizumab aan bovengenoemd immuunsuppressief schema 
aan patiënten met een laag immunologisch risico op acute afstoting zinvol is.  
Hyperglycemie en metabool syndroom 
In hoofdstuk 4 en 5 wordt gekeken naar het optreden van hyperglycemie en het 
metabool syndroom in een populatie Chinese ontvangers van een niertrans-
plantatie. 
 
In een groep van 119 Chinese niertransplantatie patiënten behandeld met 7.5 
mg prednisolon en cyclosporine of tacrolimus, werd cross-sectioneel gekeken 
naar het percentage patiënten met een abnormale glucose metabolisme (AGM) 
volgens de ADA (American Diabetes Association)-criteria. Bij patiënten die niet 
bekend waren met Post Transplantatie Diabetes Mellitus en een nuchter 
glucose >5.6 mmol/l hadden werd een orale glucose tolerantie test (OGTT) 
verricht. De resultaten van deze studie staan beschreven in hoofdstuk 4. Het 
percentage patiënten met AGM was 38% in de tacrolimus groep en 27% in de 
cyclosporine groep (verschil niet statistisch significant). Dit percentage komt 
overeen met het percentage dat in Kaukasische patiënten is gevonden. 
 
In hoofdstuk 5 werd de incidentie van het metabool syndroom cross-sectioneel 
gemeten in een Chinese groep ontvangers van een niertransplantatie. Bekend 
is dat dit percentage in ontvangers van een niertransplantaat hoger is dan in de 
algehele bevolking en in Kaukasiers varieert van 38-63%. Het optreden van het 
metabool syndroom is geassocieerd met een verminderde nierfunktie en 
atherosclerotische ziektes. In deze groep patiënten was het percentage 
patiënten met een metabool syndroom 32%. 
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Pharmacogenetica 
Tacrolimus heeft een grote inter- en intraindividuele variatie in de dosering ter 
bereiken van de streefwaarde. Daarom is hierbij Therapeutic Drug Monitoring 
(TDM) nodig. Door voorafgaand aan de transplantatie de factoren te kennen 
die (een deel van) deze variatie verklaren, kan de dosering tacrolimus beter 
geindividualiseerd worden met een geringere kans op onder- of overdosering. 
Ook kan daarmee in een later stadium beter voorspeld worden wanneer TDM 
nodig is, bijv. bij de introductie van een geneesmiddel waarvan bekend is dat 
dit de absorptie of metabolisme van tacrolimus verandert. 
Enzymsystemen van belang bij de absorptie en metabolisme van tacrolimus 
zijn met name ABCB1 (MDR-1) en cytochrome P450 (CYP) subtypes 3A4 en 
3A5. Door mutaties in de genen hiervan kan de activiteit veranderen. Deze 
mutaties kunnen in verschillende bevolkingsgroepen in verschillende mate 
aanwezig zijn.  
 
In dit proefschrift hebben we de correlatie van polymorfismes bestudeerd in 
relatie tot: 
1.  Een 2-punts verkorte AUC genormaliseerd voor de dosering (dnAUC0-12) in 
103 stabiele Chinese ontvangers van een niertransplantaat (Hoofdstuk 6) 
2.  Een 9-punt dnAUC0-12 in twee groepen Kaukasische ontvangers van een 
niertransplantaat: 26 vroeg en 37 laat na transplantatie (Hoofdstuk 7) 
 
In hoofdstuk 6, werden de Chinese ontvangers van een niertransplantaat 
ongeveer drie jaar na transplantatie onderzocht op mutaties in het ABCB1 
systeem en de correlatie hiervan met de dnAUC0-12. Er werd geen correlatie 
gevonden tussen ABCB1 systeem haplotype en dnAUC0-12. Patiënten met het 
2677TT of 3435TT genotype hadden een significant lagere dnAUC0-12 welke 
verdween indien het CYP3A polymorfisme werd geincludeerd in het model. De 
conclusie was dat de gepubliceerde correlatie tussen mutaties in het ABCB1 
systeem en dnAUC0-12 van tacrolimus komt door genetische linkage van het 
ABCB1 systeem met andere polymorfismes, zoals het CYP3A system. 
 
Polymorfisme in CYP3A5 was geassocieerd met de dosis (en dnAUC0-12) van 
tacrolimus. De frequentie van het CYP3A5*1 polymorfisme is hoger in de 
Chinese populatie (t.o.v. de Kaukasische populatie) en verklaarde ruim 35% 
van de variatie in dagelijkse tacrolimus dosis.  
 
In hoofdstuk 7 beschrijven we een onderzoek bij 63 Kaukasische ontvangers 
van een niertransplantatie waarvan een compleet 9-punts 12-uurs AUC van 
tacrolimus beschikbaar was: 26 patiënten waren onderzocht binnen 3 maanden 
na transplantatie en 37 patiënten tenminste 1 jaar na transplantatie. Zij werden 
getypeerd voor polymorfismes in het ABCB1 systeem en CYP3A. 
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Noch de individuele polymorfismes van het ABCB1 systeem, noch de ABCB1 
haplotypes waren geassocieerd met enige farmacokinetische parameter.  
Daarentegen hadden dragers van het CYP3A5*3 allel zowel in de vroege als 
late groep een significant hogere spiegels (dnC0, dnAUC0-12 en dnCmax). 
De frequentie van het CYP3A5*1 allel was in de vroege groep hoger dan 
verwacht o.b.v. prevalentie in de bevolking. Gepostuleerd werd dat deze 
patiënten na transplantatie mogelijk meer problemen hadden met het bereiken 
van de streefwaardes voor tacrolimus dan homozygote dragers van het 
CYP3A5*3 variant. Dit kan van belang zijn in de Chinese bevolking, alwaar het 
CYP3A5*1 allel een vaker voorkomt dan in de Kaukasische populatie. Het 
voorafgaand aan de transplantatie bepalen van de CYP3A5 genotype zou 
kunnen bijdragen aan het optimaleseren van de initiële tacrolimus dosering. 
Dried Blood Spot in niertransplantatie 
Dried blood spot (DBS) wordt frequent toegepast in de neonatologie en is ook 
toepasbaar bij antimalaria en anti-HIV medicatie. Tot nu toe werd het echter 
niet toegepast voor TDM van tacrolimus. In hoofdstuk 8 wordt de toepassing 
van DBS beschreven bij 36 Chinese ontvangers van een niertransplantatie. In 
totaal waren er 108 DBS monsters afgenomen middels een vingerprik, 
waarvan slechts twee niet beoordeelbaar waren. De correlatie tussen de 
bloedwaardes en de berekende verkorte AUC0-12 van monsters verkregen via 
veneuze bloedafnames (bepaald in Hong Kong) en vingerprik m.b.v. DBS 
(bepaald in Maastricht) was uitstekend (r2=0.96, P<0.0001). De test was 
reproduceerbaar en de monsters bleven stabiel ondanks de langdurige reis. 
Het voordeel van DBS voor patiënten is m.n. dat in de thuissituatie op de 
gewenste tijden een monsterafname plaats kan vinden i.p.v. afname in een 
ziekenhuis met extra reistijden en wachttijden bij de prikdienst. Bovendien kan 
de uitslag bekend zijn t.t.v. een poliklinisch bezoek. 
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